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Abstract 
 
Quantum Chemical Topology (QCT) descriptors, calculated from ab initio wave functions, have 
been utilised to model pKa and mutagenicity for data sets of pharmaceutically relevant 
compounds.  The pKa of a compound is a pivotal property in both life science and chemistry since 
the propensity of a compound to donate or accept a proton is fundamental to understanding 
chemical and biological processes.  The prediction of mutagenicity, specifically as determined by 
the Ames test, is important to aid medicinal chemists select compounds avoiding this potential 
pitfall in drug design.  Carbocyclic and heterocyclic aromatic amines were chosen because this 
compounds class is synthetically very useful but also prone to positive outcomes in the battery of 
genotoxicity assays. 
The importance of pKa and genotoxic characteristics cannot be overestimated in drug design, 
where the multivariate optimisations of properties that influence the Absorption-Distribution-
Metabolism-Excretion-Toxicity (ADMET) profiles now features very early on in the drug discovery 
process. 
Models were constructed using carboxylic acids in conjunction with the Quantum Topological 
Molecular Similarity (QTMS) method.  The models produced Root Mean Square Error of 
Prediction (RMSEP) values of less than 0.5 pKa units and compared favourably to other pKa 
prediction methods.  The ortho-substituted benzoic acids had the largest RMSEP which was 
significantly improved by splitting the compounds into high-correlation subsets.  For these 
subsets, single-term equations containing one ab initio bond length were able to accurately 
predict pKa.  The pKa prediction equations were extended to phenols and anilines. 
Quantitative Structure Activity Relationship (QSAR) models of acceptable quality were built based 
on literature data to predict the mutagenic potency (LogMP) of carbo- and heterocyclic aromatic 
amines using QTMS.  However, these models failed to predict Ames test values for compounds 
screened at GSK.  Contradictory internal and external data for several compounds motivated us to 
determine the fidelity of the Ames test for this compound class.  The systematic investigation 
involved recrystallisation to purify compounds, analytical methods to measure the purity and 
finally comparative Ames testing.  Unexpectedly, the Ames test results were very reproducible 
when 14 representative repurified molecules were tested as the freebase and the hydrochloride 
salt in two different solvents (water and DMSO).  This work formed the basis for the analysis of 
Ames data at GSK and a systematic Ames testing programme for aromatic amines.  So far, an 
unprecedentedly large list of 400 compounds has been made available to guide medicinal 
chemists.  We constructed a model for the subset of 100 meta-/para-substituted anilines that 
could predict 70% of the Ames classifications.  The experimental values of several of the model 
outliers appeared questionable after closer inspection and three of these have been retested so 
far.  The retests lead to the reclassification of two of them and thereby to improved model 
accuracy of 78%.  This demonstrates the power of the iterative process of model building, critical 
analysis of experimental data, retesting outliers and rebuilding the model.  
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QSAR  Quantitative Structure Activity Relationship 
QSPR  Quantitative Structure Property Relationship 
QTMS  Quantum Topological Molecular Similarity 
RBFNN  Radial Basis Function Neural Networks 
RMSE  Root Mean Squared Error 
RMSEE  Root Mean Squared Error of Estimation 
RMSEP  Root Mean Square Error of Prediction 
S9  Rat Liver Homogenate 
SAR  Structure-Activity Relationships 
SVM  Support Vector Machines 
VIP  Variable Importance in the Projection 
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Chapter 1                                                                                                               
Introduction and Industrial Context 
 
1.1 Introduction 
 
An Engineering Doctorate (EngD) was created in collaboration with GlaxoSmithKline (GSK) and the 
School of Chemistry at The University of Manchester.  The project focus was to use computational 
methods to impact on the progress of drug discovery.  A specific aim of the project was to extend 
the use of ‘Quantum Chemical Topology’1, 2 (QCT) descriptors3  for property predictions.  
Subsequently pKa and toxicity were identified as two important molecular properties to the 
industrial sponsor and the wider scientific community.  These selected properties enabled the 
extension and robust testing of QCT descriptors and also provided interesting results from which 
several conclusions have been drawn.      
 
1.2 Industrial Context 
 
1.2.1 GlaxoSmithKline (GSK) 
 
GlaxoSmithKline (GSK) was formed on the 27th December 2000 as a result of the merger of 
SmithKline plc and Glaxo Wellcome plc.  It is now one of the largest pharmaceutical companies in 
the world4 with 100,000 employees in 114 different countries and a market share in 150 
countries.  Sales in 2009 amounted to £28.4 billion with profits before taxation of £8 billion.  It is 
world leader in research-based pharmaceuticals engaged in the creation, discovery, development, 
manufacture and marketing of pharmaceuticals and consumer health-related products to create 
value for stakeholders. 
 
The complexity of the organisation means there are numerous stakeholders including employees, 
customers, suppliers, regulators, charities, aid workers, environmental and animal rights 
campaigners, health and safety authorities, governments, local areas and site neighbours, unions, 
academia and competitors  All have unique needs and interests.  GSK’s mission statement (below) 
places patients as central stakeholders.  
 
“We have a challenging and inspiring mission to improve the quality of human life by 
enabling people to do more, feel better and live longer.” 
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At times, this may cause conflicts with other stakeholders, particularly shareholders, who have a 
financial interest in the company.  GSK has to be profitable but has set itself the scientific goal to 
improve human health and therefore is actively involved in researching treatments for rare and 
unprofitable diseases.  GSK is also involved in patent pools, where they forgo their patent rights, 
to provide essential medicines to developing countries.  Local companies make the medicines 
generically at a mutually-agreed licence fee. 
     
1.2.2 Key Products 
 
GSK’s product portfolio is divided into Pharmaceuticals and Consumer Healthcare.  The principal 
pharmaceutical products are grouped into nine main therapeutic areas (Table 1.1).  Respiratory, 
anti-virals and vaccines represent the three therapeutic areas which provide the largest turnover 
for GSK.  In 20095 GSK had two of the world’s top 60 pharmaceutical products (Seretide/Advair 
(respiratory) and Valtrex (anti-viral)) compared to eight in 20056.  A broader range of products are 
currently maintained to provide growth and stability as opposed to a reliance on blockbuster 
drugs.  Sales were boosted by the H1N1 global influenza pandemic in 2009.  Sales of GSK’s 
pandemic vaccine, amounting to £883 million, contributed to the total vaccine turnover.  
Similarly, a significant increase in sales of Relenza contributed to the anti-virals turnover.   The 
consumer healthcare portfolio comprises of over-the-counter medicines such as cold remedies 
and nicotine replacement therapy, oral healthcare such as Aquafresh and Sensodyne and nutrition 
healthcare including Lucozade, Horlicks and Ribena.  The percentage turnover that the consumer 
healthcare portfolio contributes to the total is small (Table 1.2) compared to the sales generated 
from pharmaceutical product, but the diverse product range represents important revenue 
streams to GSK; which continue to grow.  
    
Table 1.1.  GSK pharmaceutical turnover by therapeutic area for 2009 and 2008. 
Therapy area % of total 
2009 
2009 2008 
  £m £m 
Respiratory 29 6,997 5,817 
Anti-virals 18 4,150 3,206 
Central nervous system 8 1,870 2,897 
Cardiovascular and urogenital 10 2,298 1,847 
Metabolic 5 1,181 1,191 
Anti-bacterial 7 1,592 1,429 
Oncology and emesis 3 692 496 
Vaccines 16 3,706 2,539 
Other 4 1,063 959 
  23,466 20,381 
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Table 1.2.  GSK consumer healthcare turnover for 2009 and 2008. 
 % of total 
2009 
2009 2008 
  £m £m 
Over-the-counter medicines 50 2,319 1,935 
Oral healthcare 32 1,484 1,240 
Nutritional healthcare 18 851 796 
  4,654 3,971 
 
1.2.3 Key Markets 
 
Although GSK has a market share in 150 countries, the biggest single market is the United States.  
The US market grew by 3.6% in 2009 however, sales of GSK’s pharmaceuticals declined by 13%.  
To combat the reduction in sales, GSK has placed emphasis on improving sales in the Emerging 
Markets (i.e. Brazil, Russia, India and China).  This resulted in a 20% increase in sales in 2009 to £3 
billion, representing 10% of the total sales.    Operating in different markets means GSK has to be 
adaptable to local rules and cultures.  It means the company has to liaise with different regulatory 
bodies such as the Food and Drug Administration (FDA) in the US and the European Medical 
Agency.  Furthermore, direct advertising of prescription drugs is forbidden in Europe, meaning 
marketing is directed largely at doctors and health authorities who decide which drugs to 
prescribe.  In the US, pharmaceutical companies directly target patients with marketing 
campaigns.  It is expected that the recent US health care reform will have huge implication for the 
pharmaceutical industry in the near future.  
 
Table 1.3.  Breakdown of the value of the pharmaceutical market by geographical region.        
World market by geographical 
region 
Value  
£bn 
% of total Growth % 
USA 187 40 3.6 
Europe 131 28 4 
   France 25 5 - 
   Germany 24 5 - 
   Italy 16 3 - 
   UK 12 3 - 
Rest of World 150 32 9.9 
   Emerging markets 55 14 - 
   Asia Pacific 20 4 - 
   Japan 50 11 - 
   Canada 11 2 - 
Total 468 100  
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1.2.4 Research and Development at GSK 
 
The average cost of developing a new drug is estimated to be $868 million, but can vary between 
$500 and $2000 million depending on the therapy7.  It also takes around twelve years for a drug 
to reach market and therefore the structure of GSK is vital in supporting the organisation’s 
purpose.  At a high level the business areas responsible for delivering new drugs are shown in 
Figure 1.1. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1.  The business functions and inter-relationships responsible for delivering new drugs to customers. 
 
The function of Research and Development (R&D) is to deliver new drugs to the pipeline.  The 
pressure due to this has intensified over the last few years as the increase in the discovery of 
novel drugs has not risen as predicted, regulatory approval has decreased and patent expiry has 
meant increased erosion of market share by generic drug manufacturers.  To maintain a 
competitive pipeline, research is organised into six Centres of Excellence for Drug Discovery 
(CEDDS) each focusing on defined therapy areas.  Separate R&D functions, for example biological 
pharmaceutical research, vaccine research and R&D China each have their own defined roles.  
 
In 2008, the new Chief Executive Officer of GSK, Andrew Witty, took the CEDD model one step 
further and initiated the creation of a number of smaller Discovery Performance Units (DPUs) 
within each CEDD, to focus on a particular disease area.  The DPU model was based on the success 
of small biotechnology companies over the last decade.  There are now thirty-six DPUs, each 
being a compact, fully-empowered, focused and integrated team, which is responsible for a small 
part of the drug pipeline.  Some standalone DPUs not linked to CEDDs have also been created to 
explore new therapy areas or new ways of working, such as the academic DPU which forms drug 
discovery collaborations with academia.  Each DPU has a three-year business plan defining the 
Logistics and 
Supply 
 
Marketing 
 
Manufacturing 
 
Customers 
 
Research & 
Development 
 
All supported by other business 
functions including: 
Human Resources, Regulatory 
Affairs, Sales, Law, Finance, IT 
Etc. 
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overall budget and clear objectives.  The DPUs have to present to the Drug Discovery Investment 
Board, which is made up of internal and external experts, who review the success and decide on 
future investment.  This creates internal competition and an entrepreneurial culture with the 
potential to enhance both the scientific basis and commercial value of the business.  One 
outcome of this initiative is that GSK and the healthcare providers are now in direct dialogue.  
Developing drugs that will reimburse the cost of getting the drug to market is fundamental. 
 
Molecular Discovery Research (MDR) is an R&D function that supports the CEDDs in the entire 
drug discovery process.  Within MDR is Computational and Structural Chemistry (CSC).  The 
function of CSC is to provide computational chemistry support to the CEEDs and DPUs throughout 
the drug discovery process.  The aim is to improve the quality of drug candidates, reduce attrition 
and as a consequence reducing costs and adding value to the business.  In the United Kingdom 
CSC is divided into two groups, Lead Generation (LG) and Lead Optimisation (LO), each with its 
own manager responsible for around fifteen employees.  LG and LO are sub divided into specific 
teams of around six employees aligned to the therapy area of each of the CEDDs with line 
managers responsible for each group. 
 
Patent expiries, regulatory issues and price pressures from healthcare providers have created an 
environment where the sector is associated with lower growth and higher risk.  Shortly after 
becoming CEO, Andrew Witty outlined three strategic priorities to transform GSK into a company 
that delivers more growth, less risk, and improved financial performance to overcome the 
unprecedented challenges in the pharmaceutical industry.  The focus was to grow a diversified 
global business, deliver more products of value and simplify the operating model.  The strategic 
priorities have caused changes across GSK and in particular R&D.  The business has created a 
more balanced portfolio over the last two years and moved away from the emphasis to discover 
the next ‘blockbuster’ drug.  GSK has and continues to improve its pipeline by acquiring, 
collaborating, and in-licensing promising compounds from other organisations.  This has meant 
the externalisation of approximately 30% of discovery research with 47 external partners where 
the risks associated with drug discovery are shared5.  The operating model is also evolving to 
reduce complexity and improve efficiency to ultimately reduce cost.  The evolution has seen the 
closure of a number of R&D sites across Europe but an expansion into China in line with the 
strategic priorities.  
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1.2.5 Drug Design Process 
 
The process of drug discovery is time consuming, expensive and highly risky8.  It begins with the 
identification of an unmet medical need or a judgement on the adequacy of existing therapies.  At 
this stage, a decision will be made whether to proceed with a discovery project based on a 
multitude of information including, the potential for reimbursement from a new drug, how many 
patients would use the drug, the existing expertise within the organisation, how likely a tractable 
target can be found, the cost of failure and ultimately the chance of success.  If the decision is 
made to pursue the therapeutic indication, then a research team is formed and the objectives of 
the project are set.   
 
The next stage is to identify a suitable target implicated in the mechanism of a particular illness.  
These include ion channels, kinases, nuclear receptors and other enzymes and proteins that are 
crucial to the survival of the cell or able to restore the functional capabilities of malfunctioning 
cells.  If possible a structure of the target is generated using X-ray crystallography and/or NMR.  
Assay development is also undertaken to develop tests that will be able to detect biological 
activity in vitro.   
 
High-throughput screening (HTS) is applied to a compound library to identify biologically active 
compounds (i.e. a ‘hit’).  When a number of hits have been identified, structure-activity 
relationships (SAR) are investigated and biological (e.g. P450 inhibition) and pharmacokinetic 
properties (e.g. solubility) are measured to identify promising chemotypes for the start of 
chemistry.  Only hits that have attractive properties are declared lead compounds.  Lead 
optimisation is then focused on generating analogues of the lead compounds to optimise the 
absorption, distribution, metabolism, excretion and toxicity (ADMET) properties while 
simultaneously improving the potency of the compounds.  This is a multidimensional optimisation 
procedure where properties such as solubility, ionisation and lipophilicity can impact on the 
ADMET profile.  Improving one aspect of the ADMET profile can have a detrimental affect on 
another.  Generally, one series of compounds will be optimised and, where possible, exposed to 
different assays to enhance the understanding of the ADMET.  Representative compounds from 
the series will be screened in low throughput assays (e.g. the Ames test) as early as possible to 
provide reassurance that issues relating to toxicity will not curtail the drug discovery programme 
in the future.  If undesirable properties in the chemical series are identified and cannot be 
rectified, lead optimisation starts on alternative compounds.  Some lead optimisation may have 
already been undertaken on these compounds however, switching to a new lead series is costly, 
both in terms of time and expenditure, and therefore undesirable.  If lead optimisation identifies 
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a compound that has desirable target potency and ADMET profile, further safety assessment and 
in vivo studies are conducted.  If the in vitro assays have successfully predicted the efficacy and 
safety in vivo, then the candidate will progress to clinical trials in humans.  If the candidate makes 
it through all three phases of clinical trials, regulatory approval for market access is sought. 
 
Despite the careful considerations taken before project initiation, less than 1 in 50 projects get a 
drug to market9.  In the discovery phase only 1 in 5 projects gets as far as selecting a compound 
for clinical trials.    These failures are attributed to biological problems which include poorly 
validated targets and chemistry problems such as chemical instability or toxicity. The advent of 
the target-based approach to drug discovery was expected to drive the discovery of new 
medicines. HTS has considerably expanded the number of compounds that can be evaluated for 
their biological activity10 however, in the last two decades the number of new drugs approved has 
not risen9.  
 
Recently, there has been increased emphasis on fragment-based drug design.  It is based on 
screening a smaller number of molecules, typically several thousand fragments with a molecular 
weight between 100 and 250, in the hope of finding low-affinity ligands with activity in the high 
micromolar to millimolar range.  The fragments probe key binding interactions in the protein, but 
are small enough to minimise the chances of unfavourable interactions that can prevent larger 
molecules from binding efficiently.  In comparison, conventional screening campaigns evaluate a 
million or more compounds in the hope of finding relatively potent drug leads.  The active 
fragments are then grown into a lead compounds with a binding affinity that is the sum of the 
individual parts11.  GSK have entered into a collaboration with Astex Therapeutics to apply 
fragment-based methods to multiple targets identified by GSK12 with the aim of increasing 
discovery productivity. 
 
Computers play a pivotal role throughout the drug discovery process13.  Beyond structural 
drawing, structure conversion, molecular visualisation, data handling and other techniques, 
several computation techniques have improved the efficiency of the drug design process.  At the 
lead generation stage, HTS requires a compound library to be screened against for activity.  One 
approach is to screen all the compounds in the organisation’s corporate library.  This was 
performed with two million GSK compounds to identify compounds that could be developed to 
inhibit the malaria parasite Plasmodium.  The screen took five scientists around a year to 
complete but identified 13,500 structures  for potential further investigation14.   
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Molecular modellers use methods to reduce the size of screening libraries making them more 
focused.  If the structure of the biological target is known or can be predicted by homology 
modelling, then virtual screening using docking can be applied to select the most appropriate 
compounds for screening.  De novo design may also be used to build inhibitors from scratch given 
the target binding site.    If the structure is not known but a number of active compounds have 
been identified, then pharmacophore models can be constructed for the positioning of key 
features like hydrogen-bonding and hydrophobic groups.  Such models can be used as a template 
to select the most promising compounds.  Similarity searching against active compounds is also 
useful when the target structure is unknown. 
 
Rules of thumb can be used to create libraries based on drug-likeness.  The rule-of-five15 
highlights that most orally administered drugs have a molecular weight of 500 or less, a LogP no 
higher than 5, five or fewer hydrogen-bond donor sites, and 10 or fewer hydrogen-bond acceptor 
sites.  Extending the rule-of-five, Veber and co-workers16 suggest that a maximum of seven 
rotatable bonds is optimal for bioavailability and Clark and Picket17 indicate polar surface area as 
another key property.  For fragment libraries design, a molecular weight less than 300, 3 or less 
hydrogen-bond donors and acceptors, and LogP less than three is advised for efficient lead 
discovery18.  Gleeson19 also highlighted that almost without exception absorption, distribution, 
metabolism, excretion and toxicity (ADMET) liabilities increase with increasing molecular weight 
and/or LogP.  Ionization states also play either a beneficial or detrimental role depending on the 
property in question.  Filtering a library based on rules can significantly reduce the number of 
compounds to screen and increase the chances that an identified hit will progress to market. 
 
In the lead optimisation phases, predictions need be made to investigate how changing molecular 
or structural features will affect physical properties.  They are usually predicted from Quantitative 
Structure Activity Relationships (QSARs) that have been trained on experimental data.  
Bioisosteric replacements20, 21 may be suitable to apply to lead compounds.  Bioisosteres are 
substituents or groups with similar physical or chemical properties which produce broadly similar 
biological properties to a chemical compound.  The idea is to preserve the desired activity without 
making significant changes in chemical structure.  Bioisosteric replacements may be used to 
improve properties such as solubility and hydrophobicity.  They may also be used to reduce 
undesirable features such as compound toxicity. 
 
The number of possible compounds in the small-molecule universe is estimated at 1040 - 10100. 
Typically a drug discovery programme tests 105 - 107 compounds22.  Despite this small coverage of 
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chemical space, the fact that lead compounds are identified and optimised to drug molecules is 
impressive.  The process has undoubtedly improved with the use of computers at all stages.                           
 
1.3 Project Brief 
 
This project will extend the use of QCT descriptors for property predictions  using a method 
known as Quantum Topological Molecular Similarity23 (QTMS).  Two distinct properties important 
in the ADMET profiles of drugs will be used to create models to predict the properties of new 
compounds.  Although pKa and mutagenicity are both important in ADMET and can be linked here 
we treat them separately as they were used to satisfy different objectives.   QCT descriptors will 
be used to predict pKa for large data sets of drug-like compounds.  The models will be extensively 
validated and the results compared to software frequently being used today.  QCT descriptors will 
also be applied to the prediction of toxicity, specifically mutagenicity, in an attempt to create 
models that enable chemists at GSK to predict the results for new compounds, giving an early 
indication of the likely outcome in an assay.  This will enable them to make informed choices 
about progressing with lead compounds and also rank molecules for priority testing in low 
throughput assays.   
 
1.3.1 Project Objectives 
 
The specific objectives to be completed are as follows: 
In relation to pKa 
1. Apply QTMS to a large data set of drug-like molecules. 
2. Investigate the use of different machine learning methods. 
3. Improve the validation of the results from QTMS beyond the uses of the cross-validation 
statistic   . 
4.  Compare the results to publically and commercially available pKa prediction tools. 
5. Investigate whether only ab initio bond lengths can be used to predict pKa.  
6. Test the models by predicting the pKa of drug molecules. 
In relation to mutagenicity 
7. Apply QTMS to predict mutagenic potency of carbocyclic and heterocyclic primary 
aromatic amines. 
8. Establish the experimental requirements for a reliable data set. 
9. Verify the reliability of the computational classification scheme by getting some outliers 
retested experimentally. 
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1.3.2 Project Flow 
 
A number of sub-projects have emerged that attempt to satisfy the objectives.  These projects 
represent stages in the research when findings highlighted areas for further research. 
1) pKa Prediction from “Quantum Chemical Topology” Descriptors 
2) pKa Prediction from a Single Ab Initio Bond Length 
3) Prediction of the Mutagenic Potency of Primary Aromatic Amines Using “Quantum 
Chemical Topology” Descriptors. 
4) Experimental and Computational Investigations into the Mutagenicity of Carbocyclic and 
Heterocyclic Primary Aromatic Amines. 
5) Predicting Mutagenic and Non-Mutagenic Carbocyclic and Heterocyclic Primary Aromatic 
Amines.       
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Chapter 2                                                                                                       
Background Theory                                                                                                    
 
2.1 Quantum Mechanics 
 
Electronic structure methods use the laws of quantum mechanics rather than classical physics as 
the basis for their computations.  Quantum mechanics states that the electronic structure and 
properties of any given molecule, in any of its available states, may be determined in principle by 
solutions of Schrödinger’s equation.  Equation 2.1 describes the wave function of a particle: 
 
 
   
   
            
  
  
       
  
 Equation 2.1 
 
where   is the wave function,  is the mass of the particle,   is Plank’s constant, and   is the 
potential field in which the particle is moving.    , is a differential operator, where   is equivalent 
to partial differentiation with respect to the particle’s coordinates. The Schrödinger equation for a 
collection of particles like a molecule is very similar.  In this case,   would be a function of the 
coordinates of all particles in the system.  As stated, the energy and many other properties of the 
particle can be obtained by solving  .  Many different wave functions are solutions to the 
equation, corresponding to different states of the system. 
 
For most molecular ab initio calculations the time-independent Schrödinger’s equation, which 
takes the simplified form: 
 
                        Equation 2.2 
 
Here  represents the wave function of the position of the electrons and nuclei within a 
molecule, which are denoted as   and    respectively.  E is the allowed energies of the system and 
H is the Hamiltonian operator, which is made up of kinetic and potential energy terms: 
 
      Equation 2.3 
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The kinetic energy in three dimensions is a summation of the Laplacian, denoted by   , over all 
the particles in the molecule: 
 
     
  
   
 
 
  
 
 
  
   
  
  
   
  
  
   
   Equation 2.4 
 
The potential energy component is the Coulomb interaction between each pair of charged 
entities where each atomic nucleus is treated as a single charged mass: 
 
   
 
    
  
    
    
    
 Equation 2.5 
  
where      is the distance between the two particles, and     and    are the charges on the 
particles j and k.  For an electron, the charge is -e, while for a nucleus, the charge is Ze; where Z is 
the atomic number for that atom.  Thus, the equation that represents the electron-nuclear 
attraction, the electron-electron repulsion, and the nuclear-nuclear repulsion is given by: 
 
                                                                                                                                                     
   
 
    
      
   
 
    
 
  
    
  
    
 
    
    
     
 
    
 
    
  Equation 2.6 
 
The Schrödinger equation is an eigenvalue equation with the solutions being a spectrum of 
eigenvalues (E) and corresponding eigenfunctions ( ).  It is solved to find the wave function “ ” 
from which chemical properties for the system can be determined.  Currently there is no clear 
chemical interpretation of , however,      gives the probability of finding an electron at a given 
point.  From , we can therefore generate a probability density P(r) by integrating  over all 
spatial coordinates except the set of coordinates describing one electron, and by summing over all 
spin coordinates.  This must be carried out as each electron is described by four coordinates 
(three spatial coordinates and a spin coordinate) and so the integration renders the wave function 
into three dimensions from originally residing in a high dimensional space.  The P(r) is multiplied 
by the number of electrons N to give the electron density ρ(r), or just ‘ρ’.  
 
The equation solved is time-independent, therefore the solutions are for a frozen structure at 
zero Kelvin.  The system is usually isolated, so best represents a molecule in the gas phase.  The 
gas-phase, zero Kelvin approximation is used to reduce the computational cost of the ab initio 
calculation.  It is important to consider the impact of such approximations when applying ab intio 
data to real-world systems, which are dynamic and interact with a wealth of other species in the 
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local environment.  Often solvent interactions are considered, either implicitly or explicitly, in an 
attempt to account for a proportion of these interactions. 
 
2.1.1 Level of Theory 
 
It is possible to model reactions, molecular structures and dynamic processes in silico using 
quantum chemistry.  Due to computational limitations a number of approximations must be made 
before reaching practical molecular orbital methods that can provide approximate solutions to 
the Schrödinger equation.  There are two main classes of electronic structure methods: 
 
 Semiempirical methods, such as AM1, incorporate experimental parameters in an 
attempt to predict molecular properties.  Such methods are computationally very fast, 
however, their success is determined by having appropriate experimental input for the 
system under investigation. 
 Ab initio methods rely on no experimental values; but are based solely on fundamental 
constants.  The ability of these methods to predict molecular properties solved exclusively 
by equations means that they are computationally very demanding. 
 
The ‘Born-Oppenheimer approximation’ (BOA) simplifies the general molecular problem 
experienced by ab initio calculations by separating the nuclear and electronic motion.  The 
motivation behind this is based on the fact that there is a large difference between the masses of 
electrons and nuclei, allowing electrons to respond almost instantaneously to the motion of the 
nuclei.  This means there is a large difference in timescale of electronic and nuclear motion, 
therefore allowing the electronic motion to be treated as occurring in a field of fixed nuclei, and 
so the Schrödinger equation is solved as a parametric function of the nuclear coordinate. 
 
The most basic ab initio method in common use is the Hartree-Fock ‘Self Consistent Field’ (SCF) 
method.  As well as utilising the BOA a further approximation is used.  The Schrödinger equation is 
initially solved for a single electron in a system, which experiences all remaining electrons via an 
average field of negative charge.  An initial guess is used to create the first field, and when the 
wave function for the first electron has been solved it is used to calculate the field for the next 
electron.  When the wave functions for all electrons have been calculated the process starts again 
and iterates in this manner until there is a negligible change in the wave function and the field has 
become consistent.  This method of using an electron cloud to represent all other electrons is 
known as the Hartree-Fock Approximation.  
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The Linear Combination of Atomic Orbitals (LCAO) is also introduced to make calculations of 
molecules practical.  The approximation is based on the idea that orbitals are not just centred on 
one nucleus, but on every nucleus in the molecule.  Basis sets are introduced to mathematically 
represent the atomic orbitals within a molecule, which in turn combine to approximate the total 
electronic wave function. 
 
The above approximations generate a scheme that provides solutions to the Schrödinger 
equation.  These methods, however, neglect the Coulomb correlation energy experienced by 
electrons of opposite spin.  Coulomb correlation arises from charge repulsion and its neglect 
causes electrons to move too close together, therefore the energy calculated will always remain 
above the exact energy.  The difference between these two energies is known as the correlation 
energy.  Fermi correlation between electrons of the same spin arises from the Pauli Exclusion 
Principle, and is included in the ‘exchange’ term in Hartree-Fock calculations. 
 
‘Density Functional Theory’ (DFT) and Moller-Plesset Perturbation Theory also use the Born-
Oppenheimer and LCAO approximations.  Unlike HF calculations, they partially account for the 
Coulomb correlation.  Moller-Plesset Perturbation Theory takes the estimates offered by HF 
calculations and adds a corrective contribution from the Coulomb correlation.  DFT is based on 
the theorems of Hohenberg-Kohn24 which state that the ground state energy of a non degenerate 
system, as well as its electronic properties, are solely defined by its electron density.  As such, DFT 
does not use the wave function but an electron probability density function which refers to the 
probability of finding an electron in a volume centred on a point with coordinates x, y and z.  DFT 
methods take a different approach to HF and Moller-Plesset methods by incorporating Coulomb 
correlation with an exchange-correlation energy term based directly on the electron density.  
These methods partition the energy into several terms: 
 
E DFT = E nuclear + E core + E Coulomb + E exchange-correlation 
 
  whereas HF theory contains: 
 
E HF = E nuclear + E core + E Coulomb + E exchange 
 
The tem E exchange-correlation is the only one that is not determined directly because of its 
unknown mathematical formulation.  Usually E exchange-correlation is described as a sum of the 
exchange term and the electronic correlation.  The exchange term can be calculated by using 
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approximations that applies a homogenous electron density, such as the Local Density 
Approximation25 and the Local Spin Density Approximation26, by using gradient corrected 
functional such as the Generalised Gradient Approximation (GGA) methods (e.g. Becke9527 (B95) 
and Lee-Yang-Parr28 (LYP)).  E exchange-correlation can also be calculated using hybrid density 
functionals, which combines a conventional GGA method with a percentage of Hartree-Fock 
exchange.  Examples of hybrid density functional include B3LYP29 and B3PW9130.   
 
2.1.2 Basis Sets 
 
Basis sets are functions used to represent atomic orbitals, which in turn combine to form 
molecular orbitals.  Using a linear combination of atomic orbitals a single molecular orbital (  ) 
can be constructed: 
 
       
 
   
   Equation 2.7 
 
where N is the set of functions used,    refers to an arbitrary basis function, and each has 
associated with it some coefficient    .  The total molecular wave function is then calculated as 
the antisymmetric product of the single molecular orbitals. 
 
Most ab initio programs use Gaussian-type atomic functions as basis functions.  Gaussian 
functions have the general form: 
 
                  
 
 Equation 2.8 
 
where   is composed of x, y, and z,   is a constant determining the shallowness of the function, 
and n, l, and m are integers that determine the directional dependence.  If n + l + m = 0 then there 
is no directional dependence and the Gaussian function represents an ‘s-type’ orbital.  When n + l 
+ m = 1 then the Gaussian function lies along one of the axes and represents a ‘p-type’ orbital.  A 
single Gaussian function, however, does not give an accurate representation of an orbital, so a 
combination of several is required.  The more atomic orbitals used to construct the basis set, the 
closer the energy approaches the exact value for a given molecule.  It would seem sensible to use 
very large basis sets in calculation, however, due to the large computational time and cost, the 
size of the basis sets that can be used are  limited. 
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Minimal basis sets use one (single) basis function for each type of atomic orbital occupied in the 
separate atoms.  Larger basis sets more accurately approximate the atomic orbitals by imposing 
fewer restrictions on the locations of the electrons in space, hence it is often necessary to use 
larger basis sets than the minimal.  The double and triple zeta basis sets use two and three basis 
functions for each type of atomic orbitals in atoms, respectively.  In a molecule, the electron 
density around the atom will be different to that around the separate atom, using two or three 
functions per orbital allows for variation due to bonding and other interactions.  Split valence 
basis sets are used to reduce the computational time and cost and are based on the assumption 
that the core electrons of an atom are less affected by the chemical environment than the valence 
electrons.  In other words the core electrons retain their atomic characteristics and so the 
flexibility needed to account for bonding is not so crucial.  This leads to split valence basis sets 
consisting of a minimal representation of the core electrons combined with double or triple zeta 
representations of the valence electrons. 
 
Adding polarization and diffuse functions is a further modification that improves accuracy.  
Polarization functions add orbitals of higher angular momentum to atoms in molecules that are 
not normally occupied in the separate atoms.  Using these functions improves the flexibility of the 
basis sets and better represents the electron density in bonding regions between atoms by 
allowing the electron density to be polarized.  Diffuse basis functions are extra functions that are 
added to basis sets to represent very broad electron distributions.  They allow a better 
representation of the electron density when it is spread over a large region in mid to large sized 
molecules. 
 
2.2 Quantum Chemical Topology 
 
The theory of Quantum Chemical Topology (QCT), sometimes referred to as Atoms in Molecules 
(AIM), is a partitioning method pioneered by Richard Bader and co-workers in the early 1970s.  
Essentially the theory forms a bridge between quantum mechanics and working chemical 
concepts such as the atom and the bond.  The electron density, obtained from the wave function, 
is partitioned into atomic portions, with each having its own unique properties.  This method has 
a solid basis as the electron density can also be observed experimentally, for example using X-ray 
crystallography as well as being derived computationally from ab intio calculation previously 
outlined.  The applications of QCT are continually expanding and being applied to new areas of 
chemistry. 
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2.2.1 Partitioning the Electron Density 
 
Figure 2.1 displays a relief map of the electron density ( ) in the symmetry plane of the furan 
molecule.  Figure 2.2  shows the same furan molecule but the electron density is represented by a 
2-dimensional contour map.  Inside each contour line lies a set of non-intersecting contour lines 
of higher electron density; these are nested contours.  In Figure 2.1 and Figure 2.2 it can be 
observed that the electron density is high around the atom centres and quickly drops when the 
distance from the atom centres increases.  Bonding interactions can be observed along the ridges 
of the high electron density that run between atom centres.     
 
 
Figure 2.1.  A relief map of the electron density of the furan ring in the symmetry plane.  Ridges of electron density 
can be observed running between atoms. 
 
 
Figure 2.2.  A contour plot of the electron density in the symmetry plane of furan. 
 
The gradient vector of the electron density      points in the direction of the greatest increase in 
 .  A succession of infinitesimally small gradient vectors forms the gradient path.  A gradient path 
has three important properties; its always orthogonal to the contour surface, gradient paths 
never cross except when     , and they have a beginning and an end.  An infinite collection of 
gradient paths forms the gradient vector field (Figure 2.3).  In reality, gradient vector fields of   
are shown using a finite number of gradient vector paths.  As gradient vector paths start at 
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infinity, they are traced backwards, from a small circle (the nuclei) with a certain number of 
equally spaced points, following the gradient vectors of decreasing  . 
 
Figure 2.3.  The gradient vector field superimposed on a contour map of   in the symmetry plane of furan. 
 
In Figure 2.3 there are gradient vectors paths that do not terminate at a nucleus; the places where 
they do terminate are known as critical points.  The special points between two bonded nuclei 
where gradient vector paths terminate are known as ‘bond critical points’ (BCPs).  A collection of 
vector paths in 3-dimensional space that terminate at a BCP defines the Interatomic Surface (IAS).  
The IAS, sometimes called the zero-flux surface, distinguishes itself from other arbitrary surfaces 
in that at every vector     has no component through the IAS.  This is equivalent to saying that 
the gradient vector field must be parallel to the IAS at every point on its surface.  The IAS defines 
the boundary between two atoms (Figure 2.4).  Not all atoms in a molecule will be completely 
enclosed with IAS formed between neighbouring atoms and as gradient paths extend to infinity it 
is useful to cap atoms using an outer shell to give them a finite volume.  The ‘atomic basin’ defines 
the region of an atom bound by IAS and an outer envelope (Figure 2.5).   
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Figure 2.4.  The IAS is formed from the gradient vector field lines terminating at the Bond Critical Point (purple 
sphere).  The example shows the interatomic surface defining the boundary between oxygen and carbon atoms of 
formic acid.   
 
Figure 2.5.  The 3-dimentional basin of the oxygen atom of formic acid.  The basin is surrounded by the red 
interatomic surface and capped.  Bond Critical Points are shown as purple spheres lying along the grey bond paths. 
 
2.2.2  Critical Point 
 
The idea of bond critical points has already been introduced.  A BCP forms when the gradient 
paths terminate at a point in space between two bonded nuclei, this means the BCP is the centre 
of the IAS.  The BCP is also the point where   reaches a maximum within the IAS, any 
displacement away from the BCP within the IAS reduces the value of   compared with the 
electron density at the BCP, denoted as  b.  It is important to note that  b is not a maximum in all 
directions; if this were true then the BCP would be identical to a nucleus.  In fact,  b is a minimum 
in the orthogonal direction to the IAS meaning it is a saddle point.  The orthogonal direction to the 
IAS at the BCP is referred to as the bond path (BP), and is a special type of gradient path 
connecting two nuclei.  Figure 2.4 shows the BCPs between bonded nuclei.  The gradient paths 
forming the IAS terminate at the BCP, not shown are the gradient paths that originate at the BCP 
and terminate at nuclei.  These gradient paths form the atomic interaction line (AIL).  The AIL is 
found between every pair of nuclei whose atomic basins share a common IAS.  However, the 
presence of an AIL between two nuclei does not necessarily mean they are bonded, for example, 
AILs can be found between two noble gas atoms at any separation.  An extra condition is 
required, namely that the molecule is in an energy minimum on its energy surface.  It is also 
important to note that, except for symmetrical bonds, BCPs can occur anywhere along the bond.  
In addition to BCPs there are other types of CPs.  These are the ring critical point, cage critical 
point and nuclear or non-nuclear attractor.  Each CP can be categorised by three eigenvalues, 
              calculated from the Hessian matrix at the CP.  At CP, the three eigenvalues are 
always non-zero and the signs determine the types of CP being considered.  A nuclear CP is 
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characterised by three negative eigenvalues, meaning a maximum of electron density in all 
directions.  A ring critical point is a saddle point, having two positive curvatures (i.e. two negative 
eigenvalues) and one negative curvature (i.e. positive eigenvalues).  At the ring critical point the 
electron density is a minimum in the plane of the ring and a maximum perpendicular to it.  A cage 
critical point has three positive eigenvalues meaning it is a minimum of the electron density in all 
directions.  Cage critical points appear within structures bonded by two or more rings.         
 
2.2.2.1 Bond Critical Point Properties 
 
QCT provides a means of evaluating several properties of BCPs using the electron density alone.  
Using all the BCPs in a molecule, these properties can be utilized to provide a compact 
representation of a given molecule.  The properties that have been evaluated and used in this 
work are listed below. 
 
1. The electron density ( b) derived from quantum mechanics, is the first.  It has been used to 
derive bond orders31 and also displays strong correlations with bond energy32.  
 
2. At the BCP, the Hessian of the electron density has two negative eigenvalues            
and one positive one       .  The eigenvector associated with    is tangential to the bond, 
and so    describes curvature along the bond.  The eigenvectors corresponding to    and    
are orthogonal to the bond, and so    and    describe curvature perpendicular to the bond. 
 
3. The sum of the three eigenvalues is the Laplacian of the electron density, denoted by    , 
which gives a measure of the local charge concentration or depletion at the BCP (Equation 
2.9).  If the negative eigenvalues    and   dominate, then an accumulation of charge takes 
place in the plane perpendicular to the bond.  This is common for shared interactions, such as 
covalent bonds.  This results in a negative value for the Laplacian.  If the positive eigenvalues 
  dominates, then the electron density accumulates along the bond towards the nuclei.  This 
is common for closed-shell interactions such as ionic, hydrogen and van der Waals bonds.  
This results in a positive value for the Laplacian.       
  
             Equation 2.9 
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4. The ellipticity of the electron density, denoted by   and defined in Equation 2.10, provides a 
further useful property associated with BCPs.  If   protrudes more in one of two directions 
perpendicular to a bond, then an oval pattern appears, such as pure double bonds.  This 
ovality is measured by the ellipticity.  Single bonds are characterized by     and    being 
nearly identical, and hence   is near zero. 
 
   
  
  
    Equation 2.10 
    
5. Two types of kinetic energy density, denoted by K(r) and G(r)33 can also be obtained as further 
BCP properties.  Interpreting K(r) in chemical terms is not straightforward, however a useful 
formula describing its link to the Laplacian and G(r) is given by Equation 2.11. 
     
              
   Equation 2.11 
 
6. The equilibrium bond length, denoted by Re, is not strictly a BCP property. However, it can be 
considered as the sum of the distances between the BCP and one nucleus and the distance 
between the same BCP and the other nucleus, neglecting any deviation from a straight line 
the bond path may exhibit and hence, can artificially be turned into a BCP property. 
 
2.2.2.2 Atomic Properties 
 
In order to give the full overview of QCT, it is important to mention atomic properties although 
full details will not be provided.  Unlike bond properties which are evaluated at a single point, 
volume integration over an atomic basin yields the atomic properties associated with that 
particular basin.  Obtaining the atomic properties is much more computationally demanding than 
the calculation of BCP properties.    The most commonly used atomic properties include the 
population, volume, different types of energy, and electrostatics.  It is important to note that as 
QCT strictly partitions the atoms in a molecule, summations of a group of atoms can give 
fragment properties, while summations over all atoms give the molecular properties.  This 
concept has led to much work being undertaken in the transferability of atoms and functional 
groups (fragments) with similar QCT properties. Although not strictly related to this work, 
substituent effects demonstrate that changing the chemical environment in one part of a 
molecule can induce significant changes in surrounding moieties.  This principle forms the basis 
for this work, since changes can be predicted using QCT and will be encapsulated in the wave 
function and thus in the properties calculated at the BCP used to predict the property of interest. 
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2.3 Quantitative Structure-Activity Relationships 
 
It has been known for millennia that different chemicals have different biological effects.  
However, it was not until the science of chemistry had become sufficiently developed to assign 
structures to compounds that it became possible to speculate about the causes of such biological 
properties.  These developments allowed researchers to link the structure of molecules to certain 
activities and propose structure-activity relationships (SARs).  There are however, problems 
associated with SARs, the main one being that the relationships are empirical and are semi-
quantitative, in that the changes in structure are represented as ‘all or nothing’ effects and the 
relationship only applies to the set of compounds from which it was derived34.  
 
Modern quantitative structure-activity relationship (QSAR) methods owe their origins to the work 
of Hansch and Fujita in the 1960s35.  They successfully used an approach based on applying linear 
free-energy relationships (LFERs)36 to correlate suitable physiochemical parameters to biological 
activities.  Their work was a bold extension to the work of Hammett37 almost three decades 
before.  Hammett discovered that pKa of benzoic acids and phenylacetic acid in aqueous solution 
was solely dependent on the substituent and a proportionality constant fixed by the solvent and 
temperature.  These relationships turned out to be universal and can be used to predict pKa for 
different ring substituents with known   constants38.  Since this advance, QSAR have been 
successfully applied to optimisation problems in drug and agrochemical design.  In 1995 Hansch et 
al. estimated that somewhere between 15 000 and 20 000 chemical QSARs had been published, 
while about 6000 biological equations have been published39.  These numbers must have 
significantly grown over the last 15 years.   
 
QSAR is the process by which the chemical structure of a series of molecules is quantitatively 
correlated with a well-defined process, such as biological activity (e.g. toxicity and 
biodegradability) or physiochemical properties (e.g. solubility and pKa).  The ultimate aim of all 
QSAR studies is to determine an equation of the following form: 
 
Activity = f (x1, x2, …., xn) Equation 2.12 
 
In Equation 2.12, f is a mathematical function, which is usually determined using an appropriate 
statistical technique and x represents the molecular descriptors that provide information about 
aspects of the molecular structure.  This is where the fundamental difference between SARs and 
QSARs lies. The Q in QSAR refers to the way the molecular structure is quantitatively represented 
by descriptors.  Therefore, the main challenges in QSAR are to find appropriate descriptors to 
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represent the molecular structure and a function that relates the activity to those descriptors.  
The choice of descriptors is not a simple process, since there are thousands available.  These are 
loosely characterized as theoretical, empirical or derived from readily available experimental 
characteristics of the structure40.  A good QSAR will produce an excellent correlation between the 
activity with the molecules used in the training set but should also be able to predict the activity 
of molecules outside that data set.  QSARs can however end up as a futile fitting exercise without 
true predictive power.  Some QSAR models use hundreds of descriptors to predict the required 
activity.  The high correlation between the number of brooding storks and newborn babies in 
West Germany between 1965 and 1980 highlights the potential pitfalls of using the wrong 
descriptors41.  There is a higher probability of accidental correlation the larger the number of 
independent variables in the model.   Furthermore, using a large number of descriptors may 
produce good predictive models but chemical understanding is difficult, and so it is argued that 
the use of fewer descriptors with known physical meanings provides easier interpretation of the 
models and mechanistic insight into the activity that is being predicted.        
 
2.4 Quantum Topological Molecular Similarity (QTMS) 
 
2.4.1 Background 
 
Popelier3 defined a novel similarity measure by utilising information available from QCT.  BCP 
properties for the drug Haloperidol were mapped into abstract space.  The distance     between 
two BCPs i and j is defined as simply their Euclidean distance (Equation 2.13).  Note that here only 
the values of  ,    , and   are used meaning the abstract space has three dimensions. 
 
            
 
        
    
 
        
 
 
   
 Equation 2.13 
 
 
The distance between two BCPs gives an idea about how similar the different bonds are.  Taking 
this idea further, it is suggested that BCP space can compactly and reliably describe the electronic 
structure of a molecule meaning molecules can be compared for similarity.  The distance        
between two molecules A and B is then defined as the sum of the BCP distance as calculated from 
Equation 2.14.  The lower the value of        , given by Equation 2.14, the more similar the two 
molecules are. 
 
            
      
 Equation 2.14 
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In principle every BCP in molecule A could be compared with every BCP in molecule B under this 
definition.  In the original work, a set of congeneric molecules was used so only corresponding 
BCPs in A and B were compared.  This is a priori matching procedure, but is a natural mode of 
operation for molecules typical for QSAR.  The practical use of this technique was demonstrated 
by reproducing the acidities of two sets of benzoic acids (as expressed via the Hammett equation) 
and at the same time recovering the portion of the molecule responsible for the acidity.  
Following these promising results the method was developed further by O’Brien and Popelier42 
and evolved into what is currently known as QTMS.     
 
2.4.2 QTMS Analysis 
 
 
 
Figure 2.6 summarises the main computational modules involved in a QTMS analysis together 
with the corresponding names of the computer programs that are most commonly used.  The 
details of data generation, machine learning techniques and chemometric analysis applied to 
different data sets are specifically provided in the relevant Chapters.  As with all QSAR studies, the 
first steps are to select the property of interest and a suitable data set.  Young et al.43 have 
highlighted the importance of chemical data curation in the context of QSAR modelling and others 
have demonstrated that the type of chemical descriptors has a much greater influence on the 
prediction performance of QSAR models than the nature of the optimisation techniques44, 45.  
Clearly, small structural errors or wrongly assigned experimental values within the data set can 
lead to significant loss of predictive ability of QSAR models.  Recently, Fourches et al. provided a 
procedure to prepare a data set to be as accurate and consistent as possible46.  The steps include 
removal of inorganics and mixtures, structural conversion and cleaning, normalization of specific 
chemotypes, removal of duplicates and finally manual checking.  Many of the data sets used in 
this work were taken from the literature therefore many of the steps in the outlined procedure 
had already been performed, however manual checking was carried out and errors were 
detected.  The errors and subsequent corrections are discussed in relevant chapters.  
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Figure 2.6.  Chart representing the main modules involved in a QTMS analysis.  The bond text represents the names 
of the programmes used in this work. 
 
The second step in QTMS is the generation of molecular geometries and wave functions.  An 
approximation of the geometry of each molecule is provided by MOLDEN47.  Using the 
programme GAUSSIAN03,48 geometries are optimised at a certain level of theory.  The 
optimization steps are by far the most computationally expensive stage in the QTMS process.  This 
expense is governed by the level of theory selected which can depend on time and computational 
resources available.  The electronic wave function calculated by GAUSSIAN is then passed on to a 
local version of the programme MORPHY9849, which locates the BCPs using a robust algorithm50.  
This yields a property vector for each BCP, providing a discrete “quantum fingerprint” for each 
molecule, when all BCPs appearing in a molecule are combined.  A common skeleton associated 
with each molecule is defined to allow the location of descriptors important to the statistical 
analysis to be indentified in each molecule.  In addition, the common skeleton allows the BCPs in 
one molecule to be mapped onto the BCPs in other molecules.  This is not a fundamental 
requirement of the method, and the constraint of a common skeleton can be relaxed51.  A two-
dimensional data matrix is then constructed to display and allow easy manipulation of the data.  
Usually the first column contains unique identifications (e.g. chemical names) for each molecule in 
the data set.  The second column contains the corresponding activities.  The remaining columns 
contain the BCP properties associated with particular bonds selected from the common skeleton.  
For example, if all eight BCP properties are used to describe the molecules and there are four 
bonds in the common skeleton then each molecule is described by 32 descriptors (8 descriptors 
x4 bonds).  BCP properties are inexpensive to obtain computationally and can be calculated for a 
data set of one hundred compounds on a standard PC in minutes.  The next step is to construct a 
model using a suitable machine learning technique.             
 
2.4.2.1 Partial Least Squares 
 
Projection to latent structures by means of partial least square (PLS)52 is a multivariate linear 
regression technique, which attempts to correlate independent variables with the dependent 
variable of interest.  PLS utilises latent variables (LVs) to reduce the dimensionality of the data set, 
whilst retaining the majority of the variance in the independent variables that describe the 
dependent variable.   LVs are constructed from linear combinations of the original independent 
Data Set 
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variables into a set of new variables, subject to a condition that all newly constructed LVs are 
orthogonal to one another. 
 
                       
                       
                       
 Equation 2.15 
   
Each coefficient,     , represents the contribution of each variable to a particular LV.  The sign of 
the coefficient indicates whether a particular variable makes a positive or negative contribution to 
the LV, and the magnitude of the coefficient shows how much the variable contributes to the LV.  
LVs are constructed in such a manner that the first extracted variable explains the maximum 
variance in the data set.  The second variable then explains the maximum part of the remaining 
variance in the data set and so on.  The maximum number of LVs can never exceed the smaller of 
the number of descriptors or compounds used to construct the model.  The LVs are then 
combined in a linear fashion to correlate with the variable of interest creating a model. 
 
                     Equation 2.16 
     
 
PLS may seem very similar to principal component regression (PCR), which involves principal 
component analysis (PCA) followed by multilinear regression (MLR).  They differ in that the PLS 
algorithm is actually an iterative procedure53.   Unlike, PCR, where PCA takes place followed by 
regression analysis, LVs are constructed so as to maximize their correlation with the dependent 
variables and LVs will only enter the PLS equation in the order, one, two, three etc.  The main 
advantage of PLS over PCR is its ability to handle cases where the number of independent 
descriptors greatly exceeds the number of dependent variables.  It is also capable of handling 
large numbers of noisy, incomplete, and collinear descriptors in a data set.       
 
2.4.2.2 Parameters to Assess the Quality of the Model 
 
In this work, PLS models have been constructed using the programme SIMCA-P54 to fit the 
descriptors to the experimental values of interest.  The predefined criterion for determining the 
significant number of LVs was used.  If the value of    (Equation 2.21) of the newly constructed LV 
is less than 0.097, then that LV is not considered significant, and no more LVs are computed; the 
PLS regression is then deemed complete.  The construction of models using SIMCA-P provides 
three statistics (i.e.   ,    and RMSEE) to give an indication of goodness-of-fit and goodness-of 
prediction.  We provide a general overview of these statistics here.  The uses of statistical 
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measure are explicitly stated in each Chapter, where applicable.   The first statistic is the squared 
correlation coefficient (  ), 
 
    
             
  
   
            
  
   
 Equation 2.17 
 
where n is the number of observations in the entire data set,         is the calculated value for 
molecule i from the regression equation,        is the corresponding experimental value, and   is 
the mean experimental value of the entire data set.     can take the value of 0, where the PLS 
model is explaining none of the variance up to 1 where the regression explains all of the variance.  
The Root Mean Squared Error of Estimation (RMSEE) is calculated as, 
 
        
                  
  
   
     
 Equation 2.18 
 
where n is the number of observations in the entire data set and a is the number of LVs used to 
construct the PLS model.
  
Another common error measure is the Root Mean Squared Error (RMSE), which is defined as, 
       
                  
  
   
   
 Equation 2.19 
 
In an alternative expression sometimes encountered in the literature the denominator in the 
RMSE equation is sometimes set to  .  Because the denominator of the RMSEE is always smaller 
than that of RMSE, RMSEE is always larger then RMSE.  Hence, RMSEE penalises the deviation 
between observed and calculated data more than RMSE, and is therefore a more severe error 
measure.  In turn, the RMSE is more severe than the Mean Absolute Error (MAE), which is given 
by, 
     
                 
 
   
 
 Equation 2.20 
 
In summary, the RMSEE is always larger than the RMSE, which is in turn always larger than the 
MAE, or RMSEE > RMSE > MAE.  This is important to keep in mind when comparing results to the 
literature, where RMSE and MAE frequently appear.  The MAE is also less sensitive to larger 
outliers than both the RMSE and RMSEE since all the individual differences are weighted equally 
in the average.  For the RMSE and RMSEE, the errors are squared before they are averaged. This 
means that these two measures give a relatively higher weight to large errors compared to the 
MAE.   
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It should be noted, however, that high values of    and low error values do not always indicate a 
predictive model, and can be quite misleading.   The statistic    is employed in conjunction with 
   which provides an indication of the predictive ability of the model.
  
Using K-fold Cross-
Validation (CV), this cross-validated    is calculated as 
 
      
                  
  
   
            
  
   
 Equation 2.21 
 
In K-fold CV the original set is partitioned in K CV subsets. The default setting for K in SIMCA-P is 
exactly seven, provided there are more than 7 data points in the total data set.  Hence, if the total 
number of compounds   is divisible by 7 then there are n/7 compounds in each of the 7 CV 
subsets. If   is not divisible by 7 then the remaining compounds will be evenly distributed over 
the 7 CV subsets (note that the number of subsets does not vary). The compounds in the first CV 
subset are predicted from a model constructed from the remaining six CV subsets, all combined in 
one training set. The compounds in the second CV subset are then predicted from a different 
model, now constructed from the new remaining six CV subsets, excluding the second CV subset. 
Again these six subsets are all combined in one (new) training set. This process is repeated for the 
third and higher CV subsets, until each compound has been excluded exactly once. Each 
compound will then have been predicted by its corresponding training set. The predicted pKa 
value for compound  , denoted by        , is obtained from the regression equation constructed 
from each training set.  The automatically generated    is based on ‘leave-one-seventh’ of the 
data out rather than ‘leave-one-out’, which is not recommended because of its known pitfalls34, 55.  
However, if the model is constructed from seven or less compounds then the CV is ‘leave-one-
out’.  The default ‘leave-one-seventh’ CV can be altered at the discretion of the user in the newer 
version of SIMCA-P.  One may question if the use of CV is justified against an assessment based on 
splitting data sets into a training and test set. Hawkins et al. recommend that, when the data set 
is small, then CV may be better than splitting the data set56.  The majority of the data sets used to 
create models in this work are small in the sense of Hawkins et al. who advocates CV when the 
data set is less than 100 compounds. 
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A useful statistics which are not automatically provided when models are constructed in SIMCA-P 
is given below.  The Root Mean Square Error of Prediction (RMSEP) is provided by  
 
        
                  
  
   
 
 Equation 2.22 
 
and differs from the RMSEE, looking at the numerator, because          is obtained from the 
models constructed from the training set during CV.  
 
2.4.2.3 Further  Considerations 
 
As with any data analysis, PLS models work best when the data is relatively symmetrical in its 
distribution.   If the observations lie in two distinct clusters in the y-variable, then an artificially 
good QSAR may be obtained that predicts well when the observations lie within one cluster but 
poorly if it lies in between.  An observed versus predicted plot gives insight into the distribution of 
the data so the problem can be avoided. 
 
PLS analysis provides a number of ways to identify data points with large residual errors.  The 
easiest way to identify outliers is to examine the observed versus predicted plot.  Observations 
that do not seem to fit the trend should be inspected.  This can lead to the identification of errors 
in the calculations of descriptors, which can easily be rectified.  If no errors are obvious then 
major structural or mechanistic differences relative to the rest of the data set may be responsible 
and the observation may be excluded.  If there are a number of observations that have to be 
excluded for the same reason then the use of more local models may be more appropriate. 
 
As with all regression techniques, there is a desire to reduce the number of variables used to 
construct models with the aim of improving the models predictions, reducing the number of 
calculations, and simplifying the interpretability and understanding of the models.  SIMCA-P 
provides VIP (variable importance in the projection) values, which offer a concise summary of the 
importance of each descriptor.  VIP plots can be examined and descriptor variables with a VIP 
value less than unity are considered unimportant to the model and can be removed52.  Other 
variable reduction techniques can be employed and these are discussed in subsequent chapters.  
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2.4.3   Applications of QTMS 
 
The applications of QTMS have been numerous.  The exact implementations of QTMS have varied 
over the years but, almost without exception, they follow the procedure in Figure 2.6.  After the 
incorporation of a firm statistical framework, the results of the study on para-benzoic acids 
presented in Section 2.4.1 were confirmed by  more rigorous statistical treatment, which included 
CV and randomisation of the y-variable23.    Popelier et al.51 showed that the one-to-one mapping 
between molecules in less congeneric series of molecules can be achieved.  Para- and meta-
benzoic acids were combined to model Hammet ς constants.  Furthermore, with a small 
modification para-substituted phenylacetic acids were added to the set.   
 
In further extensions to the QTMS methodology, VIP plots were introduced to highlight the bonds 
that appeared to contribute the most to the activity.  Consistently, the bonds with the highest VIP 
values were associated with the mode of activity for the data set under investigation.  For 
example, QTMS highlighted the bonds of the carboxylic group in carboxylic acids, the O-H bond in 
phenols, and the C-N bond in anilines as the most important to the prediction of pKa 
57.  These 
results are consistent with the mechanism of dissociation for the acids.  The ‘active centre’, 
highlighted by VIP plots, has also been shown to correctly move around in a data set of para-
substituted phenols depending on the activity or property being predicted.  Without any prior 
knowledge of the systems or mechanism of action, QTMS is able to reproduce the property of 
interest.  QTMS was used to predict the mutagenic potency for a set of triazenes with two 
proposed mechanisms for their metabolism to genotoxic metabolites58.  The study suggested a 
preferred mechanism; something which has yet to be confirmed experimentally.  However, if this 
information is known, then the common skeleton can, in the first instance, be reduced to the 
bonds that are expected important reducing the number of descriptors.    Ideally, the active 
centre is well localised, but there have been cases where it is turns out to be rather diffuse or 
“contaminated” with bonds one would not associate with the activity59.  No systematic 
investigation into this contamination has been performed however, this issue is revisited in 
Chapter 4. 
 
The QTMS method is closely related to another technique known as StruQT60.  This method has 
been used to predict wavelengths of the lowest UV transitions for a set of anthocyanidins and to 
distinguish between reaction pathways for the electrophilic addition of hydrochloric acid to 
propene61.  StruQT has been combined with inductive logic programming to include background 
knowledge and remove the need for molecular alignment62.  This method was tested on a large 
set of mutagenic compounds but only produced slightly better results than the original StruQT 
analysis. 
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Over the years, QTMS methods have produced excellent results of relevance to biology58, 63, 
medicinal51, 59, 64, 65, environmental66, industrial and physical organic chemistry60, 61, 67, 68.  In all 
cases the models had excellent validation statistics and also provided information about the 
active centre or region of the compounds thought to be important to the activity.  From the 
aforementioned QTMS publications it has become clear that QTMS descriptors are effective at 
capturing electronic effects.  Therefore we deduce that when QTMS fails, electronic effects are 
not as important to the predicted property or activity as, for example, solubility or steric effects.  
This was the case for the predictive QSAR models of phenols65 where LopP was introduced to 
describe the importance of hydrophobicity for hepatocyte toxicity prediction in conjunction with 
QTMS descriptors capturing the important electronic effects.  A lipophilicity descriptor, logKo/w, 
also had to be introduced to predict the toxicity of aromatic aldehydes69.  The model suggests that 
lipophilicity dominated but electronic factors are also important (this publication is in Appendix 
A).  Another example is the QTMS study70 on a remarkable and unusual set of ortho alkyl 
substituted phenols, known for their cytotoxicity and previously investigated by the Hansch 
group71.  The QTMS results do not support their proposal that a steric factor is important in the 
determination of the cytotoxicity.  In fact, QTMS results suggest no steric contribution 
whatsoever. 
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Chapter 3                                                                                                               
pKa Prediction from “Quantum Chemical Topology” 
Descriptors for Carboxylic Acids  
 
3.1 Introduction 
 
The publication relating to the work in this Chapter is provided in Appendix A. 
 
In chemistry and biochemistry, the acid dissociation constant, the acidity constant, or the acid-
ionization constant (  ) is a specific type of equilibrium constant that indicates the extent of 
dissociation of hydronium ions from an acid, which is represented by 
 
  
                 
 
      
 
     
 
     
where 
   
    
      
    
  
 
As this constant differs for each acid or base, and varies over many degrees of magnitude, it is 
represented by the symbol pKa, where 
 
              
 
In general, a larger value of    (or smaller value of pKa) indicates a stronger acid, since the extent 
of dissociation is large at the same concentration. 
 
The pKa of a compound is an important property in both life sciences and chemistry since the 
propensity of a compound to donate or accept a proton is fundamental to understanding 
chemical and biological processes. As the pKa value of a molecule also determines the amount of 
protonated and deprotonated species at a specific pH, for example at physiological pH, knowing 
the pKa of a molecule gives insight into pharmacokinetic properties.  These properties can be 
strongly effected by pKa, which therefore influences a compound’s ADMET profile.  A drug 
generally has to pass through at least one biomembrane via passive diffusion, or by carrier-
mediated uptake, before it can produce any biological effect.  Neutral molecules are easily 
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absorbed by phospholipid membranes while these lipid bilayers in the cell walls have very low 
permeability for ions and highly polar molecules.  The solubility of charged molecules is 3 to 4 log 
units higher than that of neutral counterparts, whereas the reverse is true for lipophilicity, which 
is 3-4 log units lower if the compound is charged72.  Ionisable groups also affect the ability of 
molecules to interact with biological targets as they can influence binding orientation in protein 
active sites.  Many biological systems also use proton-transfer reactions to communicate between 
the intra- and extracellular media and the rate of the proton-transfer reaction depends, in-part, 
on the pKa values of the species involved
73.  It is estimated that ninety-five percent of medicinal 
compounds are ionisable, to some extent at physiological pH74, while approximately sixty percent 
of drug molecules listed in the World Drug Index can be ionised between pH 2 and 1275.  Beyond 
ADMET profiles, pKa  can be important in drug formulation and chemical synthesis.  The benefit of 
in silico pKa prediction is that physical samples are not needed. Therefore, predictions can 
influence decision-making in a drug development process before expensive and time-consuming 
synthetic work is undertaken.   
 
There are a number of well established experimental techniques76, such as spectroscopy, 
potentiometry, conductometry, competitive reactions and titrometry that can accurately 
determine pKa values for a molecule. However, experimental determinations of the acidity of a 
specific part of a large biological molecule, such as a protein, is not a straightforward task77 and is 
often associated with large uncertainties in the results.  For small molecules, the accuracy of pKa 
measurements can be affected by choice of experimental method, pH meter calibration, 
temperature control, solvent composition and chemical stability78.  The benefits of a technique 
that accurately predicts the dissociation constant without the need for “wet” experiments are 
clear. The chemical industry, in particular the pharmaceutical and agrochemical sectors, screen 
thousands of compounds during the discovery process for many properties simultaneously, 
including the dissociation constant. More efficient techniques are required because of the 
logistics of measuring the pKa values of these compounds.  There are also problems associated 
with certain techniques. For example, high-throughput UV absorption measurements can often 
miss groups not in close proximity to a UV-chromophore79.  
 
pKa estimation continues to receive much attention.  A recent perspective by Lee and Crippen
80 
highlighted the importance of the equilibrium constant and the multitude of methods available 
for predicting pKa values for both proteins and small molecules.  In the context of small molecules 
the methods generally fall into two main categories: (i) predictive models, using a range of 
descriptors and learning methods79, 81-86, and (ii) ab initio quantum chemical methods based on 
different thermodynamic cycles73, 87-92. The first category was reviewed by Lee and Crippen and 
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includes linear free energy relationships and quantitative structure activity/property relationships 
(QSAR/QSPR).  This category of models relies on choosing the right descriptors to model the pKa of 
a particular dataset. Structural, physiochemical, topological, geometrical, constitutional, 
electrostatic, quantum-chemical and thermodynamic descriptors have all been used to predict pKa 
with varying success. Gruber and Buss93 performed semiempirical calculations on some 190 
phenols and carboxylic acids. They used multi-linear regression, with descriptors such as heats of 
formation, molecular orbital energies and charge densities, to produce a three-term equation for 
the benzoic acid derivatives (  =0.67) and a four-term equation for the aliphatic acids (  0.80). 
Citra94 criticized this linear free energy relationship-based approach for lacking scientific bases 
and vast use of correction factors favouring quantum mechanical methods. A three-term equation 
for 57 benzoic acids (        , was reported using a method similar to that of Gruber and Buss. 
Gross and Seybold95 rejected the use of semiempirical methods, instead using density functional 
theory, after a set of survey calculations demonstrated it performed significantly better for the 
descriptors they employed.  After studying phenols they found that atomic charge (  =0.89) and, 
the difference between the HOMO and LUMO energies (  =0.95), correlated with pKa. After 
rejecting the use of ab initio methods as too computationally demanding, Tehan96, 97 and co-
workers produced QSARs for numerous classes of acids and bases using semiempirical 
descriptors. Xing and Glen83 fashioned a novel structure tree representation of atoms to align 
molecules.  Twenty-four atom types and nine group types that were of biological interest were 
used in conjunction with PLS to produce a QSAR for a large set of acids and bases (  =0.93 and 
  =0.85).  Following this procedure, Xing84 and co-workers reduced the number of atom types 
and increased the group types used, also noting that splitting the dataset improved their results. 
The approach introduced by Xing has been taken up by numerous authors82, 86, 98. For example, 
Jelfs et al.79 utilized the tree fingerprint method to develop a prediction method using 
semiempirical chemical properties, such as partial charge and electrophilic superdelocalizability of 
atoms undergoing protonation or deprotonation, to produce an online pKa prediction web-tool at 
Novartis.   
 
In the second category of methods, ab initio quantum chemical methods based on different 
thermodynamic cycles89, 90 have started to receive more attention91, 99.  The method involves 
calculating the standard change in Gibbs energy related to the dissociation of a proton from the 
compound under study in water. The method utilizes gas phase and aqueous phase ab initio 
calculations but depending on the thermodynamic cycle used, involves at least four separate 
geometry optimizations for each prediction.  The choice of thermodynamic cycle, level of theory, 
and solvation model can all affect pKa calculation
100.  Ho and Coote100 suggest that a realistic error 
margin should be in the vicinity of 2 pKa units, including a partial cancellation of errors.  The 
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calculation of pKa based entirely on first principles can be criticised for being too computationally 
demanding as it requires thermodynamic analysis and high levels of theory101.  Pulay et al.102 
produced a number of one-term equations to predict pKa.  These equations rely on entropic 
effects cancelling each other out and use only the enthalpy energy difference between the 
protonated and deprotonated forms, in conjunction with the COSMO continuum solvation 
model103, to describe the solvation.  After an initial investigation using 34 molecules to compare 
methods (B3LYP, OLYP, HF and PW91) and basis sets (3-21G(d) to 6-311++G(3df,3pd)) for 
geometry optimisation and single point energy calculations, they concluded that OLYP/3-21G(d) 
for geometry optimisation, and OLYP/6-311+G** for the energy calculation, were the best 
compromise between computational expense and accuracy101.  Extending the work to a dataset of 
370 different organic acids, including carboxylic acids, phosphonic acids, alcohols, thiols, and 
oximes, they produced linear regression equations for individual classes of compounds with mean 
absolute deviations of 0.4 pKa units
102.  Out of all the commercial packages available for pKa 
prediction, Schrödinger’s Jaguar104 application is the only tool that employs this method.  The 
Jaguar package uses empirical correction terms, where calculated values are fitted to 
experimental values stored in a database, to repair deficiencies in both, the ab initio calculations 
and solvation models.  Namazian77, 105-108 and co-workers used an equation73, 87 that relates the 
standard change of Gibbs energy to the pKa of 66 carboxylic acids.  They achieved an    of 0.81 
and a MAE of 0.48. 
 
Here we evaluate QTMS descriptors in an extension to previous QTMS studies, which have shown 
good predictive ability for pKa 
57, 109.  Adam110 obtained impressive results by incorporating QCT 
into his study.  Using transferability between similar molecules, an idea at the origin of QCT111 
where any molecular property is the sum of the values of the property for the individual 
partitioned atoms , he obtained an    for aliphatic and benzoic acids greater than 0.84, in most 
cases, using the energy of the dissociating proton in solution as the only descriptor. On the other 
hand, QTMS descriptors have been successfully employed for carboxylic acids and anilines57, and 
phenols in aqueous112 and polar solvents109. 
 
Over recent years there have been a number of publications comparing pKa prediction methods. 
Dearden et al.113 compared ten prediction software packages (ADME Boxes114, VCCLAB115, ADMET 
Predictor116, Pipeline Pilot117, SPARC118, Marvin119, QikProp120, ACD/Labs121, Pallas122, ChemSilico 
pKa 
123) using an undivulged test set of 653 molecules and found a package called ADME Boxes to 
be the most accurate judged by    and the mean absolute error (MAE). As Lee and Crippen 
highlighted80, the VCCLAB predictions were actually made by ADME Boxes, since VCCLAB links to 
ADME Boxes to make the predictions.  The differing results for these two packages were 
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attributed to the difference in SMILES handling.  Pharma-algorithms, the company responsible for 
ADME Boxes, has merged with ACD/Labs keeping the ACD/Labs company name.  Therefore, 
VCCLAB now uses ACD/Labs pKa predictions.  The   
 and MAE range for the ten packages were 
0.96 to 0.57, and 0.32 to 1.48, respectively.  This comparison was based on a test set provided by 
ChemSilico. ChemSilico had verified that none of the compounds were part of their training set, 
which was not the case for the other packages.  This may be one of the reasons for ChemSilico 
performing the worst.  Meloun et al.124 used the REGDIA regression diagnostics algorithm, in the 
package S-Plus, to compare the pKa predictions of 64 drug molecules from four packages: 
ACD/Labs, Marvin, Pallas and SPARC. They found that ACD/Labs  achieved the best predictive 
power and the most accurate results.  Balogn et al.125 used 248 drugs, agrochemicals and 
intermediates to compare ACD/Labs, Epik126, Marvin, Pallas and VCCLAB.  It is clear from their 
paper that at the time the predictions were made, VCCLAB was still using ADME Boxes 
predictions.  VCCLAB was found to be the most predictive. However, it was suggested that 
ACD/Labs and Marvin are the most suitable methods for medicinal chemistry as VCCLAB only 
calculates pKa for the most acidic and basic groups.  The   
 and MAE ranged from 0.95 to 0.49, 
and 0.30 to 1.79, respectively. Liao and Nicklaus127 have compared nine programs to predict pKa, 
both commercially available and free. They used 197 pharmaceutical substances with 261 pKa 
values and found ADME Boxes, ACD/Labs and SPARC to rank the highest based on    and MAE.  
The    and MAE for all nine programs ranged from 0.94 to 0.58, and from 0.39 to 1.28, 
respectively.  It is interesting to note that when pKa was predicted for sites for which the 
experimental pKa was determined to be between medicinally more relevant interval of 5.4 to 9.4 
log units, the    ranged from 0.68 to 0.35, and the MAE from 0.45 to 1.04. The relatively poor 
performance of Jaguar128 confirms the discussion above on the second category of methods. The 
Jaguar method uses quantum mechanics to calculate the free energy change in going from the 
protonated to the deprotonated state.  Empirical correction terms are then used to repair 
deficiencies in both the ab initio calculations and the solvent models, which brings the MAE below 
2 pKa units. This error is suggested as satisfactory for this type of methods. 
 
In the past, we tended to utilize the interpretative ability of PLS at the chemometric stage to 
identify the active centre.  While this is a compelling feature of QTMS, we concentrate here on 
highly predictive models for pKa estimation. For this reason, we have used other statistical 
methods, such as support vector machines (SVM) and radial basis function neural networks 
(RBFNN), which yield models that are not so interpretable but possibly more accurate.  We have 
also extensively cross-validated our models and moved away from relying on SIMCA-P for 
validation. The 228 carboxylic acid compounds included in this study is the largest set of 
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compounds investigated with QTMS. This large set of diverse carboxylic acids facilitates the aim of 
extending the domain of applicability and producing more predictive models. 
3.2 Methods and Computational Details 
3.2.1 Data Set 
 
We seek to predict the pKa of molecules or fragments with pharmaceutical relevance. We 
therefore used the dataset of Tehan et al.97, who had previously applied a variety of filters in 
order to remove non-drug like molecules from their dataset. We selected carboxylic acids as 
compounds of interest because we want to apply the QTMS methodology to a large set of diverse 
compounds and extending previous applications of QTMS.  After iodine-containing molecules had 
been removed, since the basis sets were not readily available, our dataset contained 228 
carboxylic acids with a pKa range of 0.51-6.20.  This included 44 meta- and para-substituted 
benzoic acids, 50 ortho-substituted benzoic acids and 134 aliphatic carboxylic acids. The observed 
pKa values for all 228 carboxylic acids are listed in Appendix B. 
3.2.2 Data Generation 
 
The data generation process for QTMS can be found in Chapter 2 and a previous publication23.  In 
short, an approximation of the geometry of each molecule is provided by MOLDEN47. Using the 
programme GAUSSIAN0348 geometries were optimized successively at five different levels of 
theory: AM1, HF/3-21G(d), HF/6-31G(d), B3LYP/6-31+G(d,p) and B3LYP/6-311+G(2d,p). The levels 
are denoted by letters A, B, C, D and E, respectively, for consistency with previous publications. 
The wave function calculated by GAUSSIAN is then passed on to a local version of the programme 
MORPHY9849, which locates the BCPs.  In this study the electron density (), the three eigenvalues  
of the Hessian of the electron density (1, 2 and 3), the two types of kinetic energy (K(r) and G(r)) 
and the equilibrium bond lengths (Re) have been used to describe each BCP.  Since 
2 and  are 
calculated using 1, 2 and 3, we have chosen to exclude the former.  The numbering scheme 
given to atoms in the common skeleton of each molecule is shown in Figure 3.1. This allows the 
location of descriptors important to the statistical analysis to be identified in each molecule. 
Secondly, the scheme allows BCPs in one molecule to be mapped onto corresponding BCPs in 
other molecules. We end up with five data matrices (one for each level of theory) consisting of 
228 observations (i.e. measured pKa values) and 21 descriptors for each observation, that is, 7 
descriptors obtained for each of the three bonds in the common skeleton.   
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Figure 3.1.  Numbering scheme of the common skeleton of the carboxylic acids.   
 
3.2.3 Machine Learning and Chemometric Analysis 
3.2.3.1 Partial Least Squares  
 
Partial least squares (PLS)52 analysis was carried out to fit the BCP descriptor variables to the 
experimental pKa values. The programme SIMCA-P
54 was used along with its predefined criterion 
for determining the significant number of Latent Variables (LVs) to appear in the PLS equation. 
 
First, the initial model is constructed, involving all descriptors at each level of theory. Then the VIP 
plots are examined because they offer a concise summary of the importance of each of the 
descriptors. Descriptor variables with a VIP value less than unity are considered unimportant to 
the model and hence discarded52, 129. The models are then reconstructed with the reduced set of 
variables. We also built models using just the Re of the three bonds in the common skeleton to 
demonstrate that using BCP properties as descriptors provides more information than Re alone.  
As well as producing global models for the carboxylic acids, we repeated the PLS analysis after 
splitting the dataset into aliphatic and benzoic acids, which were further split into meta/para-
substituted and ortho-substituted sets.  Altogether there are three subsets. 
3.2.3.2  Support Vector Machines  
 
Support vector machines (SVM), originally proposed by Vapnik130 to solve pattern recognition 
problems131, were extended in 1996 for linear and nonlinear support vector regression (SVR)132.  
SVM have found numerous applications in chemistry including drug design, QSAR/QSPR, 
chemometrics, sensors, chemical engineering and text mining133. 
 
As with other multivariate statistical methods, the performance of SVM for regression depends on 
the combination of several parameters.  We employed a Gaussian Radial Basis Function kernel for 
SVR because of its effectiveness and speed in the training process134.  This function contains an 
extra parameter γ (a constant) that controls the amplitude of the Gaussian function, thereby 
controlling the generalization ability of the SVM to some extent.  The user-prescribed parameters 
(i.e. γ, ε of the ε-insensitive loss function and capacity parameter C) were chosen based on the 
lowest root mean squared error (RMSE) of the training data. The SVR programmes were written 
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by former group member C.X. Xue in an R-file, based on a script written in the R language for 
SVM, which utilized the e1071 package135. The scripts were compiled using the R 2.5.1 compiler136 
and run on a Pentium D PC with 1GB RAM. 
 
3.2.3.3 Radial Basis Function Neural Networks (RBFNN) 
 
The subject of neural networks is covered in depth in the work by Haykin137 and Gurney138.  The 
theory of RBFNNs as applied to QSARs has been extensively described in the paper of Yao et al.139. 
The training procedure involved the forward subset selection routine, which selected the centres 
for the RBF one at a time and adjusted the weights between the hidden layer and the output layer 
after the addition of each centre, using a least-squares140 solution. One third of the training set 
was randomly selected and ‘held back’ as test data, and training was terminated when the error 
on the test data showed no further improvement. RBFNN training was carried out using a range of 
RBF widths between 0.2 and 5.0 and the width yielding the lowest error on the test set was 
selected. 
3.2.3.4 Comparison of the Methods 
 
To compare these three machine learning methods we used k-fold cross validation (CV), where 
the datasets were divided in 4, 7 (as implemented in SIMCA-P) and 10 CV groups.  The division of 
the datasets was carried out using systematic sampling where the compounds were ordered 
according to their pKa values and assigned to a group accordingly. For example, for 4-fold CV the 
first compound was grouped with the fifth, ninth, thirteenth, etc. In random sampling method, 
the compounds were ordered by random numbers and divided into groups of different sizes 
depending of the k-fold CV being used (e.g. for 10-fold CV for the 50 ortho-substituted benzoic 
acids the first five compounds were group one, the next five group 2 etc.). Each CV group was 
excluded in turn so that each compound was excluded from the training data exactly once, and 
the RMSEP of prediction and    were calculated for the CV group according to Equation 2.22 and 
Equation 2.21, respectively.  The method that produced the lowest RMSEP in conjunction with the 
highest    was considered to be the most accurate. 
 
3.3 Results and Discussion 
3.3.1 Choice of Level of Theory 
 
Table 3.1 shows a summary of the initial PLS analysis at the five different levels of theory for the 
dataset and subsets. At each level, three different models were generated: a bond length only 
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model, a model with bond length involving all BCP descriptors (amounting to 21, which derives 
from 3 bonds and 7 descriptors per bond), and a model including only those descriptors from the 
bond length and BCP descriptor model having a VIP score greater than one. At level A, only a bond 
length model can be generated. This is because semiempirical (AM1) wave functions do not 
contain core densities, which corrupts the topology by affecting the position or even appearance 
of BCPs3, 100. The level A results are rather disappointing compared to the previous QTMS study of 
carboxylic acids57, where an    and    of 0.920 and 0.891 were obtained, respectively, and 
compared to the results in the literature discussed in the introduction earlier.  
 
Table 3.1.  Summary of the initial PLS analysis to determine the level of theory to use for the comparison of learning 
methods
b
.  
                          
  All acids ortho subset para/meta subset aliphatic subset 
Level Descriptors LVa       LV
a       LV
a       LV
a       
A bond lengths 2 0.554 0.537 1 0.733 0.717 1 0.768 0.756 2 0.795 0.767 
B bond lengths 2 0.506 0.484 1 0.741 0.717 1 0.664 0.573 2 0.728 0.693 
 BCP properties 1 0.600 0.595 1 0.761 0.716 1 0.683 0.601 2 0.771 0.731 
 BCP properties (VIP>1) 3 0.638 0.616 1 0.757 0.718 1 0.708 0.651 2 0.726 0.713 
C bond lengths 2 0.593 0.581 1 0.770 0.754 1 0.783 0.758 2 0.729 0.696 
 BCP properties 2 0.660 0.637 1 0.770 0.747 1 0.779 0.750 3 0.805 0.744 
 BCP properties (VIP>1) 2 0.661 0.648 1 0.783 0.763 1 0.779 0.752 4 0.823 0.791 
D bond lengths 2 0.448 0.431 1 0.745 0.728 1 0.720 0.672 2 0.704 0.674 
 BCP properties 6 0.783 0.742 1 0.769 0.752 1 0.759 0.724 5 0.815 0.768 
 BCP properties (VIP>1) 7 0.696 0.646 1 0.794 0.775 1 0.772 0.742 2 0.788 0.758 
E bond lengths 2 0.462 0.446 1 0.767 0.757 1 0.737 0.700 2 0.700 0.672 
 BCP properties 6 0.766 0.731 1 0.767 0.754 1 0.749 0.710 5 0.813 0.763 
 BCP properties (VIP>1) 7 0.728 0.693 1 0.792 0.782 1 0.750 0.712 4 0.808 0.778 
              
 
a Number of latent variables. b The bold text highlights the best models for each set (i.e. all, ortho, para/meta and 
aliphatic) based on the highest   .  
 
Outlier detection was undertaken using the subset models as they were more easily 
distinguishable from correct predictions than in the models containing all the carboxylic acids.  In 
all the para- and meta-substituted models, compound 37 (3,4-diamino-benzoic acid) was always 
an outlier. This compound was one of three zwitterions in the subset including compound 15 (3-
aminobenzoic acid) and 21 (4-aminobenzoic acid).  These compounds were predicted reasonably 
well (observed pKa values of 4.74 and 4.85 and predicted pKa values of 4.14 and 4.82, respectively) 
according to the best para- and meta-substituted model marked in bold in Table 3.1. However, 
compound 37 was predicted consistently poorly (observed pKa of 3.49 and a predicted pKa of 4.62 
according to the same model). The zwitterions were all modelled in their neutral form, which 
sufficed for the monoamino-benzoic acids but was not appropriate for diamino-benzoic acid, 
which was predicted to have a larger pKa value due to the fact that the increased stability in its 
zwitterionic form is not encapsulated in the BCP descriptors.  As in this work, Tehan97 and co-
workers struggled to model this effect and had few problems with the monoamino-benzoic acids. 
In line with Tehan’s approach we omitted 37 as an outlier.  In the ortho-substituted models, two 
compounds were identified as outliers and removed from the models, namely 72 (2,6-
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dihydroxybenzoic acid) and 79 (2-hydroxy-3,5-dinitro-benzoic acid) whose pKa values were 
predicted to be 2.60 and 1.86 compared to observed values of 1.05 and 0.70, respectively. The 
hydroxyl group at the ortho position(s) in these compounds could be held responsible for their 
over prediction because internal hydrogen bonding in the anionic form could increase the stability 
of the ion therefore decreasing their pKa values. This effect is not encapsulated in the BCP 
descriptors and therefore absent from the models. The issue with this reasoning is that there are 
a further 11 compounds in the subset that are hydroxyl-substituted at the 2 position and they are 
predicted well. 
 
Four further compounds were identified as outliers from the aliphatic carboxylic acid models and 
removed. They were 124 (4-[(4-chloro-2-methylphenyl)oxy]butanoic acid), 150 (cyanoacetic acid), 
155 (9-hydroxy-9H-fluorene-9-carboxylic acid/flurenol) and 228 (4-(cyclopropylcarbonyl)-3,5-
dioxocyclohexanecarboxylic acid)). Tehan97 and co-workers brought into question the reliability of 
the observed pKa value of compound 124, with which we concur. Compound 155 (Figure 3.2a) 
was excluded from their model on the basis that the proximity of the carboxyl group to the two 
aromatic rings and the presence of an α-hydroxy group make its pKa difficult to predict. 
Alternatively, the observed pKa is incorrect. We can confirm that it is the observed pKa value that is 
the most likely cause for discrepancy. Our best model predicts the pKa to be 2.87 while the 
experimental value given by Tehan (our source data set) is 1.09.  A different source141 gives the 
observed pKa value of 2.96, which is close to our predicted value and the value predicted by 
ACD/Laboratories142 as 3.04.  Furthermore, there is a similar structure (104, 
hydroxy(diphenyl)acetic acid) in the dataset that has an observed pKa of 3.05 (Figure 3.2b).  A 
literature value for the observed pKa values of these compounds (155 and 104) with their 
respective hydroxyl group removed was found to be 3.61143 for 155 (Figure 3.2c) and 3.9144 for 
104 (Figure 3.2d), a difference of only 0.3 log units. The difference of 1.96 log units (=3.05-1.09) 
between compounds 155 and 104 generated by the addition of a hydroxyl group at the same 
position in each is unlikely when considering the difference is 0.3 log units between the analogous 
compounds, thus further supporting a wrong observed pKa.  No reason for compounds 150 and 
228 being outliers can be offered but they were both excluded. 
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Figure 3.2.  Structures and experimental pKa values for compounds 155 and 104 and their analogues fluorine-9-
carboxylic acid and diphenyacetic acid. 
 
Table 3.2 shows the results of the PLS analysis after the outliers were removed.  Here, one of the 
BCP property models always outperforms the bond length model at each level of theory in terms 
of both    and   . Generally, the models improved when the VIP<1 “cut-off” was used.  After 
considering the    and    for all of the models, we found that level C gave the optimum results 
for the subsets. However, level E gave the best results for a model involving all carboxylic acids, 
although this model is constructed from 6 LVs.   
 
Table 3.2.  Summary of the initial PLS analysis after the outliers had been removed.  
  All acids ortho subset para/meta subset aliphatic subset 
Level Descriptors LV
a
       LV
a
       LV
a
       LV
a
       
A bond lengths 2 0.630 0.612 2 0.797 0.787 1 0.900 0.896 2 0.795 0.748 
B bond lengths 2 0.601 0.581 2 0.838 0.801 1 0.905 0.902 2 0.837 0.828 
 BCP properties 4 0.769 0.730 1 0.837 0.810 1 0.912 0.911 2 0.863 0.852 
 BCP properties (VIP>1) 4 0.764 0.749 1 0.835 0.815 1 0.909 0.908 6 0.895 0.861 
C bond lengths 2 0.696 0.688 1 0.841 0.832 1 0.931 0.929 1 0.875 0.875 
 BCP properties 3 0.802 0.779 1 0.837 0.819 1 0.931 0.928 3 0.897 0.873 
 BCP properties (VIP>1) 2 0.787 0.782 1 0.848 0.836 1 0.933 0.932 4 0.911 0.901 
D bond lengths 2 0.486 0.455 1 0.777 0.762 1 0.912 0.906 3 0.807 0.784 
 BCP properties 6 0.860 0.839 2 0.851 0.813 1 0.923 0.919 3 0.882 0.869 
 BCP properties (VIP>1) 4 0.738 0.689 1 0.842 0.833 1 0.927 0.925 2 0.890 0.881 
E bond lengths 2 0.535 0.498 1 0.803 0.794 2 0.917 0.907 2 0.810 0.788 
 BCP properties 6 0.879 0.844 2 0.866 0.818 1 0.917 0.913 2 0.875 0.858 
 BCP properties (VIP>1) 7 0.845 0.818 1 0.844 0.835 1 0.918 0.913 3 0.897 0.886 
              
  
a Number of latent variables.  b The bold text highlights the best models for each group based on having the highest   . 
  
 
 
Figure 3.3 shows a comparison of the CPU time needed for optimization for nine of the 
compounds (three from each subset) that converged at each level of theory without any restarts 
versus the highest    from each level of theory.  This demonstrates that apart from the models 
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involving all the carboxylic acids, there is no improvement in    above level C despite a significant 
increase in computational expense. Level A and B are inferior in all cases.  At this stage, we are in 
a position to explore different statistical learning methods to predict pKa values based of BCP 
properties.  To test the suitability of Level C in pKa prediction and to examine whether the initial 
results still hold, we carried out the analysis with level C and the more computationally expensive 
level E. 
 
 
Figure 3.3.  Comparison of the CPU times needed to optimize the compounds versus the highest    value at each 
level of theory (A, B, C, D and E). 
 
3.3.2 Comparison of the Statistical Learning Methods 
  
The data for all comparisons in Section 3.3.2 to Section 3.3.5 can be found in Table 3.3.  For each 
learning method, there are four groups of compounds to test: all carboxylic acids, aliphatic acids, 
meta/para- and ortho-substituted acids. There are three different sizes of CV sets for both the 
systematic and random sampling method. This gave 24 values (= 4 groups of compounds  3 CV 
set sizes  2 sampling methods) of    and RMSEP to compare for each learning method employed. 
At level C, SVM gave the lowest RMSEP value 16 times out of 24 comparisons, PLS 7 out of 24 
comparisons, and RBFNN 2 times out of 24 comparisons (the RMSEP for the random sampling 
para/meta 10-fold CV models were identical for PLS and SVM). Again out of 24 comparisons but at 
level E this time, SVM gave the lowest RMSEP 21 times, PLS 3 times and RBFNN 2 times (the 
RMSEP for the systematic sampling para/meta 4-fold CV models and the random sampling 7-fold 
CV models were identical for PLS and SVM). This clearly demonstrates that SVM is superior to 
both PLS and RBFNN, at both levels of theory. 
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Table 3.3.  Summary of the results obtained from the three machine learning methods at level C and E.  The values in 
bold are the lowest RMSEP and the values in italics are the next lowest RMSEP. 
            
   PLS SVM RBFNN 
 
k-fold 
validation set    RMSEP    RMSEP    RMSEP 
Level C         
systematic  4-fold all 0.782 0.422 0.897 0.288 0.878 0.316 
sampling   ortho 0.812 0.408 0.797 0.398 0.746 0.472 
   para/Meta 0.917 0.121 0.915 0.117 0.847 0.147 
   aliphatic 0.893 0.288 0.899 0.28 0.874 0.317 
  7-fold all 0.778 0.424 0.895 0.291 0.927 0.256 
   ortho 0.844 0.361 0.819 0.391 0.774 0.437 
   para/Meta 0.934 0.104 0.915 0.126 0.900 0.129 
   aliphatic 0.920 0.265 0.904 0.27 0.910 0.267 
  10-fold all 0.779 0.420 0.888 0.295 0.884 0.308 
   ortho 0.845 0.355 0.848 0.352 0.832 0.372 
   para/Meta 0.939 0.101 0.942 0.096 0.942 0.107 
   aliphatic 0.905 0.335 0.907 0.262 0.889 0.298 
random 4-fold all 0.775 0.440 0.891 0.295 0.860 0.338 
sampling  ortho 0.836 0.379 0.836 0.378 0.807 0.407 
   para/Meta 0.927 0.120 0.910 0.129 0.235 0.325 
   aliphatic 0.907 0.267 0.900 0.282 0.883 0.305 
  7-fold all 0.778 0.426 0.860 0.290 0.912 0.282 
   ortho 0.801 0.382 0.807 0.395 0.753 0.460 
   para/Meta 0.928 0.112 0.925 0.105 0.789 0.177 
   aliphatic 0.903 0.273 0.915 0.251 0.881 0.308 
  10-fold all 0.778 0.423 0.885 0.300 0.855 0.345 
   ortho 0.827 0.369 0.843 0.352 0.761 0.412 
   para/Meta 0.929 0.097 0.930 0.097 0.878 0.135 
    aliphatic 0.903 0.269 0.911 0.261 0.891 0.295 
Level E           
systematic  4-fold all 0.814 0.391 0.873 0.269 0.849 0.352 
sampling   ortho 0.806 0.417 0.842 0.372 0.690 0.520 
   para/Meta 0.916 0.131 0.916 0.131 0.920 0.126 
   aliphatic 0.875 0.313 0.900 0.275 0.902 0.280 
  7-fold all 0.821 0.375 0.885 0.301 0.907 0.289 
   ortho 0.836 0.370 0.851 0.354 0.852 0.350 
   para/Meta 0.906 0.133 0.913 0.125 0.869 0.159 
   aliphatic 0.894 0.285 0.909 0.263 0.893 0.293 
  10-fold all 0.816 0.377 0.881 0.303 0.859 0.339 
   ortho 0.834 0.371 0.861 0.342 0.749 0.423 
   para/Meta 0.917 0.122 0.919 0.119 0.892 0.146 
   aliphatic 0.883 0.299 0.906 0.262 0.762 0.435 
random 4-fold all 0.787 0.407 0.888 0.298 0.864 0.334 
sampling  ortho 0.825 0.390 0.846 0.366 0.712 0.487 
   para/Meta 0.870 0.160 0.908 0.137 0.760 0.220 
   aliphatic 0.877 0.307 0.901 0.280 0.876 0.314 
  7-fold all 0.814 0.387 0.886 0.289 0.897 0.304 
   ortho 0.879 0.398 0.788 0.405 0.641 0.554 
   para/Meta 0.911 0.129 0.913 0.129 0.848 0.167 
   aliphatic 0.884 0.299 0.905 0.269 0.903 0.279 
  10-fold all 0.814 0.383 0.886 0.299 0.882 0.311 
   ortho 0.879 0.380 0.832 0.368 0.704 0.483 
   para/Meta 0.908 0.119 0.914 0.116 0.853 0.139 
    aliphatic 0.883 0.295 0.904 0.269 0.878 0.312 
         
62 
 
3.3.3 Comparison of the Level of Theory 
 
Comparing the results of each    and RMSEP values obtained at both levels of theory, level C 
produces the highest    46 times out of 72 (=324) comparisons and the lowest RMSEP 45 times 
out of the 72 comparisons, with one value being the same for level C and E. This suggests that 
level C is superior to level E because it has the highest number of higher    and RMSEP values.   
 
3.3.4 Comparison of the Validation Set Selection Method 
 
At each level of theory, there are 36 RMSEP and    values to compare because there are 3 
machine learning methods, 3 values for r in k-fold CV and 4 compound groups (36=334).  At 
level C, there are 24 higher    values for systematic sampling compared to 11 for random 
sampling and 1    value that is the same (36=24+11+1). There are 22 RMSEP values lower for 
systematic sampling compared to 13 lower RMSEP values for random sampling and 1 RMSEP 
value that is the same (36=22+13+1).  At level E, there are 19 higher    values for systematic 
sampling compared to 16 for random sampling and 1    value that is the same (36=19+16+1). 
There are 21 RMSEP values that are lower for systematic sampling compared to 15 values for 
random sampling (36=21+15).  The better results gained from systematic sampling is not 
surprising because this method ensures the maximum value for the denominator in the    
equation. Using systematic sampling means that the most dissimilar compounds in relation to 
their pKa values are excluded and so it is more likely that the training set will contain similar 
compounds to the CV set therefore leading to better predictions145. When random sampling is 
used one cannot ascertain that the CV sets contain all similar compounds in terms of their pKa 
values. Hence, the models are possibly trained using compounds dissimilar to the CV set, which 
can lead to poor prediction statistics. If the CV sets contain similar compounds in terms of their 
pKa values, then this can lead to a small denominator in the   , thus increasing the   
 value. 
 
3.3.5 Comparison of Validation Set Size 
 
With regards to the k-fold validation, 10-fold validation generally provided the highest    and the 
lowest RMSEP values, although this was not always the case. When the difference is calculated 
between the highest and lowest    values for the k-fold CV set size for each subset and each 
method, the mean difference is 0.057 (standard deviation (SD) of 0.127) and 0.039 (SD=0.042) for 
level C and E, respectively. When the same is calculated for the RMSEP values, then the mean 
difference is 0.041 (SD=0.040) and 0.042 (SD=0.042) for level C and E, respectively. When the poor 
result for 4-fold-para/meta-random sampling using RBFNN at level C is omitted, then the mean 
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difference for    is 0.032 (SD=0.025) and the mean value for RMSEP is 0.035 (SD=0.024). The k-
fold CV does give different results but the difference is small. It is not surprising that 10-fold CV 
generally gives the best validation statistics because the smaller the CV groups, the more 
compounds there are to train the models.  What these results do suggest is that the models still 
provide good predictions even when 25% of the compounds are omitted in training when using 4-
fold CV. 
 
3.3.6 Confirmation of Finding Based on Averages  
 
Table 3.4, Figure 3.4 and Figure 3.5 show the results of all the subsets and learning methods when 
the k-fold CV results have been averaged and the results of the subsets and learning methods 
when the sampling methods have been averaged from Table 3.3.  These results confirm what had 
previously been suggested. There is little difference between the CV statistics for the random and 
systematic sampling methods.  Excluding the RBFNN para/meta results at level C, the largest 
difference in    and RMSEP values is 0.021 and 0.029, respectively, for the RBFNN all acid models.  
At level E, the largest difference in    and RMSEP is 0.078 and 0.077, respectively, for the RBFNN 
ortho models. Based on the final average results of the k-fold and sampling methods, it is clear 
that SVM generally gives the best CV statistics.  However, at level C the PLS statistics for the 
para/meta and ortho models provide the highest    value and lowest RMSEP. However, these are 
close to the    value and RMSEP value provided by SVM.  Comparing the “all acid” models and the 
aliphatic models, the    value and RMSEP for SVM are much better than the    and RMSEP for 
PLS.  At level E, SVM provides the highest    and lowest RMSEP in all cases. Although PLS was 
better than SVM in two cases at level C, we chose SVM as the best learning method. This decision 
is based on the fact that, when PLS was superior, the difference between the statistics was small 
and, when SVM was better, then the difference between the statistics was large. Comparing the 
averages of systematic and random sampling for SVM level E only provides better CV statistics for 
the ortho dataset.  The difference between the statistics is small but this may suggest that the 
more expensive level E accounts more for the steric effects than level C in some way. 
 
Improved models were created when the dataset was split into aliphatic and aromatic subsets, 
which were further split into meta/para and ortho-substituted carboxylic acids.  The subset 
models provided significant improvements on the “all acid” model.  The para/meta model was the 
most accurate in prediction, followed by the aliphatic and then the ortho model.  The excellent CV 
results of the para/meta models are not surprising because the pKa difference caused by 
substituent changes can be accurately predicted by the Hammett equation and BCP properties 
display a strong correlation with Hammett’s sigma parameter3.  The lower    value and higher 
RMSEP for the ortho model can be explained in terms of steric effects146.  Whereas the pKa of 
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meta- and para-substituted carboxylic acids is affected mainly by inductive and resonance 
contributions, the pKa of ortho-substituted carboxylic acids is highly sensitive to steric 
contributions. Primary steric hindrance to deprotonation is important where there are bulky 
groups around the acidic centre.  Secondary steric effects may either be acid-weakening (if there 
is steric hindrance to solvation), or acid-strengthening (if there is steric inhibition of resonance in 
the neutral molecule).  We have already stated that when QTMS fails, one can be certain that 
steric effects are very important.  Since the BCP properties do not account for steric effects, we 
can be confident that this is the reason for the poorer results.  Since the results of the aliphatic 
subset are an improvement on the ortho subset, the steric effects must be less important for the 
former subset (Table 3.4). 
 
Table 3.4.   Average values of the results from Table 3.3. 
   PLS SVM RBFNN 
   set    RMSEP    RMSEP    RMSEP 
Level C        
systematic sampling all 0.780 0.422 0.893 0.291 0.897 0.293 
   ortho 0.834 0.375 0.821 0.380 0.784 0.427 
   para/Meta 0.930 0.109 0.924 0.113 0.896 0.128 
   aliphatic 0.906 0.296 0.903 0.271 0.891 0.294 
random sampling all 0.777 0.430 0.879 0.295 0.875 0.322 
   ortho 0.821 0.377 0.829 0.375 0.774 0.426 
   para/Meta 0.928 0.110 0.922 0.110 0.634 0.212 
   aliphatic 0.904 0.270 0.909 0.265 0.885 0.303 
average of systematic  all 0.778 0.426 0.886 0.293 0.886 0.307 
and random sampling ortho 0.828 0.376 0.825 0.378 0.779 0.427 
   para/Meta 0.929 0.109 0.923 0.112 0.765 0.170 
    aliphatic 0.905 0.283 0.906 0.268 0.888 0.298 
Level E           
systematic sampling all 0.817 0.381 0.880 0.291 0.872 0.327 
   ortho 0.825 0.386 0.851 0.356 0.763 0.431 
   para/Meta 0.913 0.129 0.916 0.125 0.893 0.144 
   aliphatic 0.884 0.299 0.905 0.267 0.852 0.336 
random sampling all 0.805 0.392 0.887 0.295 0.881 0.316 
   ortho 0.861 0.389 0.822 0.380 0.686 0.508 
   para/Meta 0.896 0.136 0.912 0.127 0.820 0.176 
   aliphatic 0.881 0.300 0.903 0.273 0.886 0.301 
average of systematic  all 0.811 0.387 0.883 0.293 0.876 0.322 
and random sampling ortho 0.843 0.388 0.837 0.368 0.724 0.469 
   para/Meta 0.905 0.132 0.914 0.126 0.857 0.160 
    aliphatic 0.883 0.300 0.904 0.270 0.869 0.319 
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Figure 3.4.  A graphical representation of Table 3.4 for level C.  The bar charts represent the RMSEP, and the lines 
represent the    values obtained. 
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Figure 3.5.  A graphical representation of Table 3.4 for level E.  The bar charts represent the RMSEP, and the lines 
represent the    values obtained. 
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3.3.7 Comparison to pKa Prediction Software 
 
To compare pKa prediction by the QTMS method with available (commercial) software, we have 
used the methods provided by a number of organizations, namely  ACD/Labs’ pKa DB
142, the 
SPARC147 online calculator (SPARC Performs Automated Reasoning in Chemistry), VCCLAB’s web-
based ALOGPS 2.1 program148, and ChemAxon’s pKa Plugin
149 for the Marvin software package. 
Recently, it was stated that the web-version of the SPARC performs 50,000-100,000 calculations 
per month124.  Each software package enables the user to input the structures in SMILES 
format150. 
   
We removed each of the compounds in turn from the global and subset carboxylic acid models 
built using PLS, SVM and RBFNN, for both level C and E and rebuilt the models using the new 
model to predict the pKa of the compound omitted
85. Using this method, we acknowledge that the 
compounds are not an external test set (e.g. they have been used for initial variable and 
parameter selection in some cases) nor can we be sure that they have not been used to train the 
packages we investigated.  Table 3.5 gives the RMSEP for the methods based on leave-one-out.  
The RMSEP obtained from testing the alternative computer programs are also given in Table 3.5.  
These results confirm that SVM provides the best models to predict pKa.  The SVM models have 
the lowest RMSEP in all the LOO cases apart from the level C ortho and para/meta carboxylic acid 
models, where the PLS models have the lowest RMSEP of 0.388 for the ortho model and 0.121 for 
the para/meta model, compared to 0.407 and 0.123 for the SVM models, respectively. Comparing 
levels of theory confirms that level C is the best as it generally provides the lowest RMSEP for the 
models.  There are some exceptions to this. For example, the ortho model at level E, using SVM 
has an RMSEP of 0.367 compared to 0.407 for level C.  Where level E provides a lower RMSEP the 
largest difference observed in RMSEP between level C and E is 0.04 for the SVM ortho models and 
the PLS all carboxylic acid models.  In fact, the difference between the models at the different 
levels judged by RMSEP (based on LOO) is negligible when considering the large increase in CPU 
time needed to optimize the compounds at level E (See Figure 3.3). 
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Table 3.5.  The RMSEP for the three learning methods based on leave-one-out.  The RMSEP for the commercial 
computer programmes are given at the bottom of the table. 
  RMSEP 
 method PLS SVM RBFNN 
 Level C    
 QTMS (all) 
0.427 0.293 0.363 
 QTMS (subset avg.) 
0.285 0.276 0.321 
 QTMS ortho subset 
0.388 0.407 0.477 
 QTMS para/meta subset 
0.121 0.123 0.138 
 QTMS aliphatic subset 
0.278 0.252 0.291 
 Level E    
 QTMS (all) 
0.396 0.301 0.323 
 QTMS (subset avg.) 
0.311 0.278 0.323 
 QTMS ortho subset 
0.407 0.367 0.486 
 QTMS para/meta subset 
0.136 0.131 0.168 
 QTMS aliphatic subset 
0.313 0.276 0.285 
 Compared software/tools RMSE   
 ACD/Laboratories 0.263   
 VCCLAB 0.279   
 SPARC 0.356   
 ChemAxon 0.398   
 
 
 
Figure 3.6.  Comparison between QTMS and other pKa prediction software, based on the RMSEP. 
 
Figure 3.6 graphically compares our QTMS SVM models to the results obtained from the 
commercial predictions.  Recently, Meloun and Bordovská124 have rigorously compared the same 
packages using 64 drugs and other organic molecules with complex and diverse structural 
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patterns.  Although we only base our ranking on the RMSEP, we too found ACD/pKa to be the 
most accurate method. This conclusion contradicts the findings of Dearden et al.113 who 
compared ten prediction tools using a test set of 653 compounds. They found that ACD/pKa  was 
the least accurate out of the four programs we investigated, with and without inclusion of 
tautomeric compounds. The other three programs were ordered in the same way as in our study: 
VCCLAB being the most accurate followed by SPARC and then ChemAxon.  Apart from ACD/Labs, 
which is consistent across all the subsets, the other methods vary in their prediction ability. Out of 
all the methods, QTMS has the lowest RMSEP for the para/meta substituted benzoic acids and 
aliphatic carboxylic acids, but has the highest RMSEP for the ortho-substituted benzoic acids. As 
has been previously pointed out59, 70, QTMS fails when steric effects are important, which is the 
case for the ortho substituted benzoic acids. 
3.4 Summary 
 
The results presented in this systematic study indicate that BCP descriptors are effective in 
predicting the pKa of small- to large-sized carboxylic acids of pharmaceutical relevance. 
Furthermore, extensive cross validation shows that there is no need to use the computationally 
more expensive level E when level C provides similar, if not superior, CV statistics.  More 
predictive models were gained from splitting the dataset.  Generally, SVM provides the best 
learning method although the lack of interpretability may mean it is not necessarily the most 
suitable method when mechanistic understanding is important. Finally, we have also 
demonstrated that predictions from our QTMS method compete with frequently used pKa 
prediction tools. 
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Chapter 4                                                                                                                
pKa Prediction from an ab initio Bond Length for Phenols, Benzoic 
Acids and Anilines 
 
4.1 Introduction 
 
QTMS51, 59, 63 is a new approach to solving QSAR/QSPR problems using properties defined by QCT1, 
2, 151.  QCT defines so-called critical points inside a given molecule, where quantum mechanical 
functions such as the electron density are evaluated. These and other values are QTMS 
descriptors. In Chapter 3 and our publication152 we modelled the pKa of 228 carboxylic acids using 
the QTMS methodology, in which equilibrium bond lengths are usually added to the descriptor 
pool152. Indeed, as early as 2002, ab initio equilibrium bond lengths featured in the rationalisation 
of antitumor activity of (E)-1-phenylbut-1-en-3-ones63. Better models were achieved using the 
descriptors defined by QCT than with bond lengths alone.  This has generally been the case in 
previous QTMS studies that predicted pKa and other properties
57, 69, 153, 154.  Superior models were 
achieved when the benzoic acids were split into ortho- and meta-/para-substituted groups.  
However, we believe that if the focus is placed on accuracy rather than globality, which means 
splitting chemical classes beyond the common aliphatic, ortho-, para- and meta-substituted 
groups, then strong correlations between a single ab initio bond length and pKa are achievable, 
without the need for the computation of QCT descriptors. This is the approach and strategy in this 
Chapter.  Furthermore, simple linear equations using just one bond length will be constructed and 
shown to be equal to if not better than using several bond lengths in more sophisticated multi-
term equations. Quantum mechanical methods are becoming standard in computational drug 
design155 and the equations presented here offer a simple and practical way to predict pKa using 
information generated from first principles. 
   
Using the accuracy of first-principle methods, Han and co-workers studied the complete series of 
chlorophenols156.  Using B3LYP/6-311++G(d,p) for geometry optimisation, in conjunction with a 
molecular probe to simulate the acid-base interaction, they found that several molecular 
parameters correlated well with the acidity of the phenols.  They found ammonia to be a better 
molecular probe than water because it is a stronger base and induces larger measurable changes 
in the molecular properties.  The C-O bond length (r(C-O)), O-H bond length (r(O-H)) and O-H…N 
hydrogen bond length (r(O-H...N)) all correlated well with the experimental pKa, with correlation 
coefficients (  ) ranging from 0.89 to 0.97 for the phenol-ammonia complexes.    The complete 
series of bromophenols, fluorophenols and hydroxybenzoic acids was also investigated using the 
same methods and similar correlations were noted157, 158.  The authors of these papers 
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demonstrated that weaker correlations were observed with the molecular properties of 
monomeric phenols without using the molecular probe159, 160.  Strong correlations (   > 0.92) were 
also found for aliphatic and carboxylic acids161 with the use of a molecular probe.  These 
correlations demonstrated that specific bond lengths could be used to predict pKa beyond the 
complete series of halogen phenols, although ortho-substituted benzoic acids had to be modelled 
separately and all the benzoic acids were mono-substituted, apart from one compound.  It was 
suggested that bond lengths were more practical to use because the calculation of vibration 
frequencies was computationally more demanding. 
 
Yu et al.162 have recently compared the semiempirical approach to predict pKa, originally purposed 
by Tehan and co-workers97, to ACD/Labs121 and SPARC118.  The semiempirical method performed 
significantly better when the data set was split into compound class-specific subsets. However, 
the overall performance was inferior to both that of ACD/Labs and SPARC.  The authors suggest 
that improvements may be possible using higher-level quantum chemical methods to calculate 
the descriptors and the exploration of other quantum chemical parameters.      
   
With the end-user in mind, we will demonstrate that the required accuracy in pKa prediction can 
be achieved with a relatively low level of ab initio theory.  This offers the opportunity for pKa 
predictions of large data sets within an acceptable time.  A comparison with previous work will 
show that the use of the probe molecule is unnecessary.  The correlations are generated for 
phenols, carboxylic acids, and anilines, and subsequently used to predict the pKa values of drug 
molecules. The advantage of single-term linear regression equations over multi-term equations 
will also be discussed.  One advantage is the easier detection of outliers, allowing that the 
experimental data can be challenged. A second advantage is a reduced potential of over-fitting.  
Finally, we will describe a procedure that can be followed to predict pKa. While this work is limited 
to three classes of compounds, the procedure is expected to be generic and hence applicable to a 
diverse range of compounds.  
 
4.2 Methods and Computational Detail 
 
4.2.1 Data Sets 
 
Table 4.1 provides the constitution of the data sets for the phenols, benzoic acids and anilines.  
The experimental pKa values for the phenols and benzoic acids were taken from a paper by Tehan 
et al.97 while the anilines’ experimental pKa values were taken another paper
96 by Tehan et al., 
unless otherwise stated. These authors had previously applied a variety of filters in order to 
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remove non-druglike molecules.  Where we have used other sources for experimental pKa values 
to correct experimental values from our original data source, expanded the data set or tested our 
models, we explicitly highlight these occurrences in the text. The experimental pKa values are 
listed in Appendix C with the corresponding chemical name and the identification numbers used 
in this Chapter.   
 
Table 4.1.  A summary of the data sets investigated.   
Compound Class  # of compounds 
Phenols  171 
 Meta/Para
a 55 
 Ortho
b 90 
 Ortho, capable of forming Internal 
Hydrogen Bonds (ortho-phenols-IHB)c 
26 
Benzoic Acids  94 
 Meta/Para
d 44 
 Ortho
e 50 
Anilines  52 
 Meta/Para
f 24 
 Ortho
g 28 
 
a Two iodine containing compounds removed (4-iodophenol (compound 35) and 3-iodophenol (compound 
50).  4-hydroxyacetophenone (compound 58) was also removed since the CAS number and name provided 
did not match, therefore causing ambiguity. The name given was hydroxyacetophenone whilst the CAS 
number relates to 4-hydroxyphenylacetaldehyde. The experimental pKa quoted is 8.05, which is the same as 
that of 4-hydroxyacetophenone (compound 12).  
b One iodine containing compound removed 2-iodophenol (compound 134).  2-methyl-4-chlorophenol 
(compound 90) corrected since the name and CAS number provided did not match.  The name provided for 
compound 90 was already in the dataset (compound 174) so the CAS number was trusted and the structure 
corrected to 2-chloro-4-methylphenol.  
c The name provided for compound 83 was incorrect and was corrected to 3,5-4’-trichloro-2’-nitro 
salicylanilide. 
d Two iodine containing compounds removed (3-iodobenzoic acid (compound 207) and 4-iodobenzoic acid 
(compound 212)).   
e Three iodine containing compounds removed (2-iodobenzoic acid (compound 233), 2-hydroxy-5-iodo-
benzoic acid (compound 247) and 3,5-diiodosalicylic acid (compound 249)) . 
f Two iodine containing compounds (3-iodoaniline (compound 297) and 4-iodoaniline (compound 298)) 
were removed.  The macro pKa value (3.07) for 3-aminobenzoic acid (compound 275) was provided in the 
original data set.  The micro pKa value (4.53) was found in the literature
72 and  subsequently adopted.  
g  One iodine-containing compound removed (2-iodoaniline (compound 325)). 
 
4.2.2 Data Generation and Analysis 
 
The phenols, benzoic acids and anilines were treated separately.  The discussion below provides a 
general overview of the data generation and analysis.  More details about the exact analysis of 
each data set are given in the results (Section 4.3).   An initial guess of the geometry of each 
compound was provided by MOLDEN47.  Using the programme GAUSSIAN0348, geometries were 
optimised at HF/6-31G(d) level.  The bond lengths of interest  were then extracted and a PLS52 
analysis was carried out to fit the bond lengths to the experimental pKa values. SIMCA-P
54 was 
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used for the majority of the data analysis.  Models using all the bond lengths of interest were 
initially created using the predefined criterion for determining the significant number of Latent 
Variables (LVs) to appear in the PLS equation.  If the value of    of the newly constructed LV is less 
than 0.097, then no more LVs are computed; the PLS regression is then deemed complete.  
Separate models were also created for the ortho-, para- and meta-substituted compounds.  
Variable Important in the Projection (VIP) plots for the models were subsequently examined.  VIP 
plots provide a condensed summary of the relative importance of each variable to the model, in 
this case the contribution of specific bond lengths.  The bond lengths that contributed the most to 
the models were then used to construct one-term bond length models for the compound classes 
and the results analysed.  Attempts were then made to separate these models into chemically 
meaningful groups of compounds where one common bond length showed high correlation with 
the experimental pKa values.  We refer to these groups of compounds as high-correlation subsets.  
Through the analysis of the single-bond-length equations, the influence of conformation was 
investigated.  Outliers and errors were detected and where possible corrected.  Higher levels of 
ab initio theory were examined and comparisons of the results with and without an ammonia 
probe were made for a selection of the high-correlation subsets.  The predictions made from the 
high-correlation subsets were compared to the predictions made from models constructed using 
all the bond lengths and more diverse training sets.  Models were validated using leave-many-out 
and compared using a variety of statistics discussed in Section 4.2.3 below.  Finally, we tested the 
power of these models to predict the pKa of drug molecules
127. 
 
4.2.3 Statistics 
 
In this work we report   , RMSEE and    values for the constructed models. We assess our 
models by means of RMSEE, which is the strictest criterion of quality, both in terms of outlier 
assessment and the series of inequalities mentioned in Chapter 2. We base our comparisons on 
RMSEE and use this as a guide to indicate which models should be cross validated.  We only 
performed full k-fold CV on the most promising models.  In the current work k is set to exactly 
seven throughout, provided there are more than 7 data points in the total data set.  
   
One may question whether the use of CV is justified against an assessment based on splitting the 
data set into a training and test set. Hawkins et al.56 recommend that, when the data set is small, 
then CV may be better than splitting the data set into training and test sets. The high-correlation 
subsets we use to create models are small in the sense of Hawkins et al. who advocate CV when 
the data set contains less than 100 compounds. CV should involve using a suitable variable 
selection technique to select the variables important to the training set, each time a CV subset is 
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excluded. This procedure renders a ‘true   ’ rather than a ‘naïve   ’, where variable selection is 
not performed each time a CV subset is removed. Below we argue that our assessment procedure 
is generating a true   . Essentially, the main argument is that variable selection does not apply to 
our way of setting up a model. This is because we only consider either an all-bond-length model 
or a single-bond-length model. The latter type of model was based on the most important 
variable in the VIP plot of the all-bond-length model.   During the CV of the all-bond-length model, 
the VIP plots for the seven models created in CV were monitored and in the vast majority of 
cases, the most important bond length remained the same for all the models. Furthermore, 
SIMCA-P automatically selects the number of LVs to construct the all-bond-length models.  
Because a new model is constructed for each of the seven training sets, variable selection is 
performed by default.  For these reasons we consider the    value quoted to be the ‘true   ’.  By 
default, SIMCA-P automatically produces a    value when models are constructed.   
 
CV also provides a means to calculate the RMSEP (Equation 2.22) for the cross-validated models.  
The squared correlation coefficient also obtained through CV and denoted by    
 , which is not be 
confused with   , is calculated as, 
   
   
             
  
   
            
  
   
 Equation 4.1 
 
where the variables have already been explained. 
 
We also use a further metric denoted as   
 , which is calculated as, 
  
      
         
        
   Equation 4.2 
 
Here,    
  and      
  are the squared correlation coefficient values between the observed (X-
variable) and predicted (Y-variable) pKa values, obtained through CV, with intercept not set to 
zero and set to zero, respectively. 
   
A high    
  value does not necessarily indicate that the predicted values are very close to the 
experimental values.  There may be considerable numerical differences between the observed 
and predicted values in spite of the presence of a good overall correlation.  When this is the case 
there will be substantial differences between    
  and      
 , which the   
  statistic penalises 
heavily.  Mitra et al.154 have shown that in the case of small data sets,   
  calculated from a CV 
when variable selection is performed at each CV step, reflects the external validation 
characteristics of the developed model.  Based on the reasoning above about ‘true   ’ we believe 
that our quoted   
  values are ‘true                           
 ’.  Ultimately, we judge the 
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performance of the models based on RMSEP. However, we stress that RMSEE is used to decide 
which models to perform full CV on. 
4.3 Results 
4.3.1 Phenols 
 
Figure 4.1 shows the common skeleton and bonds screened to predict the pKa of the phenol 
compounds (Table 4.1).  In previous QTMS studies, conformation has not been taken into account 
with the knowledge that the substitution effects have a greater influence on the models.  We 
show that conformation is important in some cases (discussed later).  We initially investigated the 
use of the 8 phenol bond lengths of the common skeleton in order to model all the phenol 
compounds together and the common groupings of ortho, meta/para  and ortho-phenols that we 
deemed capable of forming internal hydrogen bonds97.  During the course of this work, suspected 
errors in the initial dataset were corrected and the importance of conformation was examined. 
 
 
Figure 4.1.  The eight bond lengths used to predict the pKa of the phenol compounds.  The main text refers to bond 
lengths 1-7 and 7-8 as r(C-O) and r(O-H), respectively. Reference to other bonds makes use of this numbering scheme 
to distinguish between the C-C bonds, e.g. r(C1-C2). 
 
Inspection of the VIP plot modelling all the phenol compounds showed that r(C-O) and r(O-H) 
contributed most to the model.  Therefore, these bonds were monitored to see if they could 
model the 171 phenol compounds individually (Table 4.2), in line with our motivation discussed in 
the Introduction.  The    decreased and the RMSEE increased when these two bond lengths were 
used individually.  The reduction in the quality of the model was less for r(C-O) on its own than for 
r(O-H) on its own.  We determined what influence splitting the data set into meta-/para- and 
ortho-substituted phenols (common for compounds of this type) had on the quality of the 
models.  The RMSEE for the model constructed using all the bond lengths for meta-/para-
substituted phenols decreased by approximately 50% but the RMSEE for the ortho-substituted 
phenols increased.  The reduction in the quality of the models of the meta-/para-substituted 
phenols when using r(C-O) on its own or r(O-H) on its own is also small compared to the all-bond-
length model.  This suggests that the meta-/para-substituted phenols can be modelled using just 
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one bond length. The RMSEE for the ortho-substituted model increased when using r(C-O) on its 
own or r(O-H) on its own. This is not surprising since different ortho-substituents can affect the 
pKa of compounds because of their close proximity to the acidic hydrogen.  These effects include 
steric hindrance to protonation or deprotonation and internal hydrogen bonding. 
 
To investigate the large deterioration of the ortho-substituted phenol model, when using all the 
bond lengths compared to using just r(C-O) or r(O-H) on their own, we inspected the predicted  
versus observed pKa plots. Figure 4.2a shows such a plot for all 171 phenols using a regression 
model using only r(C-O). Inspection of Figure 4.2a suggests subsets of phenols that have a higher 
   value than the full set of 171 phenols. It was rewarding to find that such high-correlation 
subsets, identified by eye, later turned out to be meaningful chemical subsets. For example, in 
Figure 4.2b it is clear that o-halogen phenols (shown in dark blue) and o-nitro (shown in light blue) 
phenols are separate high-correlation subsets.  This was seen for other o-phenols depending on 
the o-substituent.  It appeared that meta-/para-phenols were a high-correlation subset 
irrespective of the different substituents.  A number of compounds appeared to be outliers from 
the high-correlation subset to which they would have been expected to belong to.  An example of 
this is shown in Figure 2b for 4,6-dinitro-o-cresol (compound 135).  4,6-dinitro-o-cresol appeared 
to belong to the o-halogen high-correlation subset (dark blue in Figure 4.2b), which was 
inconsistent with the compound’s structure. Inspection of the optimised structures showed that 
this was caused by the anti conformation of the acidic proton being used instead of the syn 
conformation that was found for the other o-nitrophenols.  When this compound was optimised 
as the syn conformer, it correctly moved into the o-nitrophenol high-correlation subset (light blue 
in Figure 4.2b).  This example illustrates the situation for a number of other compounds that 
appeared to belong to high-correlation subsets different to the chemically meaningful subsets we 
had identified. All the ortho-phenols were subsequently optimised in the syn and anti form and 
the energies were used as a guide to decide which high-correlation subset they belonged to.  
Because of symmetry conformation plays no role in di-ortho-substituted phenols with identical 
substituents. However, for the asymmetrical di-ortho-substituted and the mono-ortho-
substituted compounds, the orientation of the acidic hydrogen can have a large influence on bond 
lengths.  The results of the detailed modelling of the o-phenols and identification of high-
correlation subsets are reported in the following section. 
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Table 4.2.  The results of the phenol compounds modelled with the bond lengths calculated at the HF/6-31G(d) level 
of theory. 
 
 
 
 
 
 
 
 
 
 
 
Subsets # LV # Bonds # Compounds       RMSEE 
All 4 All 171 0.92 0.88 0.67 
All 1 r(C-O) 171 0.86 0.85 0.88 
All 1 r(O-H) 171 0.52 0.51 1.62 
Meta/Para 2 All 55 0.91 0.87 0.34 
Meta/Para 1 r(C-O) 55 0.87 0.85 0.41 
Meta/Para 1 r(O-H) 55 0.84 0.83 0.45 
Ortho 4 All 116 0.92 0.86 0.72 
Ortho 1 r(C-O) 116 0.85 0.85 0.99 
Ortho 1 r(O-H) 116 0.47 0.46 1.84 
Ortho without Ortho-IHB 5 All 90 0.94 0.88 0.65 
Ortho without Ortho-IHB 1 r(C-O) 90 0.88 0.87 0.94 
Ortho without Ortho-IHB 1 r(O-H) 90 0.59 0.58 1.72 
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Figure 4.2.  (a)  Plot of predicted vs. observed pKa for the phenols using r(C-O).  (b)  Plot of the predicted vs. observed 
pKa for the phenols using r(C-O) separated by colour into chemically meaningful high-correlation subsets.  The 
different pKa values of 4,6-dinitro-o-cresol calculated from r(C-O) for the syn and anti conformer is highlighted in red 
as an example. 
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4.3.2 Ortho-Phenols 
 
By Inspection of the structures of the compounds belonging to high-correlation subsets and their 
energies, rules were determined based on the o-phenols in the data set to assign the compounds 
to specific o-phenol high-correlation subsets.  These rules were confirmed by the detailed 
investigation of the high-correlation subsets.  In Sections 4.3.2.1 to 4.3.2.6 we discuss the results 
that allowed us to state the rules here.   In the case of the o-phenols it was fortuitous that the 
energies could be used as a guide, without exception. These rules are encapsulated in the flow 
chart below (Figure 4.3) showing which high-correlation subset a phenol of interest should be 
predicted from. 
 
It should be noted that certain phenols can belong to different high-correlation subsets. For 
example, 2-nitro-6-chlorophenol (compound 141) can be predicted by the o-nitro and the o-
halogen models depending on the direction of the acidic hydrogen (i.e. syn and anti). We will 
show that the better prediction is made by the o-nitro model because nitro substituents decrease 
the pKa more than chlorine substituents as the former are more electron-withdrawing. We will 
also show that for meta-/para-substituted phenols the influence of conformation on the quality of 
the models is minimal.  We screened the compounds in search of high-correlation subsets from 
different classes of compounds in the ortho subset, previously (see RMSEE values larger than 0.5 
in Table 4.2) shown to produce poor correlations when modelled together.  We compare all-
bond-length models to single-bond-length models using CV discussed in Section 4.2.3. 
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Figure 4.3.  Flow chart describing which high-correlation subset a new compound should be predicted from. 
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4.3.2.1 o-Nitrophenols 
 
Table 4.3.  The statistical details of the models created for the o-nitrophenols. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF Syn All 4 23 0.97 0.37 0.91 0.65 0.88 0.87 0.79 
HF Syn r(C-O) 1 23 0.91 0.58 0.91 0.58 0.91 0.90 0.82 
HF Syn r(O-H) 1 23 0.85 0.77 0.84 0.78 0.83 0.80 0.70 
HF Syn All 2 22  0.97 0.38 0.93 0.51 0.94 0.94 0.93 
HF Syn r(C-O) 1 22  0.94 0.48 0.94 0.50 0.93 0.93 0.87 
HF Syn r(O-H) 1 22 0.88 0.71 0.87 0.73 0.85 0.84 0.75 
HF Anti All 2 23 0.98 0.33 0.88 0.81 0.82 0.80 0.70 
HF Anti r(C-O) 1 23 0.79 0.90 0.78 0.91 0.77 0.71 0.58 
B3LYP Syn All 2 23 0.94 0.50 0.90 0.61 0.89 0.89 0.82 
B3LYP Syn r(C-O) 1 23 0.91 0.58 0.91 0.59 0.90 0.89 0.81 
 
The results from CV are reported in Table 4.3 to allow comparisons between models.  Inspection 
of the VIP plot for the all-bond model using all the o-nitrophenols revealed that r(C-O) was the 
most important descriptor followed by r(O-H). For this reason we created separate models for 
each of these two bond lengths. Looking at    it is surprising that this value remains high for 
either of the single-bond-length models compared to the all-bond-length model. Inspection of the 
plot showing observed versus predicted pKa values for the single-bond-length models caused 
suspicion about the experimental pKa of 2,3-dinitrophenol (compound 87, experimental pKa given 
as 4.96).  Another source109 quoted the experimental pKa of this compound to be 5.24.  This 
increase in pKa moves it towards a value of approximately 6 log units predicted by our different 
models.  Removal of compound 87 from the fitting procedure improved the model statistics.  
When compound 87 was removed during CV of the all-bond-length model, the resulting model 
used only two LVs compared to the three LVs making up the models with compound 87 included. 
This suggests that the program SIMCA-P had added a LV to fit compound 87. This was not the case 
for the single-bond-length models as the fitting was minimal here.  During CV, the VIP plots of the 
models were inspected when each CV group was removed in turn.  r(C-O) followed by r(O-H) were 
the most important bonds to all the models in CV.  The r(C-O) model, when compound 87 was 
removed, produced the lowest RMSEP (0.50) and a high   
  (0.87).  This was pleasing considering 
only one bond length is used. 
  
Table 4.3 also provides the statistics relating to the models built using anti conformations.  The all-
bond-length model has the highest    value in conjunction with the lowest RMSEE. However, the 
model is shown to be weaker when CV is performed compared to that constructed using the 
lower energy syn conformations.  The r(C-O) model using the anti conformations is also poorer 
than when the syn conformers are used.  The VIP plot for the all-bond-length anti model showed 
r(C-O) to be the most important, however, r(C5-C6) was the next most important and r(O-H) was 
ranked sixth. 
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The use of a higher level of theory, B3LYP/6-311+G(2d,p), did not improve the results (Table 4.3) 
and produced very similar statistics suggesting the more economical HF/6-31G(d) is sufficient.   
This conclusion is supported by a study of 2,4-dinitrophenol where the HF/6-31G(d) level of 
theory performed very well for predicting the geometrical parameters163.  In that work, the HF 
method failed to reproduce the vibration frequency of the O-H bond stretch. However, this is of 
no importance as we only use the bond lengths. 
 
4.3.2.2 o-Halogen Phenols 
 
Table 4.4.  The statistical details of the models created using o-halogen phenols. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF Syn All 1 32 0.75 0.89 0.71 1.05 0.64 0.55 0.45 
HF Syn r(C-O) 1 32 0.88 0.61 0.87 0.62 0.87 0.86 0.79 
HF Syn r(O-H) 1 32 0.63 1.08 0.63 -
a
 - - - 
HF Syn All 2 26 0.95 0.40 0.91 0.44 0.93 0.91 0.81 
HF Syn r(C-O) 1 26 0.97 0.27 0.97 0.29 0.97 0.97 0.94 
HF Syn r(O-H) 1 26 0.60 1.06 0.58 - - - - 
HF Anti All 2 32 0.83 0.74 0.70 - - - - 
HF Anti rC-O) 1 32 0.83 0.72 0.81 - - - - 
HF Anti r(O-H) 1 32 0.61 1.12 0.53 - - - - 
HF Anti All 2 26 0.94 0.40 0.91 0.46 0.92 0.91 0.81 
HF Anti r(C-O) 1 26 0.96 0.35 0.96 0.35 0.95 0.95 0.91 
HF Anti r(O-H) 1 26 0.78 0.79 0.76 - - - - 
B3LYP Syn All 1 32 0.71 0.97 0.65 - - - - 
B3LYP Syn r(C-O) 1 32 0.87 0.64 0.86 - - - - 
B3LYP Syn r(O-H) 1 32 0.52 1.24 0.44 - - - - 
B3LYP Syn All 2 26 0.93 0.46 0.86 0.67 0.83 0.81 0.70 
B3LYP Syn r(C-O) 1 26 0.96 0.32 0.96 0.33 0.96 0.96 0.92 
B3LYP Syn r(O-H) 1 26 0.72 0.89 0.70 - - - - 
a A dash in this Table 4.5 to Table 4.33 indicates that various cross-validation statistics were not collected as 
justified in the main text. 
 
The statistics relating to the o-halogen phenols are given in Table 4.4.  The o-halogen phenols 
were initially modelled as syn conformations.  The models built from all the compounds were 
inspected.  The VIP plot for the all-bond-length model showed r(C-O) was the most important 
followed by r(O-H).  The r(C-O) model gave better statistics than the all-bond-length model.  
Inspection of the observed versus predicted plot for this model revealed six suspicious data 
points.  The structures of the compounds that represent these points are shown in Figure 4.4.  We 
will discuss each outlier in turn starting with 2,4,6-tribromophenol. A different experimental pKa 
of 6.1 for 2,4,6-tribromophenol (compound 120) was found109 instead of the value of 6.8 given in 
the source we used for the experimental pKa values.  The value of 6.1 was much closer to that 
predicted from our correlation and was hence adopted.  
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Figure 4.4.  Structures (and their compound numbers) that belong to the data points that seemed to be outliers in the 
o-halogenphenol models. 
 
Next we explain why 6-chloro-2-nitrophenol (compounds 141) and 6-chloro-2,4-dinitrophenol 
(compound 160) should only be predicted from the o-nitro high-correlation subset model.  We 
note that these compounds have both o-nitro and o-halogen substituents and so the pKa could be 
predicted by either the o-nitro or o-halogen high-correlation subsets.  To obtain a reasonable 
prediction from the latter for compounds 141 and compound 160, we used the conformation in 
which the acidic hydrogen points towards the halogen, which we note is not the lowest energy, 
but is consistent with the conformations used for the other o-halogen phenols.   6-chloro-2,4-
dinitrophenol (compound 160) was predicted reasonably well by the r(C-O) model (experimental 
pKa of 1.6 compared to a predicted pKa of 2.1).  However, 6-chloro-2-nitrophenol (compound 141) 
had an error of 1 pKa.  These two compounds were predicted more accurately by the o-nitro high-
correlation subset, where the acidic hydrogen points towards the nitro groups, which were the 
lowest energy conformations.  From these two compounds, we conclude that phenols with a nitro 
and a halogen substituent in either ortho positions should be predicted from the o-nitro high-
correlation subset and not the o-halogen high-correlation subset. 
  
Pentafluorophenol (compound 156) showed the largest discrepancy between observed and 
predicted pKa.  2-fluorophenol (compound 129) was the only other compound in our data set that 
had an o-fluoro substituent and appeared to belong to the o-halogen high-correlation subset.  It 
was clear that o-chlorophenols and o-bromophenols formed a single high-correlation subset. 
However, because we only had two o-fluorophenols in the dataset it was impossible to establish if 
this class of compounds needed to be modelled separately or if the experimental pKa of 
pentafluorophenol (compound 156) should be challenged.  The experimental value we adopted 
from the work of Tehan et al. was verified against an alternative literature source157, where the 
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same pKa value of 5.53 was used to produce excellent correlations. This check confirmed that the 
experimental value used is accurate. We therefore calculated the bond lengths of a further three 
o-fluorophenols, for which we had experimental pKa values, to verify that they produce a separate 
high-correlation subset. The r(C-O) of 2,4-difluorophenol (compound 330), 2,6-difluorophenol 
(compound 331) and 2,3,5,6-tetrafluorophenol (compound 332) were calculated and the 
correlation between r(C-O) of the five o-fluorophenols  and pKa was checked.   An   
 of 0.91 and 
RMSEP of 0.40 suggested that o-fluorophenols indeed produce their own high-correlation subset 
and cannot be included with the other o-halogen compounds.  To confirm that this was not a 
fortuitous result based on the HF/6-31G(d) level of theory, we compared our result to that 
obtained by Han and Toa157 using B3LYP/6-311++G(d,p) and an ammonia probe.  Using their r(C-
O) equation to predict the pKa for the same five o-fluorophenols, we obtained an   
 and RMSEP of 
0.90 and 0.41, respectively. After this confirmation we removed 2-fluorophenol (compound 129) 
and pentafluorophenol (compound 156) from subsequent analysis of the o-halogen high-
correlation subset because it was clear they produced a separate o-fluorophenol high-correlation 
subset.  Reasons for 3-chloro-4-hydroxybenzoic acid (compounds 171) and bromofenoxim 
(compound 175) having large residuals were unclear but they were also excluded. 
   
Now we focus on the influence of the omission of outliers. Table 4.4 shows how the models 
improved when the six compounds were removed, resulting in good CV results.   Table 4.4 shows 
that the single-bond-length models benefit approximately equally from this omission compared to 
the all-bond-length models. For example, upon omission of six outliers the RMSEE for the r(C-O) 
model roughly halves, from 0.61 to 0.27. Equally, the RMSEE for all-bond-length model also halves 
from 0.89 to 0.40.  A similar trend is observed for RMSEP.  The most dramatic improvement due 
to the omission of outliers is seen in the   
  statistic.  For the all-bond-length models with outliers 
included, a   
   value of 0.45 suggests that poor predictions are made in CV, while reasonable 
predictions are made for the single-bond-length model, suggested by an   
  of 0.79.  After outlier 
omission, the   
  value for the all-bond-length model improves to 0.81, suggesting a large 
improvement in prediction.  However, the r(C-O) model without outliers is superior based on an 
  
  of 0.94. It is interesting to note that the r(C-O) models are always superior to the all-bond-
length models in the original model fit and in CV. The r(O-H) models were not cross-validated as 
they were inferior to the other models based on the original fitting statistics. This is why the 
corresponding CV statistics are not listed in Table 4.4. 
  
High-correlation subsets using the anti conformations were also investigated with and without 
the identified outliers.  The outliers were still suspicious data points in the inspected correlations.  
These were removed and models with all bond lengths and r(C-O) were cross-validated to 
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compare to the models constructed using the syn conformations.  Using just the r(C-O) provided a 
better model than using all bond lengths, as with the syn conformer models, but not as good as 
the models where the syn conformers were used.  Using r(O-H) once again provided a poor 
correlation.  Inspection of the observed pKa versus predictive pKa plot from r(O-H) revealed  high-
correlation subsets different to those seen when all the phenols were modelled with r(C-O).  The 
structures of the phenols producing these separate high-correlation subsets were inspected and 
showed that di-o-bromophenols, di-o-chlorophenols and mono-orthophenols (i.e. those 
substituted with a chlorine or bromine at the ortho position) belong to their own subsets.  This is 
not surprising, as r(O-H) is affected by the substituent that it points towards, resulting in separate 
models for the di-o-phenols and a single high-correlation subset for the mono-o-phenols as the 
acid hydrogen points towards a hydrogen in each case.  This observation is confirmed by 2-chloro-
6-methylphenol (compound 90) not belonging to any high-correlation subset as the methyl group 
has a different influence to that of a hydrogen.  These results confirm the success of r(C-O) and 
the syn conformation models. The statistics of the models constructed with and without the six 
outliers using B3LYP/6-311+G(2d,p) geometries and the syn conformation offer no improvement 
to those created using HF/6-31G(d). 
 
4.3.2.3 o-Alkylphenols 
Table 4.5.  The statistical details of the models created using o-alkylphenols. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF anti All 3 29 0.96 0.44 0.94 - - - - 
HF anti r(C-O) 1 29 0.93 0.58 0.3 - - - - 
HF anti r(O-H) 1 29 0.79 1.00 0.78 - - - - 
HF anti All 2 25 0.94 0.28 0.83 0.42 0.79 0.76 0.64 
HF anti r(C-O) 1 25 0.91 0.34 0.9 0.37 0.89 0.87 0.78 
HF anti r(O-H) 1 25 0.36 0.90 0.36 0.91 0.30 -1.06 -0.05 
B3LYP anti All 3 29 0.95 0.52 0.91 - - - - 
B3LYP anti r(C-O) 1 29 0.92 0.62 0.92 - - - - 
B3LYP anti r(O-H) 1 29 0.83 0.91 0.83 - - - - 
B3LYP anti All 2 25 0.92 0.33 0.76 - - - - 
B3LYP anti r(C-O) 1 25 0.92 0.32 0.91 - - - - 
B3LYP anti r(O-H) 1 25 0.37 0.90 0.35 - - - - 
 
The anti conformation is the lowest energy for the o-alkylphenols, which is opposite to the syn 
conformation favoured by the o-nitro and o-halogenphenols.  For symmetrical 2,6-substituted 
phenols the conformation is irrelevant. However, the acidic hydrogen pointing towards an alkyl 
group is more stable than it pointing out of plane between the two ortho substituents.  For 
asymmetrical 2,6-substituted phenols, e.g. 2-(1,1-dimethylethyl)-4,6-dimethylphenol (compound 
164), the conformation with the hydrogen pointing towards the methyl group has the lowest 
energy.  Three compounds that also had o-nitro and o-halogen substituents were initially included 
in the modelling (Table 4.6) as the conformation where the acidic hydrogen pointed towards the 
alkyl substituent, which we note is not the lowest energy.  These compounds fitted into the alkyl 
high-correlation subset relatively well. However, they are modelled better in the lower energy 
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conformation by the o-nitro and o-halogen high-correlation subsets. Therefore, the compounds 
were excluded from CV in agreement with two rules listed in Section 4.3.2. The models using all 
the bond lengths are comparable to the model using just r(C-O) (Table 4.5).  The correlation 
obtained using r(O-H) was inferior to that obtained using r(C-O).  There was no notable 
improvement when using B3LYP/6-311+G(2d,p)  generated bond lengths compared to those 
calculated with HF/6-31G(d).     
4.3.2.4 o-Phenols Capable of Forming Internal Hydrogen Bonds.  
 
Table 4.6.  The statistical details of the models created using o-phenols capable of forming internal hydrogen bonds. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF O-H-O All 2 26 0.83 0.71 0.8 - - - - 
HF O-H-O r(C-O) 1 26 0.77 0.81 0.76 - - - - 
HF O-H-O r(O-H) 1 26 0.30 1.41 0.27 - - - - 
HF O-H-O r(C2-C3) 1 26 0.72 0.90 0.69 - - - - 
HF O-H-O All 1 23 0.88 0.50 0.83 0.79 0.74 0.74 0.71 
HF O-H-O r(C-O) 1 23 0.95 0.32 0.95 0.33 0.94 0.94 0.92 
HF O-H-O r(O-H) 1 23 0.35 1.16 0.23 1.31 0.15 -1.50 -0.04 
HF O-H-O r(C2-C3) 1 23 0.85 0.56 0.82 0.62 0.80 0.78 0.69 
 
Twenty-three out of the 26 compounds in this high-correlation subset had the same common 
skeleton with different substituents around both aromatic rings (Figure 4.5).  Two different 
internal hydrogen bonds can be formed i.e. O…H-N and O-H…O. Because the latter structure 
corresponds to the lowest energy this was the only conformation considered.  The three 
compounds that did not have the same common skeleton are shown in (Figure 4.6).  
 
Figure 4.5.  The common skeletons and different hydrogen bonds than can be formed by the o-phenols capable of 
forming internal hydrogen bonds. 
 
 
Figure 4.6.  The three compounds in the class of phenols capable of forming internal hydrogen bonds that did not 
have the same common skeleton as the rest of the compounds. 
 
The observed versus predicted plots for the models containing all 26 compounds were inspected.  
The three compounds, 2-hydroxybenzamide (compounds 59), methyl salicylate (compound 61) 
and 2-vanillin (compound 62), which did not have the same common skeleton as the majority of 
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the compounds in this high-correlation subset, appeared to be outliers.  Methyl salicylate was 
identified as an outlier by Tehan et al.97.  One would not be surprised if this compound did not fit 
the models because of its similarity to compounds 59 and 62.  The reason for these outliers could 
be the lack of structural similarity between these three compounds and the rest of the o-phenols 
capable of forming an internal hydrogen bond.  We suggest that these compounds belong to their 
own high-correlation subset needed to predict pKa using just r(C-O).  This was confirmed by an    
value of 0.95 for the correlation of pKa and r(C-O), although more data points for these types of 
compounds are needed to confirm this.  The pKa of the remaining 23 compounds were modelled 
using all the bond lengths (Table 4.6).  Once again the r(C-O) was most important in the VIP plot, 
however, it was followed by r(C2-C3) and not r(O-H).  The r(C-O) model gave the best statistics for 
the original model and CV statistics compared to the all-bond-length model and the other single-
bond-length models. 
4.3.2.5  o-Methoxy/ethoxyphenols 
 
This high-correlation subset consisted of only eight compounds.  The pKa range was small (7.4 for 
vanillin (compound 124) to 10.28 for 4-methyl-2-methoxyphenol (compound 104)).  Removing 
vanillin, which had a much lower pKa value than the rest, resulted in a range of only 0.74 log units.  
The syn conformation is the lowest energy in all cases.  According to the statistics, the models 
deteriorate when vanillin is included (Table 4.7).  To increase the size of the dataset we sourced 
21 compounds from Ragnar et al.164.  Five of these compounds were already present in our 
dataset. A comparison of the given pKa values in that publication and in our dataset showed they 
were in good agreement, the largest difference being 0.05 pKa units.  We used the 16 remaining 
compounds as a test set for the syn models.  It was pleasing to note that including vanillin gave 
lower values for RMSEP in all cases and that the r(C-O) bond length model gave the lowest RMSEP 
(Table 4.8).  The models created without vanillin had rather poor CV statistics (i.e.   ) because of 
the small pKa range. However, these models actually produced reasonable predictions for the test 
set, which included extrapolation outside the range of pKa values used to create the models.  We 
added the 16 compounds to the Tehan compounds and created new models containing more 
compounds to increase the domain of applicability of the model (Table 4.7). 
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Table 4.7.  The statistical details of the model created using o-methoxy/ethoxyphenols. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF syn All 1 8 0.76 0.52 0.25 0.75 0.42 0.25 0.24 
HF syn r(C-O) 1 8 0.87 0.37 0.85 0.63 0.83 0.78 0.64 
HF syn r(O-H) 1 8 0.82 0.44 0.82 0.44 0.77 0.67 0.52 
HF syn All 1 7  0.76 0.26 0.14 - - - - 
HF syn r(C-O) 1 7  0.47 0.39 0.17 - - - - 
HF syn r(O-H) 1 7  0.15 0.49 -0.10 - - - - 
HF anti All 1 8 0.82 0.44 0.29 - - - - 
HF anti r(C-O) 1 8 0.88 0.36 0.86 - - - - 
HF anti r(O-H) 1 8 0.91 0.31 0.90 - - - - 
HF anti All 1 7 0.82 0.23 0.44 - - - - 
HF anti r(C-O) 1 7 0.51 0.37 0.09 - - - - 
HF anti r(O-H) 1 7  0.64 0.32 0.28 - - - - 
HF syn All 1 24 0.84 0.39 0.79 0.82 0.39 0.19 0.21 
HF syn r(C-O) 1 24 0.91 0.29 0.89 0.53 0.69 0.57 0.45 
HF syn r(O-H) 1 24 0.85 0.37 0.83 0.58 0.61 0.43 0.35 
 
Table 4.8.  The results of testing 16 methoxyphenols in the methoxy/ethoxyphenol models. 
     Model Statistics 16 Compound Test Set 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP 
HF syn All 1 8 0.76 0.52 0.25 0.43 
HF syn r(C-O) 1 8 0.87 0.37 0.85 0.30 
HF syn r(O-H) 1 8 0.82 0.44 0.82 0.41 
HF syn All 1 7 0.76 0.26 0.14 0.53 
HF syn r(C-O) 1 7  0.47 0.39 0.17 0.77 
HF syn r(O-H) 1 7  0.15 0.49 -0.10 0.42 
 
4.3.2.6 Miscellaneous o-Phenols 
 
2-cyanophenol, 2-hydroxybiphenyl, 2-amino-4-nitrophenol and 2-aminophenol are the only 
representatives of these classes of o-phenol compounds.  It is expected that these would produce 
separate high-correlation subsets but as there are few examples, this was not investigated.  
  
4.3.3 Meta- and Para-Phenols 
 
The meta/para phenol models were already of high quality using just r(C-O) with an  
   value of 0.87 and an RMSEE of 0.41, without taking into account conformation (Table 4.2).  The 
r(C-O) and r(O-H) were the most important to the all-bond-length model according to the VIP plot.  
We investigated conformations to see if it was important as seen in the case of the o-phenols.  
Different conformations are only possible for the asymmetrical meta- and meta-/para-phenols.  
Different conformations based on the direction of the acidic hydrogen were optimised and an r(C-
O) model was created using all the conformations and all the compounds.  The differences 
between the predicted pKa values for the same compounds in the different conformations were 
calculated.  The average difference was found to be less than 0.1 log unit.  For this reason we 
decided that conformational differences would not be considered in the subsequent 
investigations for the meta- and para-phenols.  After modelling the para-phenols and meta-
phenols separately and finding little improvement to the models, we investigated high-correlation 
subsets between similar compound classes.  The dataset contained 6 nitrophenols, including 3-
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trifluoromethyl-4-nitrophenol and 3-nitro-4-cresol, 14 halogen phenols, including 3-
trifluoromethylphenol, 4-trifluoromethylphenol, 4-chloro-3,5-dimethylphenol, 3-methyl-4-
chlorophenol, 15 alkylphenols, 5 methoxy/ethoxyphenols, 2 hydroxybenzaldehydes, 2 
hydroxyacetophenones, and 11 compounds we classed as miscellaneous, which included 
compounds such as m/p-cyanophenol, m/p-phenylphenol and m/p-aminophenol.  We 
investigated the nitro, halogen and alkylphenols to see if treating these classes of compounds 
separately produced high-correlation subsets. 
4.3.3.1 m-/p-Nitrophenols  
 
Table 4.9.  The statistical details of the model created using m-/p-nitrophenols. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF N/A All 2 6 0.98 0.25 0.91 0.52 0.83 0.83 0.83 
HF N/A r(C-O) 1 6 0.90 0.45 0.89 0.47 0.83 0.81 0.69 
HF N/A r(O-H) 1 6 0.98 0.21 0.97 0.27 0.95 0.95 0.94 
 
The r(O-H) model produced the highest correlation and the lowest RMSEE (Table 4.9).  As there 
were only 6 compounds, we tested the model using 5 compounds for which pKa values could be 
found in the literature. These were 3-methyl-4-nitrophenol (compound 351), 3,5-dimethyl-4-
nitrophenol (compound 352) and 3-chloro-4-nitrophenol (compound 353), 3-fluoro-4-nitrophenol  
(compound 349) and 3,5-difluoro-4-nitrophenol (compound 350)165-167.  The RMSEP for these 
compounds is shown in (Table 4.10).  The results are above the 0.5 pKa unit threshold that we aim 
for but it must be considered that there are no halogen-substituted compounds in the training set 
and that the predictions for 3-fluoro-4-nitrophenol and 3,5-difluoro-4-nitrophenol are 
extrapolations as there are no stronger acids in this high-correlation subset. 
 
Table 4.10.  The statistics relating to the 5 compound test set. 
     Model Statistics 5 Compound Test Set 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP 
HF N/A All 2 6 0.98 0.25 0.91 0.62 
HF N/A r(C-O) 1 6 0.90 0.45 0.89 0.64 
HF N/A r(O-H) 1 6 0.98 0.21 0.97 0.62 
 
4.3.3.2 m-/p-Halogen Phenols 
 
The all-bond-length model produced the best statistics, however, the r(C-O) model was very 
similar in terms of RMSEE (Table 4.11).  Three compounds were tested by the models with the 
RMSEP shown in Table 4.12.  The test compounds were 3-chloro-4-nitrophenol (compound 353), 
3,5-difluoro-4-nitrophenol (compound 350) and 3-fluoro-4-nitrophenol (compound 349).  Their 
predictions are extrapolations because no compounds in the training set are stronger acids.  The 
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predictions are poor, suggesting that the nitro group has the greatest effect and they should be 
predicted by the nitro model.   
 
Table 4.11.  The statistical details of the models created using m-/p-halogen phenols. 
     Model 
Statistics 
CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF N/A All 2 14 0.93 0.17 0.78 0.32 0.74 0.73 0.66 
HF N/A r(C-O) 1 14 0.86 0.23 0.81 0.30 0.76 0.75 0.69 
HF N/A r(O-H) 1 14 0.79 0.29 0.70 0.38 0.65 0.63 0.55 
 
Table 4.12.  Results of the 3 compound test set.  
     Model Statistics 3 Compound Test Set 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP 
HF N/A All 2 14 0.93 0.17 0.78 1.05 
HF N/A r(C-O) 1 14 0.86 0.23 0.81 1.06 
HF N/A r(O-H) 1 14 0.79 0.29 0.70 1.46 
 
4.3.3.3 m-/p-Alkylphenols 
 
Modelling of the alkyl phenols was attempted but as Table 4.13 shows, proved unsuccessful 
because of the small pKa range (0.53 pKa units) of this class.  For these compounds the best 
prediction would come from using the mean pKa value of this high-correlation subset (10.2) 
knowing that the error is approximately 0.25 pKa units. 
 
Table 4.13.  The statistical details of the models created using m-/p-alkylphenols 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF N/A All 2 15 0.38 0.13 0.13 0.32 0.18 0.02 -1.94 
HF N/A C-O 1 15 0.19 0.15 0.15 0.30 0.15 0.09 -3.04 
HF N/A O-H 1 15 0.02 0.16 -0.04 0.38 0.17 0.04 -19.52 
 
4.3.3.4 Comparison of the models created for the high-correlation subsets of phenols to 
those constructed using different subsets of all the phenols.   
 
Table 4.14 provides the statistics for different subsets of o-phenols to compare to the predictions 
from the high-correlation subset models constructed separately for o-nitro, o-halogen, o-alkyl, o-
methoxy/ethoxy and the o-phenols capable of forming internal hydrogen bonds.  We performed 
this analysis to prove that the predictions from the single-bond-length high-correlation subset 
models were better than those made by models constructed using all the o-phenols and all bond 
lengths. The eight outliers that were identified from the high-correlation subsets have been 
removed to give a fair comparison.  The lowest energy conformation was used for all the 
compounds.  The models created for all the o-phenols with the eight outliers removed (116 
compounds – 8 outliers = 108 compounds) have lower RMSEEs than the models created with the 
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outliers included (Table 4.2).  Removal of the miscellaneous compounds has only a small effect on 
the statistics, however, the models improve slightly when the o-phenols capable of forming 
internal hydrogen bonds are removed.  In all cases the internal statistics and CV statistics are the 
best for the models created using all the bond lengths compared to those created using r(C-O) 
and r(O-H).  The CV statistics confirm that the models created using r(C-O) are better than those 
that created using r(O-H).    
 
Table 4.14.  The statistics relating to the models constructed for subsets of o-phenols. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF 
Lowest 
energy 
All 4 
108  outliers 
identified in 
previous 
sections 
removed) 
0.93 0.67 0.90 0.81 0.90 0.89 0.83 
HF 
Lowest 
energy 
r(C-O) 1 108 0.88 0.89 0.88 0.89 0.88 0.86 0.77 
HF 
Lowest 
energy 
r(O-H) 1 108 0.53 1.76 0.52 1.76 0.52 0.14 0.20 
HF 
Lowest 
energy 
All 4 
104 (ibid but 
without 
miscellaneous 
compounds) 
0.95 0.60 0.92 0.72 0.92 0.92 0.87 
HF 
Lowest 
energy 
r(C-O) 1 104 0.89 0.89 0.89 0.88 0.88 0.87 0.78 
HF 
Lowest 
energy 
r(O-H) 1 104 0.54 1.76 0.54 1.76 0.53 0.18 0.22 
HF 
Lowest 
energy 
All 5 
81 (ibid 
without o-
phenols IHB) 
0.96 0.57 0.93 0.67 0.94 0.93 0.88 
HF 
Lowest 
energy 
r(C-O) 1 81 0.89 0.92 0.89 0.91 0.89 0.87 0.79 
HF 
Lowest 
energy 
r(O-H) 1 81 0.62 1.68 0.62 1.68 0.61 0.41 0.34 
 
 
Table 4.15.   The statistics relating to the models constructed for subsets of m-/p-phenols. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF N/A All 2 55 0.91 0.34 0.87 0.37 0.89 0.88 0.81 
HF N/A r(C-O) 1 55 0.87 0.41 0.85 0.43 0.85 0.83 0.72 
HF N/A r(O-H) 1 55 0.84 0.45 0.83 0.48 0.82 0.78 0.66 
HF N/A All 2 
35 (only nitro, 
halogen, alkyl 
compound) 
0.96 0.26 0.94 0.30 0.94 0.94 0.88 
HF N/A r(C-O) 1 35 0.95 0.30 0.94 0.31 0.94 0.94 0.89 
HF N/A r(O-H) 1 35 0.95 0.29 0.95 0.30 0.95 0.94 0.90 
 
Table 4.15 provides the statistics for different subsets of m/p-phenols to compare to the 
predictions from the high-correlation subsets.  The internal model statistics are the same as those 
given in Table 4.2 since no outliers were indentified.  Here we also provide the CV statistics for 
these models.  The all-bond-length model has the best statistics followed by the r(C-O) and the 
r(O-H) models, respectively.  The CV statistics confirm that models of high quality have been 
generated and the RMSEP is below 0.5 pKa units for all the models.  An improvement in the 
models is noticeable when only the m-/p-nitro, halogen and alkyl phenols are investigated as 
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high-correlation subsets are used to construct models.  The all-bond-length, r(C-O) and r(O-H) 
models have virtually the same statistics.  
 
Table 4.16.  The statistics relating to the models constructed using all the phenols 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF  ALL 8 4 163 0.93 0.63 0.91 0.68 0.92 0.91 0.84 
HF  C-O 1 163 0.89 0.80 0.88 0.80 0.88 0.87 0.78 
HF  O-H 1 163 0.57 1.55 0.56 1.55 0.56 0.24 0.25 
 
Table 4.16 provides the statistics for the models created using all the phenols without the eight o-
phenol outliers identified from the high-correlation subsets.  Small improvements in the internal 
statistics are observed compared to the models with the eight outliers included in Table 4.2.  The 
all-bond-length models has the best CV statistics followed by r(C-O) and r(O-H), respectively. 
 
We now compare the predictions made from the high-correlation subsets to those made by the 
models constructed from combinations of compounds from the high-correlation subsets and the 
models constructed with all the phenol compounds (171-8(outliers)=163).  To compare the 
predictions from the high-correlation-subsets to those obtained from the different subset models 
of the o-phenols, m-/p-phenols and all the phenols shown in Table 4.14, Table 4.15 and Table 
4.16, respectively, we use the RMSEP.  From the CV of the different models we calculated the 
RMSEP for only the compounds that belonged to high-correlation subsets.  For the o-phenols this 
involved five high-correlation subsets (i.e. o-nitro, o-halogen, o-alkyl, o-phenols capable of 
forming IHB and o-methoxy/ethoxy) and three different models (i.e. all-bond-length, r(C-O) and 
r(O-H)).  We then calculated the mean RMSEP from all-bond-length, r(C-O) and r(O-H) models 
constructed using all the compounds that belonged to high-correlation subsets.  This provided 
three average RMSEP values.  This was repeated for only the compounds that formed high-
correlation subsets from the models constructed from the o-phenols without the o-phenols 
capable of forming internal hydrogen bonds and miscellaneous compounds, all the o-phenols 
without the miscellaneous compounds, all the o-phenols (Table 4.14) and all the phenols (Table 
4.16).  The average RMSEP values obtained for the compounds belonging to high-correlation 
subsets are given in Table 4.17.  Note that the models constructed without the o-phenols capable 
of forming internal hydrogen-bonds were not used to calculate an RMSEP for this high-correlation 
subset. Therefore the value is based on the remaining four high-correlation subset compounds.  
The RMSEP from the high-correlation subsets is lower in all cases and the r(C-O) models provide 
the lowest RMSEP compared to the all-bond-length models and the r(O-H) model.  This indicated 
that better predictions are made by the high-correlation sets and proves the ability of a single ab 
initio bond length to predict pKa of o-phenols. 
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Table 4.17.  The average RMSEP for the o-phenols predicted from the relevant models. 
 Compounds used to build models 
# Bonds All phenols  All o-phenols 
All o-phenols 
without 
miscellaneous o-
phenols 
All Ortho without 
miscellaneous o-
phenols and o-
phenols capable of 
forming IHB 
High-correlation 
subsets 
All 0.69 0.77 0.72 0.73 0.58 
r(C-O) 0.83 0.81 0.81 0.84 0.42 
r(O-H) 1.67 1.68 1.70 1.66 0.85 
 
The same was performed for the m-/p-phenols for the compounds identified as forming high-
correlation subsets.  The results are shown in Table 4.18.  The improvement in the RMSEP from 
using the predictions made by the high-correlation subsets is much less than that observed for the 
o-phenols.  However, it is interesting to note that both the r(C-O) and r(O-H) models have lower 
RMSEP than the models constructed from all the bond lengths.  These results suggest that either 
r(C-O) or r(O-H) can be used to predict the pKa for m-/p-phenols.     
 
Table 4.18.  The average RMSEP for the m/p-phenols predicted from the relevant models. 
 Compounds used to build models 
# Bonds All phenols All m-/p-phenols 
Nitro, halogen and  
alkyl phenols 
High-correlation 
subsets 
All 0.41 0.36 0.32 0.34 
r(C-O) 0.67 0.39 0.34 0.31 
r(O-H) 1.21 0.43 0.30 0.27 
 
4.3.4 Benzoic Acids 
 
The pKa of these compounds have been previously modelled using QTMS
152 where inevitably, the 
importance of the COOH group was identified.  Reasonable bond length models were created 
using r(C=O), r(C-O) and r(O-H), but these models were inferior to those using QTMS descriptors.  
We added the bond linking the carboxylic group to the benzene ring, r(C-C), as this type of bond 
produced strong correlations for the phenols.  The common skeleton of the benzoic acids is 
shown in Figure 4.7 and the constitution of the data set is shown in Table 4.1.  All-bond-length 
models and single-bond-length models were constructed for all the compounds and the subsets 
of meta-/para- and ortho substituted benzoic acids to investigate which bonds correlated the 
strongest with pKa (Table 4.19).  For all the benzoic acids, the all-bond-length model produced the 
best correlation followed by r(O-H).  For the o-benzoic acids, r(O-H) produced the best 
correlations followed by the all-bond-length-model.  For the m-/p-benzoic acids the all-bond-
length-model and r(O-H) models were very similar and so we focus here on the high-correlation 
subsets for the o-benzoic acids since little improvement was found using high-correlation subsets 
for the m-/p-phenols.  A brief discussion of the modelling of the m-/p-benzoic acids is provided in 
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Section 4.3.5.4.    Outliers in the benzoic acid data set have previously been detected152, so in line 
with our motivation, we investigated high-correlation subsets and identified these compounds. 
 
Figure 4.7.  The 4 bond lengths used to predict the pKa of the benzoic acids.  The main text refers to bond lengths 1-2, 
1-3, 3-4, and 1-5 as r(C=O), r(C-O), r(O-H) and r(C-C), respectively.  
 
 
Table 4.19.  The results for the benzoic acids. 
 
 
4.3.5 Ortho-Benzoic Acids 
 
Inspection of the observed versus predicted plot for the all-bond-length model highlighted 2,6-
dihydroxybenzoic acid (compounds 252) and 2-hydroxy-3,5-dinitro-benzoic acid (compound 259) 
as outliers.  When these compounds were removed all the models improved (Table 4.20).  An 
explanation of these outliers is included in the o-hydroxybenzoic acid section.  According to the 
VIP plot, r(C-C) now contributed most to the all-bond-length model and also produced the lowest 
RMSEE when the single-bond-length models were constructed.  High-correlation subsets seen in 
the observed versus predicted plots were not as pronounced as for the phenols, but inspection of 
the structures in the data set revealed that o-halogen benzoic acids and o-hydroxybenzoic acids 
Subsets # LV # Bonds # Compounds       RMSEE 
All 2 All 94 0.83 0.72 0.40 
All 1 r(O-H) 94 0.77 0.76 0.47 
All 1 r(C-O) 94 0.57 0.56 0.64 
All 1 r(C-C) 94 0.39 0.34 0.76 
All 1 r(C=O) 94 0.15 0.07 0.90 
Ortho 1 All 50 0.59 0.53 0.66 
Ortho 1 r(O-H) 50 0.69 0.68 0.57 
Ortho 1 r(C-O) 50 0.36 0.33 0.82 
Ortho 1 r(C-C) 50 0.28 0.13 0.87 
Ortho 1 r(C=O) 50 0.27 0.17 0.88 
Meta/Para 2 All 44 0.79 0.74 0.22 
Meta/Para 1 r(O-H) 44 0.79 0.78 0.21 
Meta/Para 1 r(C-O) 44 0.72 0.67 0.25 
Meta/Para 1 r(C=O) 44 0.70 0.68 0.26 
Meta/Para 1 r(C-C) 44 0.49 0.45 0.34 
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formed high-correlation subsets.  These observations were partly due to the number of examples 
of these classes of compounds in the data set.  There were 15 o-halogen benzoic acids and 14 o-
hydroxybenzoic acids.  There were only 3 examples of o-nitrobenzoic acids and a further 18 
compounds that were classed as miscellaneous, including o-amine, o-alkyl and o-methoxy 
substituted benzoic acids.  The sufficiently large number of o-halogen benzoic acids and o-
hydroxybenzoic allowed us to investigate the performance of simple linear regression against PLS 
using all the bond lengths.  
 
Table 4.20.  The statistical details of the models created for the o-benzoic acids.  
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF N/A All 2 48 0.80 0.43 0.79 - - - - 
HF N/A r(C-C) 1 48 0.69 0.53 0.69 - - - - 
HF N/A r(O-H) 1 48 0.65 0.56 0.65 - - - - 
HF N/A r(C-O) 1 48 0.60 0.60 0.60 - - - - 
HF N/A r(C=O) 1 48 0.55 0.64 0.53 - - - - 
 
4.3.5.1   o-Halogen Benzoic Acids 
 
Considering the carboxyl group, the planar syn conformation was used due to the stability 
resulting from intramolecular hydrogen bonding.  Depending on the nature and number of the 
ortho substitutions the carboxyl group can adopt different conformations.  Full geometry 
optimisation was performed using the HF/6-31G(d) level of theory on the different possible 
conformations and the energies inspected.   For 2-monohalogen-substituted benzoic acids, two 
minimum energy conformations were found.  In one conformation the carboxylic O-H was closest 
to the halogen, while in the other the carboxylic C=O was closest.  For symmetrical benzoic acids, 
the carboxylic groups were almost perpendicular to the aromatic ring.  For asymmetric o-halogen 
benzoic acids, the lowest energy conformation could be either that with the carboxylic O-H being 
closest to the halogen or vice versa. 
  
For seven of the 2-monohalogen-substituted benzoic acids, the carboxylic O-H closest to the 
halogen was the most stable.  For o-bromobenzoic acid (compound 234) and 2-chloro-5-
nitrobenzoic acid (compound 269) the carboxylic C=O closest to the halogen was the most stable.  
The anomaly with o-bromobenzoic acid is interesting as the opposite conformation is favoured by 
2-chlorobenzoic acid (compound 245) and 2-fluorobenzoic acid (compound 254) and is 
presumably due to steric hindrance caused by the bulky bromine substitution.  It should also be 
noted that the difference in energies between the two conformations of o-bromobenzoic acid 
was less than 0.15 kJmol-1 calculated at the HF/6-31G(d) level of theory.  The presence of the 5-
nitro substitution in 2-chloro-5-nitrophenol (compound 269) could be the cause of this compound 
favouring a different conformation.  For asymmetric o-halogen benzoic acids, the carboxylic OH 
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closest to the halogen was found to be the lower energy conformation.  The influence the 
conformation can have on the modelling can be seen from the observed versus predicted plot in 
Figure 4.8.  The different conformations of the same compound cause the predicted pKa to be 
quite different. 
 
 
Figure 4.8.  Observed versus predicted plot of the o-halogen benzoic acids from the PLS model constructed using all 
the bond lengths and different conformations for the same compound where applicable. 
 
Models were constructed using the all-bond-length and single-bond-length models employing the 
lowest energy conformations (Table 4.21).  The observed versus predicted plot was inspected and 
3-amino-2,5-dichlorobenzoic acid (compound 250) was identified as an outlier, which may also 
exist as a zwitterion.  Both forms were modelled but it remained an outlier and so was removed 
from all subsequent analysis.  r(C-C) and r(O-H) were identified as the most important bonds from 
the VIP plot for the all-bond-length model and so were the only bonds considered for further 
analysis (Table 4.22).  In the r(C-C) model, 2-chloro-5-nitrobenzoic acid (compound 269) and 2-
chloro-6-methyl-benzoic acid (compound 273) had the largest errors from their experimental 
values.  When these compounds were removed the models improved.  2-chloro-6-methyl-benzoic 
acid had a predicted pKa of 2.20, which is lower than the experimental value of 2.75.  It is known 
that any ortho substitutions increase the acidity of benzoic acids, regardless of the electronic 
effect of the ortho substitution on the benzoic acids.  Toa and co-workers demonstrated that this 
effect was not captured by the molecular properties, including bond lengths, in the set of benzoic 
acids they investigated and led to a higher predicted pKa for 2-methylbenzoic acids compared to 
experiment.  However, this does not explain the lower pKa predicted by r(C-C), which must be due 
to steric interference from the o-methyl substitution.  2-chloro-5-nitrobenzoic was one of the two 
compounds that had a lower energy with the carboxylic C=O bond being closer to the halogen 
than the OH.  Using the bond length from this conformation appears to corrupt the correlation.  
Using r(C-C) from the higher energy conformation moved this compound back into the 
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correlation.  2-Bromobenzoic acid (compound 234), which also had a different low energy 
conformation compared to the majority of the halogen benzoic acids, fitted the correlation when 
either conformation was used.  For the r(O-H) model, 2-chloro-5-nitrobenzoic acid and 2-chloro-6-
methyl-benzoic acid did not fit the correlation, for what appeared to be the same reasons given 
for the r(C-C) model.  However, these compounds were not the worst predicted because 2,3,5,6-
tetrafluoro-4-methyl-benzoic acid (compound 262) also had a predicted value of 1.56 compared 
to an experimental pKa of 2.00.  When 2-chloro-5-nitrobenzoic acid and 2-chloro-6-methyl-
benzoic acid were removed, the models improved.  The reason for 2,3,5,6-tetrafluoro-4-methyl-
benzoic acid not fitting the correlation is unclear, but for the o-halogen phenol high-correlation 
subset, o-fluorophenols could not be included, which was probably the case here.  When 2,3,5,6-
tetrafluoro-4-methyl-benzoic acid was removed, the correlation improved further.  When 2-
chloro-5-nitrobenzoic acid was modelled using the higher energy conformation and the one that 
was consistent with the majority of the other compounds, it fitted the correlation.  The same was 
true for 2-bromobenzoic acid with an improvement in the model observed.  These results suggest 
that r(O-H) is more sensitive to conformation than r(C-C) and also demonstrates that inconsistent 
conformations can corrupt the correlations. 
   
To attempt to solve the conformation issues with 2-bromobenzoic acid and 2-chloro-5-
nitrobenzoic acid we reoptimised the halogen benzoic acids at the HF/6-31G(d,p) level of theory, 
that is, now adding p functions on the hydrogen atoms.  2-bromobenzoic acid, with the carboxylic 
OH closest to the bromine, became the lowest energy conformer; however, the lowest energy 
conformation for compound 2-chloro-5-nitrobenzoic acid did not change.  The models created 
using the geometries calculated using additional polarisation functions were very similar to those 
created using HF/6-31G(d) bond lengths (data not shown). 
 
The best models obtained from r(C-C) and r(O-H) were exposed to CV.  The r(C-C) model produced 
the best CV statistics, which included the lowest RMSEP compared to the r(O-H) model.  It is also 
noteworthy that this model included 2,3,5,6-tetrafluoro-4-methyl-benzoic acid (compound 262), 
which was not included in the r(O-H) model. 
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 Table 4.21.  The statistical details of the models created for the o-halogen benzoic acids.    
     Model Statistics CV 
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF Lowest Energy All 2 15 0.72 0.35 0.68 - - - - 
HF Lowest Energy r(C-C) 1 15 0.63 0.40 0.59 - - - - 
HF Lowest Energy r(O-H) 1 15 0.61 0.41 0.57 - - - - 
HF Lowest Energy r(C-O) 1 15 0.61 0.41 0.57 - - - - 
HF Lowest Energy r(C=O) 1 15 0.05 0.64 -0.04 - - - - 
HF Lowest Energy All 2 14 (-250) 0.86 0.22 0.84 - - - - 
HF Lowest Energy r(C-C) 1 14 (-250) 0.83 0.25 0.81 - - - - 
HF Lowest Energy r(O-H) 1 14 (-250) 0.70 0.33 0.66 - - - - 
HF Lowest Energy r(C-O) 1 14 (-250) 0.68 0.34 0.62 - - - - 
HF Lowest Energy r(C=O) 1 14 (-250) 0.09 0.57 -0.01 - - - - 
 
 
Table 4.22.  The statistical details of the models created using r(C-C) and r(O-H) for the o-halogen benzoic acids. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF Lowest Energy r(C-C) 1 14 (-250) 0.84 0.25 0.83 - - - - 
HF Lowest Energy r(C-C) 1 13 (-250, 273) 0.90 0.20 0.88 - - - - 
HF Lowest Energy r(C-C) 1 
12 (-250, 273 
and 269) 
0.94 0.16 0.92 - - - - 
HF Mixed r(C-C) 1 
13 (-250, 
273)(269 conf 
a) 
0.93 0.16 0.91 - - - - 
HF Mixed r(C-C) 1 
13 (-250, 
273)(269 conf 
a, 234 conf a) 
0.93 0.16 0.92 0.19 0.90 0.89 0.82 
HF Lowest Energy r(O-H) 1 14 (-250) 0.70 0.33 0.66 - - - - 
HF Lowest Energy r(O-H) 1 13 (-250, 273) 0.76 0.30 0.71 - - - - 
HF Lowest Energy r(O-H) 1 
12 (-250, 273 
and 269) 
0.81 0.28 0.77 - - - - 
HF Lowest Energy r(O-H) 1 
12 (-250, 273 , 
269 and 262) 
0.89 0.22 0.85 - - - - 
HF Mixed r(O-H) 1 
12 (-250, 273 , 
and 262) (269 
conf a) 
0.88 0.22 0.85 - - - - 
HF Mixed r(O-H) 1 
12 (-250, 273 , 
and 262) (269 
and 234 conf a) 
0.92 0.18 0.90 0.26 0.84 0.83 0.79 
 
 
4.3.5.2 o-Hydroxybenzoic Acids 
 
As with the o-halogen benzoic acids, the syn conformation was used for the carboxylic group.  
Unconstrained optimisation of the carboxylic group resulted in it being coplanar with the 
aromatic ring.  Taking the simplest o-hydroxybenzoic acid in the data set, salicylic acid (compound 
23), four stable conformations were found (Figure 4.9).  Full geometry optimisation was 
performed on the 14 o-hydroxybenzoic acids in each of the four conformations. The most stable 
conformation was always the one where the hydroxyl hydrogen forms an intramolecular 
hydrogen bond with the C=O oxygen (Figure 4.9d). The bond lengths from these conformations 
were used in modelling (Table 4.23).  2,6-Dihydroxybenzoic acid (compound 252) and 2-hydroxy-
3,5-dinitro-benzoic acid (compound 259) were omitted as outliers in Chapter 3 and our 
publication152 on the basis of the presence of the hydroxyl group at the ortho position(s).  We 
were therefore cautious with including these compounds, but interested to investigate whether 
the previous omissions were justified.    
99 
 
OO
O
H
H
OO
O
H
H
OO
O
H
H
OO
O
H
H
a b
c d  
Figure 4.9.  The stable conformations of salicylic acid. 
 
 
Table 4.23.  The statistical details of the models created for the o-hydroxybenzoic acids. 
     Model Statistics CV  
Statistics 
Method Conformation 
# 
Bonds 
# LV # Compounds    RMSEE    RMSEP    
       
    
  
HF Lowest Energy All 3 14 0.97 0.16 0.91 0.74 0.73 0.67 0.55 
HF Lowest Energy r(O-H) 1 14 0.98 0.13 0.97 0.15 0.96 0.96 0.92 
HF Lowest Energy r(C=O) 1 14 0.54 0.59 0.45 - - - - 
HF Lowest Energy r(C-C) 1 14 0.15 0.80 -0.07 - - - - 
HF Lowest Energy r(C-O) 1 14 0.00 0.87 -0.10 - - - - 
HF Lowest Energy All 2 12 (-252 and 259) 0.92 0.12 0.82 - - - - 
HF Lowest Energy r(O-H) 1 12 (-252 and 259) 0.92 0.12 0.90 - - - - 
HF Lowest Energy r(C-O) 1 12 (-252 and 259) 0.87 0.15 0.79 - - - - 
HF Lowest Energy r(C=O) 1 12 (-252 and 259) 0.72 0.21 0.62 - - - - 
HF Lowest Energy r(C-C) 1 12 (-252 and 259) 0.55 0.27 0.37 - - - - 
HF Lowest Energy All 3 13 (-252) 0.97 0.13 0.87 - - - - 
HF Lowest Energy r(O-H) 1 13 (-252) 0.97 0.14 0.94 - - - - 
HF Lowest Energy r(C-O) 1 13 (-252) 0.89 0.25 0.78 - - - - 
HF Lowest Energy r(C=O) 1 13 (-252) 0.63 0.46 0.45 - - - - 
HF Lowest Energy r(C-C) 1 13 (-252) 0.49 0.54 0.30 - - - - 
HF Lowest Energy All 3 13 (-259) 0.98 0.12 0.69 - - - - 
HF Lowest Energy r(O-H) 1 13 (-259) 0.97 0.11 0.97 - - - - 
HF Lowest Energy r(C=O) 1 13 (-259) 0.42 0.51 0.38 - - - - 
HF Lowest Energy r(C-O) 1 13 (-259) 0.19 0.60 -0.1 - - - - 
HF Lowest Energy r(C-C) 1 13 (-259) 0.03 0.66 -0.1 - - - - 
 
In all the single-bond-length models involving all compounds, r(O-H) produced the best 
correlations compared to any other single-bond-length model or the all-bond-length model.  For 
the all-bond-length model and the r(O-H) model, 2,6-dihydroxybenzoic acid and 2-hydroxy-3,5-
dinitro-benzoic acid were found lying on the regression line. However, these two compounds did 
not lie on the regression line corresponding to single-bond-length models other than r(O-H).  Also, 
when these compounds were excluded, these models did improve. Sequentially removing these 
compounds demonstrated that 2,6-dihydroxybenzoic acid had the greatest influence in reducing 
the correlation statistics.  This is probably due to the fact that 2,6-dihydroxybenzoic acid is the 
only 2,6-substituted benzoic acid. Indeed, the r(C=O), r(C-O) and r(C-C) models suffer from the 
presence of the second substitution, which is not the case for the r(O-H) model.  r(O-H) and r(C-O) 
produce good models when 2-hydroxy-3,5-dinitro-benzoic acid is included.  The two highly 
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electron-withdrawing nitro groups in the meta positions deteriorated the correlation for the 
r(C=O) and r(C-C) models.  It is interesting to note that r(C-C) produces the worst correlations for 
o-hydroxybenzoic acids but the best for the o-halogen benzoic acids.  We have demonstrated that 
r(O-H) gives good correlations with pKa when 2,6-dihydroxybenzoic acid and 2-hydroxy-3,5-
dinitro-benzoic acid are included but models obtained from bond lengths other than r(O-H) suffer 
from their inclusion.  The current work and its conclusion can be used to explain why we had to 
exclude these two compounds in Chapter 3 and our publication152 where we did not restrict 
ourselves to a single-bond-length model, nor concentrated on particular high-correlation subsets.  
In this previous publication, properties from bonds other than r(O-H) were used to model the pKa. 
We have shown above that these bonds cause deterioration in the models for 2,6-
dihydroxybenzoic acid and 2-hydroxy-3,5-dinitro-benzoic acid.  This is confirmed by the CV 
statistics for the all-bond-length model. 
 
We also constructed similar models with the different conformations.  It was interesting to find 
that strong correlations were found but different bond lengths became important according to 
the VIP plot.  Good models can also be constructed using different conformations and all the bond 
lengths in a PLS model. However, when only one bond length is used, the models drastically 
deteriorate.  
  
4.3.5.3 Comparison of the models created for the high-correlation subsets of o-benzoic 
acids to those constructed using different subsets of all the benzoic acids.  
  
A comparison between the RMSEP values, as performed from the o-phenols, is not worthwhile 
here because different bonds gave better results.  
4.3.5.4 Meta-/Para-Benzoic Acids  
  
The models and statistics for the m-/p-benzoic acids are given in Table 4.24.  Inspection of the 
observed versus predicted plot for the all-bond-length model and all the single-bond-length 
models highlighted 3,4-diamino-benzoic acid as a large outlier.  This compound was excluded by 
Tehan et al. and also in Chapter 3 and our publication152 for the reason that it may be partially in a 
zwitterionic form in solution.  After excluding this compound, the models significantly improved.  
The all-bond-length model and four single-bond-length models were cross-validated, constructed 
from the remaining 43 m-/p-benzoic acids.  The results in Table 4.24 show that only r(O-H) is 
required to predict the pKa for these compounds.  The corresponding statistics are almost exactly 
the same as those of the all-bond-length model.  Furthermore, the r(C-O) model demonstrated 
good predictive ability, which decreases for the r(C=O) model and further for the r(C-C) model. 
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Table 4.24.  The statistical details of the models created for the m-/p-benzoic acids. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF N/A All 2 44 0.79 0.22 0.74 - - - - 
HF N/A r(O-H) 1 44 0.79 0.21 0.78 - - - - 
HF N/A r(C-O) 1 44 0.72 0.25 0.67 - - - - 
HF N/A r(C=O) 1 44 0.70 0.26 0.68 - - - - 
HF N/A r(C-C) 1 44 0.49 0.34 0.45 - - - - 
HF N/A All 2 43 0.93 0.12 0.92 0.13 0.92 0.92 0.85 
HF N/A r(O-H) 1 43 0.92 0.13 0.91 0.13 0.91 0.91 0.84 
HF N/A r(C-O) 1 43 0.90 0.15 0.90 0.15 0.90 0.89 0.80 
HF N/A r(C=O) 1 43 0.83 0.19 0.83 0.20 0.82 0.78 0.65 
HF N/A r(C-C) 1 43 0.61 0.29 0.59 0.30 0.57 0.29 0.27 
 
4.3.6 Anilines 
 
Figure 4.10 shows the common skeleton and bonds screened to predict pKa of the aniline 
compounds.  Table 4.1 provides the constitution of the data set for the aniline compounds.  Here 
we use the pKa values associated with the dissociation of the hydrogen from the conjugated acid.  
Of course, the protonation of the substituted anilines are associated with pKb values but because 
pKa + pKb = 14, all the pKa values are related to the pKb values. Therefore, using either pKa or pKb 
does not change the models’ statistics.  In contrast to phenol and benzoic acid, aniline is 
symmetrical and therefore most compounds have only one stable conformation.   We used the 
conformation with the lowest energy.  All-bond-length models were created for all the anilines 
and for o-aniline and m-/p-aniline subsets (Table 4.25).  It was pleasing to note that the VIP plot 
for the all-bond-length model with all the anilines highlighted r(C-N) as the most important bond 
followed by r(N7-H8) and r(N7-H9).  Models were subsequently constructed using a three-bond-
length model r(CNH2) and single-bond-length models using r(C-N), r(N7 -H8) and r(N7 -H9).  The 
RMSEE for these models was higher than the RMSEE obtained using all the bond lengths. 
However, r(C-N) gave a lower RMSEE than r(CNH2).  The r(N7 -H8) and  r(N7 -H9) gave similar 
statistics.  Models were constructed for the m-/p- and o-aniline subsets using the same bonds to 
investigate whether the models improved.  For the m-/p-anilines all the RMSEE values decreased 
compared to the same models built from all the compounds.  The opposite occurred for the o-
anilines where the RMSEE increased compared to the models built using all the anilines 
suggesting that the o-anilines caused the high RMSEE in these models.  In both cases the r(N-H) 
models were very similar but were inferior to those constructed using r(C-N).  We also noted that 
the RMSEE for the majority of the models was greater than 0.5 and the statistics for the m-/p-
aniline models were especially poor compared to those obtained for the phenols and benzoic 
acids.  Next we attempted to identify high-correlation subsets in line with our motivation.   
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Figure 4.10.  The nine bond lengths used to predict the pKa of the aniline compounds.  The main text refers to bond 
lengths 1-7 as r(C-N), and bond lengths 7-8 and 7-9 as r(N7-H8) and r(N7-H9), respectively.  References to other bonds 
make use of this numbering scheme to distinguish between the C-C bonds, e.g. r(C1-C2).  Where just the bonds 
associated to the NH2 group are used, i.e. r(C-N), r(N7-H8) and r(N7-H9), then r(CNH2) is used. 
 
Table 4.25.  The results of the aniline compounds modelled with the bond lengths calculated at the HF/6-31G(d) level 
of theory. 
 
4.3.7 Ortho-Anilines 
 
The observed versus predicted plots and the VIP plots for all the o-aniline models in Figure 4.11 
were inspected.  In contrast to the all-bond-length model constructed from all the anilines, the 
VIP plot for the all-bond-length model constructed from only the o-anilines gave r(C2-C3) as the 
second most important bond.  Pentafluoroaniline (compound 313) has an experimental pKa of -
0.28, however, the model predicted it to be 1.21.  When this compound was removed the VIP plot 
gave r(C2-C3) as the fourth most important bond behind the three bonds associated with the C-
NH2 group.  It is not surprising that this compound caused problems since o-fluorophenols appear 
to form their own high-correlation subset and 2,3,5,6-tetrafluoro-4-methyl-benzoic acid had been 
excluded from the benzoic acid modelling.  As pentafluoroaniline was the only o-fluoroaniline in 
the data set, we excluded it and rebuilt the models (Table 4.26).  The models for the o-anilines 
improved compared to those in Table 4.25.  This time the correlation between r(C-N) and pKa 
Subsets # LV # Bonds # Compounds       RMSEE 
All 3 All 52 0.89 0.84 0.70 
All 1 r(CNH2) 52 0.74 0.73 1.06 
All 1 r(C-N) 52 0.78 0.78 0.96 
All 1 r(N7-H8) 52 0.67 0.65 1.18 
All 1 r(N7-H9) 52 0.66 0.63 1.21 
Meta/Para 4 All 24 0.90 0.76 0.40 
Meta/Para 2 r(CNH2) 24 0.77 0.71 0.58 
Meta/Para 1 r(C-N) 24 0.66 0.63 0.69 
Meta/Para 1 r(N7-H8) 24 0.59 0.55 0.76 
Meta/Para 1 r(N7-H9) 24 0.58 0.55 0.77 
Ortho 3 All 28 0.89 0.81 0.79 
Ortho 1 r(CNH2) 28 0.69 0.64 1.29 
Ortho 1 r(C-N) 28 0.76 0.73 1.14 
Ortho 1 r(N7-H8) 28 0.60 0.54 1.46 
Ortho 1 r(N7-H9) 28 0.59 0.49 1.49 
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(Figure 4.11) was inspected in conjunction with the structures of the compounds in an attempt to 
identify high-correlation subsets.  Ten o-halogen anilines, five o-nitro anilines and four o-alkyl 
halogen allowed us to investigated high-correlation subsets for these compounds.  
Table 4.26.  The statistical details of the models created for the o-anilines. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF Lowest Energy All 3 27 0.91 0.72 0.83 1.16 0.76 0.74 0.66 
HF Lowest Energy r(CNH2) 1 27 0.74 1.19 0.64 1.40 0.61 0.56 0.48 
HF Lowest Energy r(C-N) 1 27 0.80 1.06 0.74 1.20 0.72 0.68 0.57 
HF Lowest Energy r(N7-H8) 1 27 0.66 1.37 0.54 1.58 0.51 0.43 0.36 
HF Lowest Energy r(N7-H9) 1 27 0.65 1.38 0.53 1.61 0.50 0.43 0.36 
 
 
 
Figure 4.11.  Plot of r(C-N) versus pKa for the o-anilines.  
 
4.3.7.1 o-Halogen Anilines  
 
Table 4.27 gives the statistics for the models created for the o-halogen anilines.  The RMSEE and 
RMSEP for all the models are below 0.5 pKa units and are much lower than those obtained from 
the models constructed with all the o-anilines.  The r(CNH2) model has the lowest RMSEP followed 
by the r(C-N) model.  The statistics for all the models are very similar and their predictive ability is 
confirmed by high   
   values.   
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Table 4.27.  The statistical details of the models created for the o-halogen anilines. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF Lowest Energy All 1 10 0.95 0.38 0.94 0.43 0.92 0.92 0.87 
HF Lowest Energy r(CNH2) 1 10 0.97 0.32 0.96 0.42 0.93 0.93 0.90 
HF Lowest Energy r(C-N) 1 10 0.95 0.39 0.94 0.44 0.93 0.92 0.90 
HF Lowest Energy r(N7-H8) 1 10 0.94 0.44 0.93 0.48 0.91 0.90 0.85 
HF Lowest Energy r(N7-H9) 1 10 0.94 0.42 0.94 0.44 0.92 0.92 0.87 
 
4.3.7.2 o-Nitro Anilines  
 
These models were constructed with only 5 o-nitro anilines, which is probably the reason for the 
large variations in the quality of the models (Table 4.28).  r(CNH2) gave the lowest RMSEE and 
RMSEP followed by r(C-N).  It is interesting to note that for o-nitro anilines both the r(N-H) models 
were poor in contrast to the o-halogen anilines where they produced good models. 
 
Table 4.28.  The statistical details of the models created for the o-nitro anilines. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF Lowest Energy All 2 5 0.99 0.37 0.92 1.45 0.66 0.65 0.61 
HF Lowest Energy r(CNH2) 2 5 1.00 0.14 1.00 0.34 0.98 0.98 0.98 
HF Lowest Energy r(C-N) 1 5 0.98 0.40 0.97 0.54 0.95 0.95 0.95 
HF Lowest Energy r(N7-H8) 1 5 0.80 1.37 0.77 1.58 0.66 0.64 0.56 
HF Lowest Energy r(N7-H9) 1 5 0.01 3.06 -0.1 4.42 0.76 -0.12 0.05 
 
4.3.7.3 o-Alkyl Anilines  
 
The small number of examples of o-alkyl anilines was not ideal.  However, good models were 
constructed for these compounds and using only r(C-N) provided a lower RMSEP compared to any 
of the other models Table 4.29.  We note that the r(N7-H8) and r(N7-H9) models are very different.  
This can also be observed for the o-nitro anilines (Table 4.28).  For the o-alkyl anilines this 
difference is caused by two compounds having two ortho-methyl substituents in the 2 and 6 
positions, whereas the other two compounds are only mono-ortho substituted.  This reason also 
applies to the o-nitro anilines where only one compound has nitro substituents in the 2 and 6 
position.  These results highlight the drawback of using the r(N-H) bond length, a problem that 
does not  apply to the r(C-N) model.  This difference is not observed for the r(N-H) o-halogen 
anilines model (Table 4.29), which was constructed using 10 compounds, including three di-ortho 
halogen substituted compounds.  
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Table 4.29.  The statistical details of the models created for the o-alkyl anilines. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF Lowest Energy All 1 4 0.99 0.08 0.77 0.25 0.93 0.78 0.57 
HF Lowest Energy r(CNH2) 2 4 0.96 0.26 0.86 0.95 0.54 0.52 0.47 
HF Lowest Energy r(C-N) 1 4 0.97 0.16 0.95 0.23 0.90 0.90 0.88 
HF Lowest Energy r(N7-H8) 1 4 0.17 0.87 -0.1 1.22 0.98 -2.75 -0.90 
HF Lowest Energy r(N7-H9) 1 4 0.52 0.66 0.36 1.64 0.28 0.27 0.26 
4.3.8 Meta-/Para- Anilines 
 
The RMSEEs for the m-/p-anilines (Table 4.25) were much higher than those obtained for the 
phenols and benzoic acids.  Similarly to the o-anilines, the VIP plot for the all-bond-length model 
gave a bond length, r(C1-C2), not part of the CNH2 group, as the second most important bond.  The 
VIP plots and observed versus predicted plots were inspected for the r(CNH2) and single-bond-
length models.  These revealed 3,5-dinitroaniline (compound 280) as a suspicious data point.  
When this compound was removed, the VIP plot for the all-bond-length model returned r(C-N), 
r(N7 -H8) and r(N7 -H9) as the most important bonds in that order.  
 
Models were constructed without 3,5-dinitroaniline and the statistics improved (Table 4.30).  The 
RMSEE for the r(C-N) model was below 0.5 pKa units.  The observed versus predicted plot revealed 
that the meta-substituted anilines were predicted far worse than the para-substituted anilines.  
We separated the m-/p-anilines and constructed models of the separate classes (Table 4.31 and 
Table 4.32).  The r(C-N) model for the p-anilines gave an RMSEE of 0.27. However, the r(C-N) 
model for the m-anilines had an RMSEE of 0.59.  This was unexpected as the single-bond-length 
models for the p-/m-phenols and p-/m-carboxylic acids provide good correlations.  Inspection of 
the observed versus predicted plot did not reveal any suspicious data points nor any chemically 
meaningful high-correlation subsets.  Ab initio bond lengths generated at the HF/6-31G(d) level of 
theory have previously been used in our group to model the pKa of a different data set of 36 m-/p-
substituted anilines57. An    value of 0.92 and a    value of 0.88 were obtained using PLS. 
However, all the bond lengths in the common skeleton were used and the bond lengths linking 
the substituents to the aromatic ring were also included.  Twenty m-substituted anilines were 
added to our data set in an attempt to improve the r(C-N) model (Table 4.33).  The RMSEE for the 
r(C-N) model increased to 0.74 compared to 0.59 obtained previously.  Once again, no obvious 
chemically meaningful high-correlation subsets could be found. 
Table 4.30.  The statistical details of the models created for the m-/p-anilines with 3,5-dinitroaniline removed.   
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF Lowest Energy All 3 23 0.92 0.32 0.82 0.55 0.72 0.68 0.57 
HF Lowest Energy r(CNH2) 2 23 0.85 0.42 0.79 0.58 0.69 0.64 0.53 
HF Lowest Energy r(C-N) 1 23 0.80 0.48 0.76 0.54 0.73 0.68 0.57 
HF Lowest Energy r(N7-H8) 1 23 0.74 0.54 0.70 0.60 0.66 0.59 0.48 
HF Lowest Energy r(N7-H9) 1 23 0.73 0.56 0.69 0.60 0.66 0.56 0.45 
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Table 4.31.  The statistical details of the models created for the p-anilines. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF Lowest Energy All 1 11 0.90 0.38 0.87 0.50 0.80 0.79 0.70 
HF Lowest Energy r(CNH2) 2 11 0.97 0.24 0.93 0.37 0.90 0.89 0.81 
HF Lowest Energy r(C-N) 1 11 0.95 0.27 0.93 0.33 0.92 0.92 0.92 
HF Lowest Energy r(N7-H8) 1 11 0.93 0.33 0.88 0.44 0.87 0.87 0.86 
HF Lowest Energy r(N7-H9) 1 11 0.93 0.33 0.90 0.40 0.89 0.89 0.89 
 
Table 4.32.  The statistical details of the models created for the m-anilines. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF Lowest Energy All 4 12 0.97 0.21 0.91 0.53 0.67 0.46 0.36 
HF Lowest Energy r(CNH2) 2 12 0.80 0.47 0.75 0.65 0.54 0.41 0.34 
HF Lowest Energy r(C-N) 1 12 0.66 0.59 0.61 0.63 0.56 0.41 0.34 
HF Lowest Energy r(N7-H8) 1 12 0.58 0.65 0.52 0.70 0.45 0.21 0.23 
HF Lowest Energy r(N7-H9) 1 12 0.54 0.69 0.50 0.72 0.42 0.03 0.16 
 
Table 4.33. The statistical details of the models created for the m-anilines with the twenty additional m-anilines. 
     Model Statistics CV  
Statistics 
Method Conformation # Bonds # LV # Compounds    RMSEE    RMSEP    
       
    
  
HF Lowest Energy All 4 32 0.81 0.49 0.57 0.86 0.35 0.04 0.16 
HF Lowest Energy r(CNH2) 2 32 0.72 0.56 0.67 0.61 0.63 0.52 0.42 
HF Lowest Energy r(C-N) 1 32 0.49 0.74 0.44 0.78 0.41 -0.03 0.14 
HF Lowest Energy r(N7-H8) 1 32 0.41 0.81 0.34 0.83 0.32 -0.38 0.05 
HF Lowest Energy r(N7-H9) 1 32 0.37 0.83 0.34 0.85 0.30 -0.64 0.01 
 
4.3.9 Comparison of the Correlation Obtained With and Without an Ammonia Probe 
 
As mentioned in the Introduction, the complete series of chlorophenols, bromophenols and 
fluorophenols has previously been investigated separately for correlations of molecular properties 
with pKa 
156, 157, 159, 160.  Having demonstrated that strong correlations between pKa and one bond 
length can be achieved for halogen phenols, we investigated whether better results could be 
achieved using an ammonia probe and a higher level of theory.  For all the monomeric o-halogen 
phenols in the dataset, the syn conformation was the lowest in energy apart from the two 2-
halogen-6-nitrophenols.  It is suggested that when a probe molecule is introduced, the anti 
conformer (where the hydroxyl hydrogen points away from the closest halogen) is more stable156, 
157.  This can only be the case for mono-ortho-substituted halogen phenols. The ammonia, as a 
probe molecule, is positioned with its lone pair at the hydroxyl hydrogen of the halogen phenols, 
conserving the Cs symmetry if other meta-/para-substituents are ignored (Figure 4.12). 
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Figure 4.12.  The general structure and number scheme for the phenol-ammonia complex. 
 
Full geometry optimisations were performed at the HF/6-31G(d) and B3LYP/6-311++G(d,p) level 
of theory on the data set of o-halogen phenols (30 compounds), without the two 2-halogen-6-
nitrophenols, in the presence of the ammonia probe.  For the asymmetric halogen phenols, 
geometry optimisations were preformed on both the syn and anti conformers.  Contrary to the 
calculated energies of the monomeric halogen phenols, where the syn conformation was 
consistently lower in energy, the same was not found for the halogen phenol-ammonia 
complexes.  For the asymmetric halogen phenols, at both levels of theory, we generally found the 
syn conformation to be most stable.  However, in some cases the lowest energy conformer was 
not consistent at both levels of theory for the same compound.  These findings were contrasting 
with the work of Han et al.156.  For example, we find the syn conformer of 2-chlorophenol to be 
most stable using both levels of theory and including the basis-set superposition error (BSSE) in 
the HF calculation.  For this reason we constructed models based on the three possible 
combinations: each compound being in its lowest energy conformer, each in its syn conformer 
and each in its anti conformer (Table 4.34) (symmetrically substituted compounds such as 2,6-
dichlorophenol can of course not be assigned anti or syn but this fact did not exclude them from 
the dataset). The four compounds previously identified as outliers were still outliers in the models 
even after the introduction of the probing ammonia.  This can be seen by an improvement in all 
the models statistics when the outliers are removed.     
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Table 4.34  The statistics relating to the models constructed for the phenols and an ammonia probe. 
   HF B3LYP 
Conformation Bonds # Compounds # LV       RMSEE # LV       RMSEE 
Lowest Energy           
 All 30 4 0.97 0.92 0.31 2 0.94 0.88 0.42 
 C-O 30 1 0.90 0.90 0.51 1 0.91 0.90 0.50 
 O-H 30 1 0.81 0.78 0.71 1 0.73 0.70 0.84 
 O-H...N 30 1 0.54 0.44 1.11 1 0.56 0.49 1.09 
 All 26 3 0.99 0.98 0.18 2 0.98 0.96 0.26 
 C-O 26 1 0.97 0.97 0.27 1 0.95 0.95 0.36 
 O-H 26 1 0.94 0.93 0.42 1 0.88 0.87 0.59 
 O-H...N 26 1 0.72 0.70 0.89 1 0.77 0.76 0.81 
Syn           
 All 30 4 0.97 0.92 0.30 2 0.95 0.89 0.37 
 C-O 30 1 0.90 0.90 0.51 1 0.91 0.91 0.49 
 O-H 30 1 0.82 0.79 0.69 1 0.75 0.72 0.82 
 O-H...N 30 1 0.59 0.48 1.04 1 0.57 0.51 1.08 
 All 26 2 0.98 0.96 0.25 2 0.99 0.97 0.20 
 C-O 26 1 0.98 0.98 0.25 1 0.96 0.96 0.34 
 O-H 26 1 0.93 0.92 0.44 1 0.90 0.89 0.54 
 O-H...N 26 1 0.87 0.86 0.61 1 0.78 0.78 0.78 
Anti           
 All 30 1 0.87 0.84 0.58 2 0.93 0.87 0.43 
 C-O 30 1 0.91 0.91 0.49 1 0.91 0.91 0.49 
 O-H 30 1 0.85 0.82 0.62 1 0.85 0.82 0.65 
 O-H...N 30 1 0.46 0.38 1.21 1 0.61 0.55 1.02 
 All 26 3 0.98 0.95 0.24 2 0.97 0.95 0.28 
 C-O 26 1 0.97 0.97 0.29 1 0.95 0.94 0.39 
 O-H 26 1 0.90 0.84 0.54 1 0.93 0.90 0.46 
 O-H...N 26 1 0.50 0.30 1.18 1 0.70 0.60 0.91 
              
These results indicate that there is no need to use the more expensive B3LYP/6-311++G(d,p) level 
of theory as the models generated using HF/6-31G(d) are of equal and sometimes of superior 
quality.  The lowest RMSEEs are produced by the all-bond-length models followed by the r(C-O), 
r(O-H) and r(O-H…N) models, respectively.  This is confirmed by the VIP plot for the all-bond-
length models ranking the importance of these bond lengths to the models in the same order. In 
most cases the difference between the statistics for the all-bond-length models and the r(C-O) 
models is small, suggesting that the single r(C-O) models are suitable for predicting pKa of halogen 
phenols.  Considering the single-bond-length models, the syn conformation generally produces 
the lowest RMSEEs.  This is because the influence of the o-halogen substitution is constant for 
each complex considered.  For the lowest-energy and the anti-conformation models, the 
influence is not constant and therefore corrupts the correlations. For example, the anti 
conformation models created using r(O-H…N) have the highest RMSEE. This is caused by 2-chloro-
6-methylphenol (compound 174).  The presence of the methyl group causes the O-H…N bond 
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length to be much larger than it is for the other compounds, presumably because of steric 
hindrance and repulsions between the hydrogens, and therefore has a predicted pKa much higher 
than the other compounds when the experimental pKa is not the highest of all halogen phenols.  
Han and co-workers156, 157 found that separate correlations were required for pKa with r(O-H…N) 
for di-ortho halogen phenols because of steric interference.  By using the syn conformation, every 
compound is exposed to steric interference from the o-halogen substitution, although it appears 
that separate correlations may still be needed for r(O-H…N) and possibly r(O-H).  
Pentabromophenol (compound 142) corrupted the correlations for all the r(O-H…N) models.  Han 
and Tao157 excluded this compound from their equations on the basis that the full geometry 
optimisation of its complex with ammonia had not converged (note that our geometry 
optimisation of this complex did converge though).  Removing this compound from the r(O-H…N) 
model with the syn conformations, which is the best r(O-H…N) correlation, did not improve it 
enough to be better than the r(C-O) model. 
 
This investigation into using an ammonia probe demonstrates that single bond-lengths can be 
used to predict the pKa of o-halogen phenols. The results obtained from HF/6-31G(d) and 
B3LYP/6-311++G(d,p) are comparable.  The use of r(C-O) with the syn conformation produced the 
best statistics for the single-bond-length models and has the advantage of avoiding erratic 
predictions caused by non-halogen ortho-substitutions for di-orthophenols and the need for 
separate correlations for di-ortho-halogenated phenols.  However, comparing the r(C-O) model to 
that obtained using the monomeric phenols where an   ,    and RMSEE of 0.97, 0.97, and 0.27, 
were obtained, respectively, the use of an ammonia probe is unnecessary considering the 
increase in time taken to perform the geometry optimisation.  Large improvements are seen in 
the models using the r(O-H) bond length obtained from the o-halogen phenol-ammonia complex 
compared to those models obtained from the monomeric halogen phenols. However, the 
improvements are not strong enough to make the use of a probe the preferred option over the 
monomeric r(C-O) model. 
 
Zhang and co-workers performed density functional calculations (B3LYP/6-311++G(d,p)) on the 
complete series of hydroxybenzoic acids158.  They concluded that, for the twelve compounds that 
had experimental pKa values, the use of an ammonia probe produced stronger correlation than 
the monomer.  We have repeated the calculations with and without the probing ammonia and 
compared the correlations to those obtained using HF/6-31G(d) (Table 4.35).  The conformation 
with the carboxylic OH and ammonia probe on the opposite side from the ortho substitution was 
used to minimise steric hindrance161. The ammonia probe was placed collinearly with the acidic 
OH bond to form a hydrogen bonded complex with the hydroxybenzoic acids (Figure 4.13).    
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Using a higher level of theory and an ammonia probe produce slightly better correlations than 
those obtained with HF/6-31G(d).  The results obtained for the monomer using HF/6-31G(d) do 
not seem to suffer a deterioration when the probe is removed, like those obtained using B3LYP, 
which supports the use of the monomer and the lower level of theory. 
 
Figure 4.13.  The general structure and number scheme for the hydroxybenzoic acid-ammonia complex. 
 
Table 4.35.  The statistical details of the correlations for the hydroxybenzoic acids modelled by Zhang et al.
158
  
  B3LYP HF 
Compounds Bonds    RMSEE    RMSEE 
Hydroxybenzoic acids with probe      
 r(O-H) 0.98 0.15 0.97 0.20 
 r(O-H…N) 0.99 0.12 0.98 0.17 
Hydroxybenzoic acids monomer      
 r(O-H) 0.85 0.44 0.96 0.23 
 
Nine of the fourteen o-hydroxybenzoic acids from the benzoic acid data set (modelled above) 
were not considered by Zhang et al. as they had different substitutions in the meta and para 
positions (i.e. methyl, bromine, benzene, nitro, chlorine, amine). Our current work expands on 
theirs by showing that the correlations obtained including these nine compounds with 
hydroxybenzoic acids retains the very good statistics of the single-bond length models, as shown 
in Table 4.36.  The results are consistent with those for the twelve acids and suggest that only 
small improvements are achieved by using a probing molecule compared to using the monomer in 
conjunction with the HF/6-31G(d) level of theory.  
 
Table 4.36.  The statistical details of the correlations for the hydroxybenzoic acids modelled by Zhang et al.
158
 
including nine o-hydroxybenzoic acids with non-hydroxyl substitutions in the meta and para positions.    
  B3LYP HF 
Compounds Bonds    RMSEE    RMSEE 
Hydroxybenzoic acids with probe      
 r(O-H) 0.97 0.19 0.96 0.21 
 r(O-H…N) 0.98 0.16 0.97 0.19 
Hydroxybenzoic acids monomer      
 r(O-H) 0.78 0.48 0.94 0.25 
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4.4 Discussion: Summary and Application 
 
Data sets of phenols, benzoic acids and anilines have been deconstructed and high-correlation 
subsets have been identified where one ab initio bond length, calculated at the HF/6-31G(d) level 
of theory, can be used to predict pKa.  For the phenol dataset, lower RMSEEs were found when 
they were modelled as o-phenols and m-/p-phenols separately.  The o-phenols had an RMSEE 
greater than 0.5 pKa units when they were modelled together using all the bond lengths.  When 
r(C-O) and r(O-H) were used alone to predict pKa, the models drastically reduced in quality. 
Subsequent analysis of the observed versus predicted plots for these two bond lengths revealed 
the possibility of improving the predictions by further deconstructing the data set in to high-
correlation subsets.  Notably, that the high-correlation subsets, identified in the predicted versus 
observed correlation plots, were chemically meaningful.  These high-correlation subsets, which 
included o-nitrophenols, o-halogenphenols, o-alkylphenols, o-phenols capable of forming internal 
hydrogen bonds and o-methoxy/ethoxyphenols, were fully analysed by comparing all-bond-length 
models to single-bond-length models.  All-bond-length models differ from single-bond-length 
models in their capacity to highlight outliers.  Outliers are readily exposed in single-bond-length 
models, where they cannot benefit from the fitting flexibility offered by all-bond-length models.  
In other words, the simplicity of the single-bond-length models calls for the obligatory 
investigation of a number of suspicious compounds. The majority of outliers could be explained 
by wrong conformations, erroneous experimental pKa values and structural differences with the 
rest of the compounds in the high-correlation subset.  In most cases, r(C-O) models were the best, 
compared to all-bond-length and r(O-H) models. 
       
The m-/p-phenol models for r(C-O) and r(O-H), constructed using all the compounds, were 
comparable to the all-bond-length model, which was not the case for the o-phenols.  However, 
because improved models were found by separating the o-phenols into high-correlation subsets, 
the same separation was carried out for the m-/p-phenols.  Small improvements were noted but 
these were not comparable to the improvements seen for the high-correlation subsets of o-
phenols.  For all the phenols, r(C-O) consistently provided the best models. 
   
Through analysis of the phenol data set, we proposed rules to decide in which conformation the 
phenols need to be optimised in order to make the best possible prediction. Secondly, these rules 
also determined which high-correlation subset scores the best prediction.  In the cases of the 
phenols, these rules were decided based on the energy of each compound. We note that no 
compound violated these rules. 
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The benzoic acids were subjected to a similar analysis as the phenols.  From previous work on this 
data set in Chapter 3, it was known that the bonds making up the carboxylic acid group produced 
the best correlation with pKa and therefore we limited the analysis to just these four bonds.  The 
m-/p-benzoic acids showed excellent statistics for single-bond-length models compared to the all-
bond-length model. Hence, no high-correlation subsets were determined for these compounds.  
For the m-/p-benzoic acids, r(C-O) provided the highest    value and the lowest RMSEE.  High-
correlation subsets were identified from the o-benzoic acids, for o-halogenbenzoic acids and o-
hydroxybenzoic acids. 
 
The energy of the different o-halogenbenzoic acids could not be used as a definitive guide to 
determine from which conformation the bond lengths should be taken.  Two single-bond-length 
models, r(C-C) and r(O-H), showed comparable statistics to the all-bond-length model.  The r(C-C) 
produced the lowest RMSEP when outliers had been removed. Furthermore, the low RMSEP 
obtained for the r(C-C) model required two compounds to be optimised in the syn conformation, 
which we know was not the lowest energy. However, the syn conformation was required to 
comply with the rest of the high-correlation subset.  
 
The lowest energy conformers of the o-hydroxybenzoic acids were of the same conformation 
across the series and were used to build the models for this high-correlation subset.  The four 
bonds investigated for single-bond-length models produced varying statistics.  The r(O-H) model 
produced the lowest RMSEE out of all the single-bond-length models and it was also lower than 
the all bond-length model.  By investigating this high-correlation subset with different bond 
lengths we were able to explain why two compounds (2,6-dihydroxybenzoic acid (compound 252) 
and 2-hydroxy-3,5-dinitro-benzoic acid (compound 259)) were determined as outliers in Chapter 3 
and our publication.  By using r(O-H) alone the pKa of these compounds can be predicted from the 
remaining compounds in this high-correlation subset. 
 
The analysis of all the bond lengths in the common skeleton of the anilines highlighted that the 
bonds associated with the CNH2 group contributed the most to the all-bond-length model.  As was 
seen for the o-phenols and o-benzoic acids, high-correlation subsets could be extracted from the 
o-anilines, which were chemically meaningful and produced good models using just one bond 
length.  r(C-N) consistently produced the best models for the o-halogen, o-nitro and o-alkylaniline.   
The models created with r(N7-H8) and r(N7-H9) were always inferior to those created with r(C-N). 
   
In contrast to the single-bond-length models for m-/p-phenols and benzoic acids, the RMSEE for 
the m-/p-aniline model using the r(C-N) was much higher than that of the all-bond-length model 
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and nearly greater than 0.5 pKa units.  Constructing separate models for the m-anilines and p-
anilines highlighted that it was the m-anilines that caused the high RMSEE.  This unusual finding 
remained when a further twenty m-anilines where added to the data set.  We were unable to 
identify high-correlation subsets from the models constructed with the thirty-two m-anilines and 
presently are unable to explain this interesting discrepancy. 
 
In this study our emphasis has been on accuracy rather than globality.  The results demonstrate 
that one bond length from the group of compounds of interest can be used to predict pKa.  In 
order for this to work however, high-correlation subsets need to be identified and treated 
separately.  Generally, properties of ortho-substituted compounds are notoriously more difficult 
to predict than m-/p-substituted compounds.  This has been demonstrated by the vast 
improvements in the statistics of the ortho models when the high-correlation subsets were 
identified.  While high-correlation subsets were identified for the m-/p-phenols, the 
improvements in modelling these separately were minor. 
   
Some may highlight certain drawbacks in attempting to model pKa with a single bond-length.  
These include the need for many highly localised models that require experimental pKa values to 
construct models and may not be applicable to a compound for which a pKa prediction is needed.  
Furthermore, the need to consider different conformations may be regarded an unnecessary 
hindrance.  However, we argue that these are advantages of using a single bond-length.  We have 
shown that the predictions from high-correlation subsets are more accurate, modelled with a 
single bond-length, compared to using multiple bond lengths and combining more diverse 
compounds.  The use of high-correlation subsets and a single bond-length revealed compounds 
with wrongly assigned experimental pKa values that were not clearly obvious from all-bond-length 
and all compound models.  In the majority of cases the lowest energy conformer for each 
compound was the same as that of the other compounds and so was used as a guide to 
determine which conformer should be used.  Where this was not the case, e.g. for two of the 
halogenbenzoic acids, the lowest energy conformation of the other compounds in the high-
correlation subset was used to correct the conformation from which the bond lengths were 
calculated and restore consistency for all compounds.  The energy can also be used to determine 
which high-correlation subset a compound belongs to or should be predicted from.  We have 
even demonstrated the ability of the single bond- length models to extrapolate outside the pKa 
range of the compounds used to construct it. 
   
The division of the data sets in order to find high-correlation subsets was not a trivial task. 
However, the resulting procedure offers a practical and simple approach to predict pKa and can be 
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applied to more complex structures.  Drug discovery programmes generate numerous, similar 
structures when a SAR is being explored.  If pKa is important to the activity and the compounds 
form a high-correlation subset then this procedure can be used.  The most time consuming step 
would be the determination of the high-correlation subsets and identification of the bond length 
that correlates the strongest with pKa.  Producing a pKa prediction tool that contains hundreds of 
equations and programming it to know which equation is the right one to use is straightforward 
and computationally undemanding. 
 
The use of the HF/6-31G(d) level of theory stems from recent work69, 152 where using higher levels 
of theory did not improve the models created.  We confirmed this by comparing the correlations 
obtained using B3LYP/6-311+G(2d,p) for some of the high-correlation subsets and the statistics 
did not improve.  The use of an ammonia probe also did not improve the results either.  The most 
time consuming step in predicting the pKa of a new compound is the geometry optimisation.  We 
compared the time for an example compound (benzoic acid), at HF/6-31G(d) and the higher level 
B3LYP/6-311++G(d,p) using the ammonia probe.  For the monomer the optimisation took 7 mins 
using HF/6-31G(d) and 1 hour 23 mins using B3LYP/6-311++G(d,p).  The calculation time increased 
to 21 mins and 1 hour 29 mins , when the ammonia probe was included, for HF/6-31G(d) and 
B3LYP/6-311++G(d,p), respectively.   We have demonstrated that the prediction of pKa using a 
single bond-length can be applied beyond, for example chlorophenols, bromophenols and 
fluorophenols.  Furthermore, a single bond-length can be used to predict poly-substituted 
compounds with different substituents provided a suitable high-correlation subset model has 
been constructed. 
 
To test the use of single bond lengths to predict pKa, we chose 24 compounds from a data set of 
drug molecules127, that were part of a 197 compound set used to compare nine pKa prediction 
packages (Figure 4.14).  It contains 20 phenols and 4 anilines for which micro pKa values had been 
measured.  There were also 7 carboxylic acids in the original data set but we had already 
considered four of them and we had no suitable subset models from which we could predict the 
remaining three.  The structures of the 24 molecules were taken from the supplementary 
information provided by Liao and Nicklaus and optimised at the HF/6-31G* level of theory.  In line 
with our results, we optimised the ortho-substituted molecules in the conformation determined 
by our models and arbitrary conformations for meta-/para-substituted molecules.  We only 
considered the neutral forms of the drugs.  The relevant bond lengths were extracted and 
subjected to relevant bond length models to predict the pKa.   
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385     Actetaminophen 390      17α-Dihydroequilin 
  
386     Chlorotetracycline 391    17β-Dihydroequilin 
  
387     Oxytetracycline 392     17β-Dihydroequilenin 
  
388     Tetracycline 393     Enkephalin 
 
 
389     Clioquinol 394     17β-Estradiol 
N
H
O
OH
RAC
OH
OH
HH
RAC
OH O OH
OH
O O
NH
2
OH
N
H
H
H
OHCl
RAC
OH
OH
HH
RAC
OH O OH
OH
O O
NH
2
OH
N
H
OH
H
OHH
RAC
OH
OH
H
RAC
OH O OH
OH
O O
NH
2
OH
N
H
H
H
OHH RAC
OH
N
H
N
H
N
H
NH
2
O
O
O
O
N
H
S
OH O
N
OH
I
Cl
RAC
OH
OH
116 
 
  
395     Estrone 400     Normorphine 
  
396     Ethinyl estradiol 401     Morphine-6-glucuronide 
  
397     Isoproterenol 402     Tyrosine 
  
398     Labetalol 403     Vanillin 
 
 
399     Morphine 404      Iso-Vanillin 
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405     ortho-Vanillin 408      Procaine 
  
406      4-Aminobenzoic acid 409      Sulfacetamide 
 
 
407      Benzocaine  
Figure 4.14.  The structures ID and name, taken from Liao and Nicklaus
127
, of the drug molecules we predicted the pKa 
for.  The micro pKa of interest is highlighted in grey. 
 
Table 4.37 provides the experimental pKa of the 24 molecules and Table 4.38 gives the predicted 
pKa values from the nine pKa prediction programmes compared by Liao and Nicklaus
127.  Some of 
the molecules were already present in the data set that we used to create single bond-length 
models. These are highlighted in Table 4.37 with the experimental pKa used by Tehan et al.
96, 97 
included.  We also state which compound class the molecules belong too (i.e. either phenol or 
aniline), as well as from which high correlation-subset the prediction was made and which bond 
length was used.  Where the molecules were already in our models, we removed them in turn and 
reconstructed the single bond-length model to make the prediction.  We also used the 
experimental pKa provided by Liao and Nicklaus
127.  
    
We will first discuss the predictions for the phenols.   Acetaminophen (compound 385) was 
predicted to be 9.01 compared to the experimental pKa of 9.63.  An experimental value of 9.38 
was provided by Tehan et al., which is closer to the prediction made by the model constructed 
from the meta-/para-phenol high-correlation subset.  The predictions for the tetracyclic 
compounds 386, 387 and 388, which all have similar structures, were very poor.  We used the 
ortho-phenol model constructed from the ortho-phenols capable of forming internal hydrogen 
bonds.  The errors indicate that this was not a suitable model and a new model would be needed 
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to make predictions for these compounds. Compounds 390 and 391 only differed by the 
stereochemistry of a distant hydroxyl group separated by many bonds from the phenolic group of 
interest for the pKa predictions. One would expect such a distant change to have little effect on 
the pKa, which is why it is not surprising that all the pKa programmes (apart from Jaguar, see Table 
4.38) predicted the pKa of these two drugs to be identical.  However, the experimental pKa for 
these compounds curiously turned out to be 10.29 and 9.77, respectively.  Such an unexpectedly 
large pKa difference of 0.52 pKa units is difficult to accept and therefore needed resolving. Our 
original data source of Liao and Nicklaus’s work used the experimental pKa values published in a 
book78 in 2007.  A check of this source confirmed that Liao and Nicklaus correctly adopted the pKa 
values and structures from this book.  We therefore checked the primary reference168 where the 
experiments to determine the pKa values of these two compounds were performed.  The pKa of 
compound 390 was the same (i.e. 10.29) as that quoted in Liao and Nicklaus’s work.  The pKa for 
compound 391 did not relate to that compound and actually was that of 17β-dihydroequilenin168.  
The structure of 17β-dihydroequilenin is shown in Figure 4.14 and labelled 392.  We did predict a 
small difference for compounds 390 and 391, but when the correct structure was used the 
prediction was much better.  We used the correct structure and predicted the pKa from three 
(ACD, Marvin and SPARC) of the nine programmes used in the pKa comparisons.  All three 
programmes made an accurate prediction when the correct structure was used. The absolute 
error (AE) (calculated as                  ) for compound 392 was 0.35 compared to AEs for the 
nine programmes that ranged from 0.05 to 1.36.  The MAD of our predictions for steroids 393, 
394 and 395 was 0.37.  We also correctly predicted the order of the pKa values, which only Epik, 
Jaguar and SPARC achieved as well.  It is interesting to note that Marvin, Pallas and Pipeline Pilot 
predicted the same pKa values for all three compounds suggesting they do not detect the different 
structures. 
   
Compound 397 had an AE of 0.74.  We predicted it from the model constructed from the ortho-
phenols capable of forming internal hydrogen bonds.  The structure was very different from those 
used to construct this model, which probably explains the poor predictions.  The opiates 398, 399, 
400 were predicted from the model constructed from ortho-methoxy substituted phenols, 
although they do not strictly have o-methoxy substitutions.  Considering this, the predictions for 
compounds 398 (AE = 0.58) and 399 (AE = 0.62) were reasonable, but the prediction for 
compound 400 (AE = 1.96) was poor.  The predictions from seven (no prediction was provided by 
Jaguar or SPARC) of the pKa programmes were mixed, with AEs between the range of 0.07-1.83.  
Compound 401 had a very accurate prediction with an AE of 0.07.  We did not make a prediction 
for compound 404 as we had previously excluded it as an outlier.  The prediction for compounds 
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402 (AE = 0.06) was very good and only reasonable for compound 403 (0.61).  The AE of these 
three compounds for the predictions from the nine programmes ranged from 0 to 1.51. 
 
We now focus on the four aniline compounds.  Two of the four substituted anilines were already 
in our original data set.  They were all predicted from the model constructed from the para-
anilines.  Table 4.39 gives the MAE for our predictions and for the nine programmes.  For all four 
anilines, the MAE ranged from 0.11 for SPARC to 1.21 for Pipeline Pilot.  The prediction from the 
r(C-N) model was 0.29, which ranks it the fifth lowest MAE prediction in Table 4.39.  An MAE of 
0.26 was obtained for the two anilines not present in our original data set.  This MAE was ranked 
third lowest.  The MAE ranged from 0.1 for ADME Boxes and SPARC to 1.79 for Pipeline Pilot.  
These results are encouraging considering the small number of para-substituted anilines and the 
use of only r(C-N).   
     
Table 4.37.  The experimental pKa values for the 24 drug molecules.  The model used to make the prediction from is 
also highlighted.   
Compound 
Class 
ID Exp. 
pKa 
Liao 
Exp pKa 
Tehan 
High-Correlation 
subset 
Bond 
length 
used 
Predicted 
pKa 
Absolute 
Error 
Phenols        
 385 9.63 9.38 Meta/Para r(C-O) 9.01 0.62 
 386 9.30 - Ortho-IHB r(C-O) 5.06 4.24 
 387 9.11 - Ortho-IHB r(C-O) 5.76 3.35 
 388 9.69 - Ortho-IHB r(C-O) 6.06 3.63 
 389 8.16 - Iodine containing molecules were not considered in this work 
 390 10.29 - Meta/Para r(C-O) 10.15 0.14 
 391 9.77 - Meta/Para r(C-O) 10.11 0.34 
 392 9.77 - Meta/Para r(C-O) 10.00 0.23 
 393 9.89 - Meta/Para r(C-O) 9.54 0.35 
 394 10.71 - Meta/Para r(C-O) 9.95 0.76 
 395 10.34 - Meta/Para r(C-O) 10.06 0.28 
 396 10.40 - Meta/Para r(C-O) 10.33 0.07 
 397 10.07 - No suitable high-correlation subset -see structure 
 398 7.41 - Ortho-IHB r(C-O) 6.67 0.74 
 399 9.40 - Methoxy r(C-O) 9.98 0.58 
 400 9.80 - Methoxy r(C-O) 10.42 0.62 
 401 9.36 - Methoxy r(C-O) 11.32 1.96 
 402 10.27 - Meta/Para r(C-O) 10.14 0.13 
 403 7.40 7.40 Methoxy r(C-O) 7.46 0.06 
 404 8.90 8.89 Methoxy r(C-O) 9.50 0.61 
 405 7.91 7.91 Identified as outlier previously 
Anilines        
 406 2.50 2.38 Para r(C-N) 2.02 0.48 
 407 2.52 2.51 Para r(C-N) 2.33 0.19 
 408 2.29 - Para r(C-N) 2.48 0.19 
 409 1.76 - Para r(C-N) 1.46 0.30 
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Table 4.38.  The predicted pKa for the 24 drug molecules made by nine programmes.  The values were taken from the supplementary material provided by Lioa and Nicklaus
127
. 
a Site was not calculated because of complexity. 
b Programme failed to predict value.   
ID Liao pKa ACD
121
 ADME Boxes
114
 ADMET Predictor
116
 Epik
126
 Jaguar
128
 Marvin
119
 Pallas
122
 Pipeline Pilot
117
 SPARC
118
 
  
Pred AE Pred AE Pred AE Pred AE Pred AE Pred AE Pred AE Pred AE Pred AE 
385 9.63 9.86 0.23 9.8 0.2 10.02 0.39 10.12 0.49 10.0 0.4 9.46 0.17 9.48 0.15 9.50 0.13 9.49 0.14 
386 9.3 8.03 1.27 11.4 2.1 8.53 0.77 7.55 1.75 a 
 
10.97 1.67 7.56 1.74 7.33 1.97 b 
 387 9.11 8.48 0.63 12.5 3.4 8.87 0.24 7.43 1.68 a 
 
11.43 2.32 8.04 1.07 7.79 1.32 b 
 388 9.69 8.50 1.19 12.0 2.3 8.90 0.79 8.49 1.20 a 
 
11.44 1.75 8.06 1.63 7.81 1.88 b 
 389 8.16 7.23 0.93 7.9 0.3 7.91 0.25 6.15 2.01 8.3 0.1 7.34 0.82 3.83 4.33 7.90 0.26 7.80 0.36 
390 10.29 10.15 0.14 10.5 0.2 10.24 0.05 11.01 0.72 10.8 0.5 9.41 0.88 10.28 0.01 11.12 0.83 10.40 0.11 
391 9.77 10.15 0.38 10.5 0.7 10.24 0.47 11.01 1.24 10.7 0.9 9.41 0.36 10.28 0.51 11.12 1.35 10.40 0.63 
392 9.77 - - - - - - - - - - - - - - - - - - 
390* 
 
10.08 
         
9.41 
     
10.41 
 391* 
 
10.08 
         
9.41 
     
10.41 
 392* 
 
9.78 
         
9.79 
     
9.91 
 393 9.89 9.97 0.08 9.8 0.1 9.94 0.05 10.15 0.26 a 
 
9.51 0.38 9.71 0.18 8.53 1.36 10.00 0.11 
394 10.71 10.27 0.44 10.5 0.2 10.41 0.30 11.42 0.71 10.9 0.2 10.33 0.38 10.37 0.34 13.18 2.47 10.54 0.17 
395 10.34 10.25 0.09 10.4 0.1 10.30 0.04 11.19 0.85 10.7 0.4 10.33 0.01 10.37 0.03 13.18 2.84 10.48 0.14 
396 10.4 10.24 0.16 10.4 0.0 10.41 0.01 11.41 1.01 10.8 0.4 10.33 0.07 10.37 0.03 13.18 2.78 10.51 0.11 
397 10.07 9.60 0.47 9.5 0.6 9.81 0.26 9.75 0.32 a 
 
9.81 0.26 9.38 0.69 10.01 0.06 10.49 0.42 
398 7.41 8.21 0.80 7.7 0.3 9.28 1.87 8.20 0.79 a 
 
8.05 0.64 8.04 0.63 8.54 1.13 9.98 2.57 
399 9.4 9.48 0.08 9.4 0.0 9.71 0.31 11.22 1.82 a 
 
10.26 0.86 10.38 0.98 8.16 1.24 10.34 0.94 
400 9.8 9.54 0.26 9.7 0.1 8.54 1.26 9.89 0.09 a 
 
9.77 0.03 9.22 0.58 9.67 0.13 10.96 1.16 
401 9.36 9.43 0.07 9.6 0.2 9.70 0.34 11.19 1.83 a 
 
10.25 0.89 10.43 1.07 8.16 1.20 b 
 402 10.27 10.01 0.26 10.2 0.1 10.02 0.25 10.38 0.12 a 
 
9.79 0.48 9.43 0.84 10.47 0.21 10.47 0.21 
403 7.396 7.78 0.38 7.6 0.2 8.91 1.51 7.62 0.22 7.6 0.2 7.81 0.41 7.59 0.19 7.25 0.15 7.79 0.39 
404 8.889 9.25 0.36 8.7 0.2 9.53 0.64 9.12 0.23 9.2 0.3 9.39 0.50 8.98 0.09 8.89 0.00 9.18 0.29 
405 7.912 8.18 0.27 7.9 0.0 7.98 0.07 8.25 0.34 7.7 0.2 8.74 0.83 8.17 0.26 7.91 0.00 7.58 0.33 
406 2.5 2.51 0.01 2.1 0.4 2.53 0.03 2.84 0.34 a 
 
2.69 0.19 2.04 0.46 2.19 0.31 2.36 0.14 
407 2.515 2.51 0.01 2.6 0.1 2.67 0.16 2.03 0.49 2.7 0.2 2.78 0.27 2.51 0.01 3.46 0.95 2.39 0.13 
408 2.29 2.12 0.17 2.4 0.1 2.63 0.34 1.94 0.35 1.1 1.2 2.70 0.41 3.23 0.94 3.46 1.17 2.22 0.07 
409 1.76 0.93 0.83 1.9 0.1 1.81 0.05 1.51 0.25 1.8 0.0 2.14 0.38 1.87 0.11 4.16 2.40 1.64 0.12 
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Table 4.39.  MAE for all four aniline molecules and for the two anilines not in our original dataset. 
Method 
MAE 
(4 anilines) 
MAE 
(2 anilines) 
r(C-N) 0.29 0.26 
ACD 0.25 0.50 
ADME Boxes 0.2 0.1 
ADMET Predictor 0.14 0.20 
Epik 0.36 0.30 
Jaguar 0.5 0.6 
Marvin 0.31 0.40 
Pallas 0.38 0.53 
PP 1.21 1.79 
SPARC 0.11 0.10 
   
   
In Table 4.40 we present the single bond-length equations that can be applied to the prediction of 
pKa for suitable compounds.  We encourage an extension of this list of equations to cover more 
chemical space using the information and protocols we have devised.   
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Table 4.40.  The high-correlation subsets we investigated with their associated equation to predict pKa.  The number of compounds used to construct the equation and relevant statistics are also 
provided. 
 
 
 
Compound 
Class 
High-Correlation-Subset Equation # 
compounds 
   RMSEE    RMSEP rCV
2
      
    
  
Phenols o-nitro phenols pKa = 137.575r(C-O) – 337.575 22 0.94 0.48 0.94 0.50 0.93 0.93 0.87 
 o-halogen phenols pKa  = 147.411r(C-O) – 365.540 26 0.97 0.27 0.97 0.29 0.97 0.97 0.94 
 o-alkyl phenols pKa  = 162.106r(C-O) – 405.207 25 0.91 0.34 0.9 0.37 0.89 0.87 0.78 
 o-phenols-IHB pKa  = 160.912r(C-O) – 397.578 23 0.95 0.32 0.95 0.33 0.94 0.94 0.92 
 o-methoxy/ethoxyphenols pKa  = 128.767r(C-O) – 318.646 24 0.91 0.29 0.89 0.53 0.69 0.57 0.45 
 m-/p-phenols pKa  = 122.985r(C-O) – 304.553 55 0.87 0.41 0.85 0.43 0.85 0.83 0.72 
Benzoic Acids o-halogen benzoic acids pKa  = -53.316r(C-C) + 153.475 13 0.93 0.16 0.92 0.19 0.90 0.89 0.82 
 o-hydroxy benzoic acids pKa  = -975.258r(O-H) + 1758.265 14 0.98 0.13 0.97 0.15 0.96 0.96 0.92 
 m-/p-benzoic acids pKa  = -770.717r(O-H) +1390.747 43 0.92 0.13 0.91 0.13 0.91 0.91 0.84 
Anilines o-halogen anilines pKa  = 83.401r(C-N) – 216.089 10 0.95 0.39 0.94 0.44 0.93 0.92 0.90 
 o-nitro anilines pKa  = 89.774r(C-N) – 230.712 5 0.98 0.40 0.97 0.54 0.95 0.95 0.95 
 o-alkyl anilines pKa  = 47.563r(C-N) – 123.095 4 0.97 0.16 0.95 0.23 0.90 0.90 0.88 
 m-/p-anilines pKa  = 67.932r(C-N) – 175.213 23 0.80 0.48 0.76 0.54 0.73 0.68 0.57 
 p-anilines pKa  = 80.644r(C-N) – 208.635 11 0.95 0.27 0.93 0.33 0.92 0.92 0.92 
 m-aniline pKa  = 56.090r(C-N) – 144.080 12 0.66 0.59 0.61 0.63 0.56 0.41 0.34 
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4.5 Summary 
 
We have investigated the prediction of pKa for phenols, carboxylic acids and anilines.  We aimed 
to construct models that were able to predict pKa within 0.5 pKa units using a single bond length 
from a monomer geometry optimised by an affordable and sufficiently reliable ab initio method, 
which was determined to be HF/6-31G(d).  We achieved this by grouping molecules into high-
correlation subsets, which were visually identified from observed-versus-predicted plots.  It was 
pleasing to note that the structures in each subset contained a common substitution pattern, e.g. 
an OH group adjacent to a NO2 group. We have shown that improvements in model statistics are 
small for high-correlation subsets of meta-/para-substituted compounds compared to one model 
containing all these compounds. However, for ortho-substituted compounds, the statistics of 
high-correlation subsets improve much compared to a single model for all ortho compounds. 
  
In the majority of cases, the models constructed from a single bond length were superior or, at 
the very least, similar to the models constructed using all the bond lengths.  In each all-bond-
length model, the most important bonds (i.e. those with the highest VIP value) were associated 
with the functional group where the deprotonation occurs.  However, the most important bond 
differed between high-correlation subsets.  For example, for the o-halogen benzoic acids, r(C-C) 
produced the best statistics, but for the o-hydroxybenzoic acids, r(O-H) was the best.  The use of 
an ammonia probe or a higher level of theory for the o-halogen phenols and the hydroxybenzoic 
acids provided no advantage over the use of single bond lengths generated for the monomer at 
HF/6-31G(d).  The constructed models were used to predict the pKa for a set of 24 drug molecules.  
The predictions were accurate (MAE 0.06 to 0.62) for all the molecules, apart from those where a 
reason for the poor prediction was identified.  For example, one reason could be that a suitable 
high-correlation subset model was not available or that the experimental pKa turned out to be 
wrong.  We have listed fifteen single-bond-length equations from which the pKa of relevant 
compounds can be predicted.  We encourage an extension of this list of equations, which can be 
constructed in a relatively small amount of CPU time on a standard PC.  
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Chapter 5                                                                                                            
Prediction of Ames Mutagenicity of Carbocyclic and Heterocyclic 
Primary Aromatic Amines Using ab initio Charge Densities                                                                                                       
 
5.1 Introduction 
5.1.1 Drug Toxicity and Attrition Rates 
 
Toxicology is the study of adverse effects of chemicals on living organisms.  Historically, toxicology 
formed the basis of therapeutic and experimental medicine.  Today, it continues to develop and 
expand by assimilating knowledge and techniques from branches of biology, chemistry, 
mathematics and physics. 
 
Safety issues relating to drug toxicity occur throughout the drug discovery process.  Since the 
number of drugs discovered in pharmaceutical research has fallen in the last decade, it has 
become crucial to look at the reasons for failures169. 
 
There are a number of reasons why toxicity has become an important issue.  Two decades ago, a 
major problem for the pharmaceutical industry was unpredictable metabolism and 
pharmacokinetics in humans170.  Figure 5.1 shows that increased knowledge about the basic and 
practical aspects of human metabolism and distribution have helped a great deal.   Far fewer 
drugs fail in development due to the iterative process of chemical synthesis, target screening, and 
in vitro metabolism studies.  
 
 
Figure 5.1.  Reasons for the termination of drug candidates in development between 1964-1985
170
 and in 2000
171
. 
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Less progress has been made in accurately predicting human toxicity problems with drugs and the 
challenge remains considerable.  Human adverse drug reactions (ADRs) are one of the most 
common causes of pharmaceutical product recall.  An estimated 100,000 deaths per year are 
attributed to ADRs, making it the sixth leading cause of death in the United States172. 
5.1.2 Genetic Toxicology and Primary Aromatic Amines 
 
Genetic toxicology is the study of the ability of chemicals to cause heritable or somatic genetic 
defects in humans.  Genotoxicity encompasses DNA damage (chemical modification), 
mutagenicity (point mutation), clastogenicity (chromosome breakage) and aneugenicity 
(chromosome loss) caused by a chemical or its metabolites. 
 
Carbocyclic and heterocyclic primary aromatic amines (AAs) are one of the most important classes 
of industrial compounds as they are widely used in the cosmetic, dye, pesticide, petrochemical 
and pharmaceutical industries.  They are also known to be present in tobacco smoke and cooked 
meats.  The chemical reactivity of AAs is an asset to drug synthesis but a bane for biological 
systems.  While this compound class is ubiquitous in drug molecules (e.g. Ropivicaine, Lidocaine, 
Piroxicam, Lornoxicam, Tenooxicam, Atorvastatin, Leflunomide, Sorafenib and Acomplia), their 
genotoxic tendencies are perceived as a serious risk.  Cleavage of the appropriate amide bond in 
these compounds means these drugs have the potential to release aromatic amines in vivo. 
 
Cytochromes (CYPs) P450s are a family of haem-containing proteins that catalyse the metabolism 
of a broad range of molecules173, 174, including the majority of drugs175.  Fifty-seven P450s have 
been identified and they account for approximately three-quarter of the enzymes involved in drug 
metabolism.  Of the fifty-seven human P450s, five are involved in ~95% of these reactions (Figure 
5.2).  They are implicated in toxicological events because they have the ability to metabolise 
molecules that present no risk to human health into compounds that are toxic.  CYP P450 1A2 
(CYP1A2) accounts for approximately 13% of hepatic P450s176 and is implicated in the metabolism 
of drug molecules such as paracetamol and caffeine177, as well as AAs. 
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Figure 5.2.  Contributions of enzymes to the metabolism of marketed drugs.  The results are from a study of Pfizer 
drugs, and similar percentages have been reported by other pharmaceutical companies.  (A)  Fraction of reactions on 
drugs catalyzed by various human enzymes.  (B)  Fractions of P450 oxidations on drugs catalysed by individual P450 
enzymes
173
. 
 
Figure 5.3 shows the widely accepted mechanism for the conversion of AAs to DNA-reactive 
metabolites.  The initial step in the activation of AAs is enzymatic N-oxidation by CYP1A2 to yield 
an N-hydroxylamine product.  The N-hydroxyl species can be further converted to highly reactive 
N-acetoxy or N-sulphate esters that permit a more facile heterolysis of the N-O bond or undergo 
direct N-O bond cleavage.  This process generates highly reactive electrophilic nitrenium ions, 
which can bind to DNA to form adducts, resulting in genetic damage, mutations and, ultimately 
carcinogenesis.      
 
 
 
 
 
 
 
 
Figure 5.3.  A scheme representing the metabolic activation of AAs and subsequent DNA binding
178
. 
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5.1.3 Using Carbocyclic and Heterocyclic Primary Aromatic Amines in Drug 
Candidates 
 
The regulatory agencies for pharmaceutical preparations require that all drug candidates are 
tested for the potential of causing genetic mutations.  The impracticality and cost of long-term 
animal tests means that an early judgement on compound toxicology needs to be based on a 
regulatory battery of in vitro tests179.  The three obligatory assays determine 1) genetic mutations 
in bacteria (i.e. the Ames test180); 2) chromosomal damage to mammalian cells (e.g. the 
chromosome aberration assay or the mouse lymphoma assay); and 3) chromosomal damage 
using rodent haematopoietic cells.  Not all positive results in genotoxicity assays preclude  further 
development of drug candidates, however, there is a concomitant high probability of rodent 
carcinogenicity and therefore, by implication, human carcinogenicity181, 182.  The highest concern is 
attached to positive outcomes in the Ames test because of the assay’s high specificity in relation 
to rodent carcinogenicity which shows a positive correlation of between 63-90%183.  Occasionally, 
genotoxic drugs can progress to market if their therapeutic benefit outweighs the risk associated 
with them, e.g. some oncology drugs. 
The risks associated with AA drug fragments have not halted their use since 89 drugs with this 
moiety are approved and an additional 131 molecules have entered clinical trails183.  International 
regulatory guidelines require a computational SAR assessment of a drug molecule184, 185  as part of 
the development process, or at very least an investigation of chemical structure to ensure the 
standard battery of International Committees on Harmonization (ICH) genotoxicity tests will be 
suitable for the drug in question186.  Guidance on SAR assessment of putative drug metabolites is 
less clear, however metabolites that trigger SAR alerts for genotoxicity or that are known 
mutagens would obviously represent a cause for concern in any drug development programme187.  
Most attention is focussed on predicting the likely outcome of AAs in the Ames test because of its 
ability to detect rodent carcinogens.  An introduction to the principles of the Ames test is given in 
Section 5.1.4.  Experimental details are provided in the next Chapter. Section 5.1.5 contains a 
review and discussion on literature and commercial methods for predicting the Ames test result 
for AAs.                  
5.1.4 The Ames Test 
 
The Ames test uses amino acid-requiring strains of Salmonella typhimurium and Escherichia coli to 
detect point and frameshift mutations, which involves substitution, addition or deletion of one or 
a few DNA base pairs180.  The principle of this test is that it detects compounds that mutate 
mutant bacteria back to the wild type and thereby restore the functional capability of the bacteria 
(revertants) to synthesise an essential amino acid.  The revertant bacteria are detected by their 
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ability to grow in the absence of the amino acid required by the mutant strain.  Often it is the 
metabolites of compounds that are responsible for their mutagenic activity, therefore the Ames 
test is performed in the presence (+S9) and absence (-S9) of rat liver homogenate, known as S9, to 
mimic mammalian metabolism.   
 
This bacterial reverse mutation test is long-established, relatively easy to conduct by trained 
persons and inexpensive188, 189.  However, in comparison to other commonly used toxicity 
assays190, a complete assay is low-throughput, results take at least three days to generate and 
gram quantities of test compound can be required, which are not necessarily available in the early 
stages of drug development .  Further considerations associated with the Ames test include: 
 
 The test utilises prokaryotic cells, which differ from mammalian cells in such factors as 
uptake, metabolism, chromosome structure and DNA repair process. 
 The test, conducted in vitro, requires the use of exogenous sources of metabolic 
activation, which cannot mimic entirely the mammalian in vivo conditions.  Thus the 
test does not provide direct information on the mutagenic and carcinogenic potency 
of a substance in mammals. 
 Although there is a correlation between Ames positive results and mutagenic activity 
in other tests, there are examples where mutagenic compounds are not detected in 
the Ames test and vice versa.  Reasons for this include the nature of the endpoint 
detected, differences in metabolic activation, or differences in bioavailability. 
 The Ames test is not appropriate for the evaluation of certain types of compounds, for 
example highly bactericidal compounds.   
 Although many compounds that are positive in the test are mammalian carcinogens, 
the correlation is not absolute. 
 
The factors discussed above prevent the extensive and early use of the Ames test in the lead 
optimisation stage, along with the other in vitro battery of tests for genotoxicity (Figure 5.4).  
There is the possibility to employ cut-down versions of the regulatory tests.  These typically 
reduce the scale of the test, for example by reducing the Ames test to only two strains of bacteria 
instead of the five required for a full assessment to provide early indications, however, the 
number of compounds that can be screened is still limited.  In line with modern drug discovery, 
there is a desire to screen for genotoxicity early191.  Identifying compounds with possible 
genotoxic liabilities early means high investment optimising the compound, that will most likely 
fail later on, will not be made.  Higher throughput assays have been developed192, 193 to give early 
indications on the likely outcome for a greater number of compounds in the battery of 
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genotoxicity tests, but their predictions are not absolute and they are not considered a 
replacement.     
 
 
Figure 5.4.  The generic path of drug discovery and development
194
, and where safety assessment takes place. 
 
Before a compound is selected as a candidate, all chemicals involved in the complete synthetic 
route (including intermediates) and potential metabolites of the target molecule will be exposed 
to in silico toxicity prediction tools.  If any of them are flagged as possible Ames-positive, then 
they will be tested unless reliable literature data can be sourced.  For Ames-positive AAs, it is 
important to consider two issues regarding their use in drug design.  Firstly, if the AA is an 
intermediate in a synthetic route, its levels as an impurity in the final product must be controlled.  
European guidelines state that genotoxic impurities can only be present up to a limit of 1.5  
µg/day195.  Remaining below this threshold is relatively easy for low dose drugs but becomes 
increasingly difficult when high doses are required.  Secondly, a drug candidate that has an 
embedded Ames-positive AA likely to be released through metabolism acting on the parent 
compound carries high risk and identifying this early is paramount. 
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5.1.5 Methods for predicting the mutagenicity of AAs 
 
A recent review discussed the vast number of non-commercial QSAR models that have been 
published to predict mutagenicity and carcinogenicity196.  The models can be divided into two 
categories: a) “local” models, i.e. QSAR models for congeneric classes; and b) “general,” or global 
or non-local models, i.e. QSARs for non-congeneric sets of chemical.  Predictions of mutagenicity 
for AAs are usually made from local models, although there are examples of general models being 
applied to AAs197-201.  Benigni and Bossa202 highlighted that non-local QSARs for non-congeneric 
chemicals are more prone to erratic predictions because modelling large sets of chemicals acting 
by different mechanisms makes it unavoidable for the use of large numbers of descriptors.  Local 
models for AAs can be divided further into models for the graduation of mutagenic potency and 
the discrimination between positive and negative compounds.  Mutagenic potency (LogMP) is 
usually the dependent variable (y-variable) used for continuous QSAR models.  It is calculated as 
the logarithm of the number of revertants per nanomole of chemical from the linear portion of 
the dose-response curve.  For discriminant models, compounds are assigned positive and negative 
labels based on an induction factor (IF) calculated from the Ames test results.  This factor is the 
quotient of the number of revertants per plate divided by the number of revertants per plate of 
the negative control.  Substances with an IF above two or three, depending on the bacterial strain, 
are considered positive.      
Numerous papers have been published attempting to predict the mutagenic potency of AAs using 
a variety of descriptors and statistical learning methods.  Debnath et al.203 gathered from the 
literature a set of 95 AAs acting on Salmonella typhimurium TA98 and TA100 +S9.  The authors 
presented correlations for a subset of 88 of these amines based on hydrophobicity (LogP), 
energies of the highest occupied (HOMO) and lowest unoccupied molecular orbitals (LUMO), and 
an indicator variable that designates the presence of three or more fused aromatic rings.  Their 
best result for TA98 has an  =0.898 (  =0.806204), although the quality of the model deteriorated 
when all 95 compounds were used.  A subset of 67 AAs were modelled for TA100 and produced a 
model with an   =0.87.  The importance of LogP was found to be nearly identical for both models 
and the electronic descriptors played a minor role.  Since the compilation of this data set, it has 
been revisited by many authors using different classes of descriptors.  Basak et al.205 used 
topological and geometric descriptors to model all 95 compounds with similar results i.e.  =0.893 
(  =0.797204).  Maran et al.206 calculated an extensive set of constitutional, geometrical, 
topological, electrostatic, and quantum mechanical descriptors for this data set.  These workers 
produced a six-parameter correlation with   =0.913 (  =0.834204).  The use of quantum 
mechanical calculations was criticised by Cash207 as too demanding on computational resource.  
Therefore, electrotopological state indices were used to produce an r=0.876 (  =0.767204).  Basak 
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and co-workers205 revisited the data set and found that the majority of the variance could be 
explained with topological parameters and the inclusion of LogP.  Geometric and quantum 
chemical parameters did not result in significantly improved predictive models.  All these studies 
used linear techniques e.g. MLR and PLS.  Vracko et al.208 attempted to detect the possibility of 
non-linear relationships between structure and mutagenicity of these compounds using artificial 
neural networks in conjunction with topological descriptors.  They achieved an   = 0.751; lower 
compared to the linear methods.  Volkova et al.209 studied how to select the minimal training set, 
which covers the information space efficiently.  They produced an impressive model with neural 
networks trained on only 30 of the compounds with an   =0.986.  The test set twice larger than 
the training set has a correlation between experimental and predicted activity of   =0.816.  Cash 
et al.210 revisited the QSAR equation constructed from electrotopological state (E-state) indices to 
perform external validation using a data set of 29 aromatic amines.  The    of the regression 
between predicted and experimental Log MP was 0.27, indicating that their original model had 
poor predictive accuracy for compounds in the test set.  Examination of the training and test sets 
revealed that only three of the eight descriptors in their original model were represented in the 
test set.  Both data sets were combined and then randomly split into a new training and test set.  
The new six-term equation had an    of 0.77 and    of 0.70.  However, an    for the test set of 
0.44 indicated that the new model provided little improvement.  It was concluded that the 
descriptors used could describe the training set relatively well but the results from external 
validation indicated possible over-fitting. It was also noted that compounds only differing in an 
alkyl substituent far away from the amine function greatly affected the LogMP.  This is something 
that the E-state indices cannot account for.  Bhat et al.211 increased the size of the Debnath data 
set to 181 AAs using data from a variety of literature sources.  Using AM1 optimised geometries, 
they calculated hundreds of molecular descriptors.  Using multiple linear regression techniques 
they accounted for 66% of the observed variation in the mutagenic potency.  Using neural 
networks they were able to account for 90% of the variation. 
Hatch et al.212  constructed a data set of 80 AAs of diverse structure and a range of 10 orders of 
magnitude in mutagenic potency.  They investigated numerous types of descriptors including, 
structural and quantum chemical ones.  The results were interpreted to show that a main 
determinant of mutagenic potency was the extent of the aromatic π-system.  Small contributions 
were made by dipole moments and the calculated stability of the nitrenium ion. 
Many of the methods discussed above highlight lipophilicity, and the HOMO and LUMO energies 
as important in determining the mutagenic potency of AAs.  Lipophilicity, usually included as LogP, 
is commonly considered a measure of the propensity of chemicals to be absorbed and 
transported, as well as of being able to interact with the receptors responsible for metabolic 
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activation.  The inclusion of the HOMO energies of the parent AAs agrees with the fact that the 
majority of AAs are mutagenic only in the presence of the S9 microsomal preparation, by which 
they are oxidised to the mutagenic metabolite.  The importance of the LUMO energies is less 
straight forward.  Given the first step in the metabolic activation of AAs is oxidation, it is the 
HOMO energy of the parent (or the LUMO energy of the oxidized nitrenium form), rather than the 
LUMO energy of the parent amine, that might be expected to correlate with the mutagenic 
potency.  To our knowledge the reason for the importance of the LUMO energy is unresolved.  It 
may point to the importance of the stability of the nitrenium ion (discussed below).  However, the 
LUMO energy of the nitrenium ion is not necessarily coincident with that of the parent amine213.  
Felton et al.214 evaluated a set of 23 amino-carbolines related to cooked food mutagens.  Their 
results showed a reasonably strong correlation (  =0.80) between LUMO energy and the 
observed mutagenic potential of several heterocyclic amine mutagens.  They reasoned, a lower 
LUMO energy means a higher electron affinity.  Using the reasoning that electron withdrawing 
groups should lead to lower LUMO energies, two novel, highly mutagenic heterocyclic amine 
analogues were proposed, but not tested.  The HOMO-LUMO energy gap is also considered to be 
an indication of stability213.  A large HOMO-LUMO energy gap suggests low reactivity. 
LogP, HOMO and LUMO energies are clearly important in predicting the mutagenic potency of 
AAs.  However, it should be noted that not all QSAR analysis of the Debnath dataset found these 
to be the best predictors of LogMP.  Indeed, Maran et al.206 did not include any of these 
descriptors, instead finding the most important descriptor to be the number or aromatic rings.  
Other workers201, 212 have also questioned the importance of LogP to predict mutagenic potency 
because they did not find good correlation with LogMP, which suggests it may be data set 
dependent.  QSAR equations, constructed from topological parameters, can be difficult to 
interpret and they tend do not to lend themselves to easy comparison and generalisation.  
However, some of these have also highlighted the number of aromatic rings as important213.     
 
Since the nitrenium ions have been implicated as the active electrophile in the reaction with DNA 
bases, it is reasonable to expect that LogMP may correlate with properties of these ions.  Ford 
and co-workers calculated heats of formation (ΔH) for Equation 5.1 by the semiempirical AM1 
method for a series of AAs, and observed a negative correlation of LogMP with ΔH215, 216 . 
          
              Equation 5.1 
         
An explanation of the correlation provided by ΔH of Equation 5.1 is that these enthalpy values 
indirectly relate to the lifetime and, therefore the selectivity of the nitrenium ions.  According to 
this explanation, the more stable and, therefore, longer lived the ion, the greater the mutagenic 
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potency.  This hypothesis was tentatively confirmed by Novak and Rajagopal217 who indirectly 
measured the lifetimes of nitrenium ions in solution for 18 AAs and observed a strong correlation 
with ΔH (  =0.74).  However, the importance of nitrenium ion stability in determining the 
potency of AAs has been questioned on larger data sets212.   
 
Borosky studied a set of 17 AAs using higher level DFT calculation, compared to semiempirical 
AM1 and Hartree-Fock ab intio methods previously used.  It was found that the formation of the 
nitrenium ion was more plausible through the N-O dissociation reaction calculated from acetic 
and sulphuric ester of the parent amine than from the related hydroxylamine.  Correlations with 
the calculated stability of the nitrenium ion were only found when the compounds classified as 
aromatic, imidazo-carbocyclic and imidazo-heterocylic, were separated.    The low correlations 
with ab initio nitrenium ion stabilities in previous work could be caused by the diversity of the 
data set considered212.   In this study, water was included implicitly as a solvent and was found to 
significantly stabilize the nitrenium ions but the same trend was observed for the gas-phase 
calculations.  In the follow-up study Borosky218 used only gas-phase calculations on a set of 43 AAs 
for this reason.  This time, the data set had to be split into six classes; aromatic; heteroaromatic; 
imidazocarbocyclic; imidazoheterocylic; dipyridoimidazole; and quinoxalines; to detect 
correlations.  Mutagenic potential was found to increase with nitrenium ion stability and an 
increased negative charge on the exocyclic nitrogen on the ion.  Correlations were found to be 
non-linear for certain classes of compounds, which in some cases contained as little as three data 
points.  The role of hydrophobicity was also investigated, although positive correlations were 
observed for each series of compounds, they were not as strong as the other descriptors. 
During lead optimisation, medicinal/computational chemists are usually interested in QSAR 
models that describe how the potency of a series of compounds is modulated by small changes in 
structure.  However, when considering mutagenic potential, it is also important to consider what 
distinguishes the Ames-positive compounds from those that are Ames-negative.  Discriminant 
models attempt to categorise these compounds using features of the molecular structure.  In 
relation to AAs, it has been demonstrated that the factors that modulate the mutagenic potency 
are usually different from those that make the difference between positive and negative 
outcomes in the Ames test219, 220. 
Leach et al.221 studied a number of reactions implicated in causing the mutagenicity of AAs.  The 
reaction energies, computed with (U)B3LYP/6-31G* for 312 compounds, involving the formation 
of the nitrenium ion in Equation 5.2 and Equation 5.3  were the only energies that were able to 
significantly discriminate between active and inactive compounds.  However, there was an 
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overlap between the energies for both, Ames-positive and Ames-negative compounds.  This 
method was able to discriminate the AAs and because only one parameter was used, it was 
possible to assign a probability to a compound of being Ames positive.  For example, a computed 
high reactivity should be avoided when designing new compounds.  Leach et al. also compared 
the discrimination achieved to that achieved by a large number of in house descriptors for the 
same compounds.  Only two descriptors were able to provide a similar discrimination but their 
interpretation was less straight forward.  It was interesting to note that LogP descriptors were 
worse than a larger number of other descriptors.  
          
             Equation 5.2 
  
                    Equation 5.3 
 
The use of nitrenium ion stabilities, introduced by Ford et al.215, has recently been extended to 
discriminate between 257 Ames-positive and negative AAs183.  From Equation 5.1, one can 
calculate relative energies ΔΔE according to Equation 5.4.       
                                       Equation 5.4 
 
A negative value for ΔΔE indicates that the nitrenium ion for the AA of interest is more stable than 
that for the reference aniline, and a positive value for ΔΔE indicates a less stable nitrenium 
aniline.  By implication, a negative value of ΔΔE should correlate with Ames-positive result, 
whereas positive values of ΔΔE should correlate with Ames-negative compounds.  The authors 
compared four different levels of theory and found AM1 provided a good balance between speed 
and accuracy.  They were able to correctly classify 85% of the data set.  Similar to the Leach et al. 
approach, their method is based on a continuous spectrum of ΔΔE values, which allowed them to 
observe and rationalize SAR for some series of molecules.  For example,  ΔΔE captured the trends 
going from Ames-positive to Ames-negative for some para-substituted anilines.  
Another approach is to use structure alerts originally purposed by Ashby and subsequently 
revised by Ashby and Tennant222 to highlight risks of mutagenicity.  Kazius et al.223 applied 29 
toxicophores to a data set of 4337 diverse chemicals.  They defined toxicophores as substructures 
that indicate an increased potential for mutagenicity, whether this is caused by DNA reactivity or 
not.  They were able to correctly classify 82% of the training set and 85% for an external test set 
of 535.  The statistics for 441 compounds with the specific aromatic amine toxicophore shows an 
accuracy of 86%.  The use of toxicophores for discriminating Ames results for AAs was taken 
further by Casalegno et al.224. They extracted diatomic fragments from the Debnath data set using 
MLR and neural networks to produce models with    values ranging from 0.77 to 0.91.  However, 
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the leave-one-out    values were inferior to those obtained by Maran et al.206 with a QSAR 
equation for the same data set. 
There are numerous commercial software packages available for the prediction of Ames 
mutagenicity, the most well known being DEREK225, TOPKAT226 and MultiCASE227.  The underlying 
algorithms range from rule-based expert systems to QSAR based methods.  DEREK is a knowledge- 
and rule-based expert system that makes semi-quantitative estimations as to whether or not an 
Ames positive moiety is present in the input chemical structure.  The output consists of a 
prediction about the presence and probability of a specific sub structure to result in a positive 
Ames result ranked with adjectives certain, probable, plausible etc. to impossible.  On the other 
hand, TOPKAT provides a probability of mutagenicity based QSAR models constructed from 
electrotopological descriptors.  It also provides a measure of similarity between the molecule of 
interest and the chemical space covered by the models.  MultiCASE dissociates each input 
molecule into 2-10 atom fragments and statistically evaluates the strength of association between 
the fragments (toxicophores) and similar ones from the database, assigning mutagenicity scores.  
The quantitative prediction of mutagenicity is further refined by taking into account 
physicochemical properties.  While predictions from these programmes are widely used and often 
requested by regulators, their accuracy is limited228.  Furthermore, AAs have been highlighted as a 
class of compounds for which the Ames predictions from DEREK and TOPKAT were particularly 
poor229.  
It was the importance of AAs in a medicinal chemistry context and the discrepancies over the 
importance of descriptors that motivated us to investigate this class of compound.  QTMS has 
previously been shown to produce good models for a set of 23 halogenated hydroxyfuranone 
derivatives that do not require metabolic activation to cause mutations in the Ames test.  More 
importantly, QTMS was successfully applied to a set of 23 triazenes that are only active in the 
Ames test with the addition of S9.  A model, including LogP as a descriptors, produced an    and 
   (leave-one-seventh out) of 0.86 and 0.74, respectively.  The remainder of this Chapter 
discusses the modelling of literature mutagenic potency for AAs using QTMS descriptors. 
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5.2 Methodology 
 
The QCT descriptors were used to investigate correlations with LogMP for a number of literature 
data sets.  Precise details about the investigations are provided in each section.  In short, 
compounds of interest were optimised with Gaussian03 using DFT (B3LYP/6-311+G(2d,p)) to 
produce the wave function from which the BCP properties were extracted.  All the BCP properties 
were considered, which included the electron density ρ, the eigenvalues of the Hessian of 
ρ, λ1, λ2, and λ3, the Laplacian 
2, the ellipticity ε, the kinetic energy density K(r), a 
more classical kinetic energy G(r) and the equilibrium bond length Re.      
5.3 Results and Discussion 
5.3.1 Sasaki Data Set 
 
As a first step, we selected three compounds that displayed a wide range in mutagenic potency230 
(Figure 5.5). 
 
 
 
 
 
1-NA     2-NA      2-AF 
 
 Figure 5.5.  1-naphthylamine (1-NA) with the β-carbon labelled, 2-naphthylamine (2-NA), and 2-aminofluorene (2-
AF). 
 
Experimental results231 indicate that 1-NA is almost exclusively ring oxidised at the β-carbon, 2-AF 
is almost exclusively N-oxidised and 2-NA is both ring and N-oxidised, with ring oxidation rates 
generally much higher than N-oxidation.  As ring oxidation is a detoxification mechanism, it means 
that the mutagenic potency increase according to 1-NA < 2-NA < 2-AF. 
Sasaki et al.230 suggested that the nitrenium ion stability is an important factor in explaining the 
mutagenic potency of these compounds.  For this reason, we calculated the BCP properties of the 
nitrenium ions as well as the parent compounds.  In line with experimental results, it was 
expected that the BCP properties of the common bonds in the three compounds would follow the 
mutagenic potency order once mapped onto each other.  However, this was not the case for 
either the parent compounds or their nitrenium ions, as 2-AF was the median value in many 
cases.  Different LogMP values were found in the literature which ordered the mutagenic potency 
of these compounds as 2-NA < 1-NA < 2-AF in contrast to Guengerich’s 1-NA < 2-NA < 2-AF.  
However the difference between LogMP for 1-NA and 2-NA was only 0.07 log units.  It is 
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important to note that the experimental results in the first instance were collected in the same 
laboratory, while the latter results were collected from various sources (1-NA232, 2-NA203, 2-AF233).  
As the BCP properties for 2-AF were the median values of the three compounds, in most cases 
they still failed to predict the mutagenic order, even when the order of 1-NA and 2-NA were 
swapped.  
5.3.2 Hatch Data Set 
 
Hatch et al.212  published a data set of 80 AAs (Appendix D).  We constructed a variety of PLS 
models with different combinations of BCP descriptors from the bonds of the common skeleton 
shown in Figure 5.6.      
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Figure 5.6.  The common skeleton and numbering scheme used for the 80 aromatic and heteroaromatic amines. 
All the models constructed had an    below 0.25 and a    below 0.21.  An example observed 
versus predicted plot is shown in Figure 5.7.    
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Figure 5.7.  An observed versus predicted plot from one of the models constructed for the 80 aromatic and 
heteroaromatic amines using the C-NH2 bonds. 
These poor correlations led us identify subsets of compounds that would provide better 
correlations.  The data set contained 25 aromatic amines and 25 1-methyl-imidazole-2-amine 
(MIA) derivatives.  We attempted to model these separately.  The results are reported in the 
following sections. 
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5.3.2.1 Aromatic Amines 
 
The increased size of the common skeleton for the aromatic amines allowed us to include more 
bonds and therefore more BCP descriptors.  The common skeleton included 6 C-C bonds, 1 C-N 
bond, 2 N-H bonds and 5 C-R bonds, where R is hydrogen if no substituent is present.     
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Figure 5.8.  The common skeleton and numbering scheme used for the aromatic amines.  
 
Different PLS models were constructed with different combinations of compounds and bonds in 
an attempt to explain the differences in LogMP for these compounds.  Different observed versus 
predicted plots were inspected. 
Table 5.1.  PLS models generated for the aromatic amines. The compounds related to the numbering can be found in 
Appendix D. 
 
Model 
no. 
No. of 
Compounds 
No. LVs       Comment 
A
ll 
ar
o
m
at
ic
 a
m
in
es
 
M1 19 3 0.85 0.61 C-C and C-N bonds 
M2 25 1 0.41 0.07 All bonds 
M3 25 1 0.36 0.09 C-C and C-N and N-H bonds 
M4 25 1 0.37 0.08 C-C and C-N 
M5 19 1 0.58 0.22 All bonds – Outliers 80, 76, 73, 43, 41, 21 removed 
M6 19 1 0.45 0.11 As M5 but C-C and C-N bonds 
M7 18 3 0.96 0.32 As M5 – 20 also removed 
D
ia
m
in
e 
R
em
o
ve
d
 M8 15 2 0.75 0.30 
C-C and C-N bonds – diamines 38, 42, 43, 52, 54, 58, 59, 
65, 66, 68 are removed. 
M9 15 1 0.61 0.21 As M8 – but all bonds 
M10 15 1 0.59 0.24 As M8 - but C-C, C-N, and C-H bonds 
D
ia
m
in
es
 M11 10 2 0.77 0.61 
C-C and C-N bonds – only diamines 38, 42, 43, 52, 54, 58, 
59, 65, 66, 68 included 
M12 10 2 0.91 0.56 As M11 – but all bonds 
M13 10 2 0.69 0.42 As M11 – but C-C, C-N and C-H bonds. 
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Key points arising from the PLS modelling given in Table 5.1 were; 
 No reasonable models could be constructed for the 25 aromatic amines (e.g. M2, M3, and 
M4) 
 Removal of compounds identified as outliers did not significantly improve the results (see 
M5 and M6). 
 Removal of 2-aminoanthracene, whose LogMP value is ~ 1.5 log units higher than all the 
other compounds in M5, improved the correlation (M5 compared to M7) but the    of 
0.32 suggested poor predictive ability.  The spread of experimental values is too narrow to 
be able to build a good model. 
 The correlations improved when the compounds with two amino groups were removed 
(see M8, M9 and M10). 
 The diamines produced good correlations when modelled separately, however, there 
were only 10 compounds in this set (see M11, M12, and M13). 
 
5.3.2.2 1-Methyl-Imidazole-2-Amine (MIA) derivatives     
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Figure 5.9.  The common skeleton of the 1-methyl-imidazole-2-amine derivatives. 
 
The common skeleton of the 1-methyl-imidazole-2-amine (MIA) derivatives is shown in Figure 5.9.  
The structures of the compounds were examined and subsequently grouped according to the type 
of ring fused to the C6-C7 bond.  The ring was either a phenyl ring or a pyridine ring where the 
position of the nitrogen atom changed in relation to MIA.  The different groupings are given in 
Table 5.2, where the atom numbering refers to Figure 5.10.  PLS was used in an attempt to 
correlate the BCP descriptors to the LogMP.  The results are provided in Table 5.3 and an 
observed versus predicted plot is shown in Figure 5.11 for the best correlation obtained.   
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Table 5.2.  The different MIA groups with the description of the structure. 
Group Description Colour assigned No. Of 
compounds 
1 N at the 4 position Grey 7 
2 N at the 7 position Orange 5 
3 No N atom i.e. benzo Green 6 
4 N atom at the 4 position, fused furan 
ring at the 5,6 position 
Purple 1 
5 N atom at the 5 position Pink 3 
6 N atom at the 6 position  Blue 3 
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Figure 5.10.  The atom numbering scheme used for the MIA derivatives. 
 
 
 
Table 5.3.  The PLS models generated for the MIA derivatives. 
 
Model 
no. 
No. of 
Compounds 
No. LVs       Comment 
A
ll 
C
o
m
p
o
u
n
d
s M14 25 1 0.51 0.28 All bonds 
M15 25 2 0.73 0.34 C-N and C-C bonds 
M16 25 3 0.54 0.45 C-N bond 
Ty
p
e 
1
, 2
 a
n
d
 3
 M
IA
 
M17 18 2 0.72 0.59 All 
M18 18 1 0.68 0.58 C-N and C-C bonds 
M19 18 4 0.79 0.68 C-N bond 
M20 18 2 0.77 0.71 Bond 6-7 
M21 17 2 0.88 0.85 Bond 6-7, 16 removed 
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Figure 5.11.  The observed versus predicted of model M16 plot for the MIA derivatives.  
 
The number of compounds in groups 1, 2 and 3 and the range of LogMP values allowed us to 
investigate these three subgroups together.  PLS was used to construct models for the 18 
compounds belonging to these subgroups (Table 5.3).  Models using the BCP descriptors from 
different bonds gave similar results in terms of    and    (See models M16, M17 and M19).  An 
inspection of the VIP plot for model M16, which was constructed from all the BCP descriptors in 
the common skeleton (Figure 5.9), highlighted the C6-C7 bond was the most important to the 
model (Figure 5.12).   
-2
-1
0
1
2
3
4
5
6
7
-4 -2 0 2 4 6
O
b
se
rv
ed
 L
o
gM
P
Predicted LogMP
Group 1
Group 2
Group 3
Group 4
Group 5
Group 6
142 
 
 
Figure 5.12.  The VIP plot for model M16. 
 
This suggested that the C6-C7 bond is most sensitive to structural changes in the MIA derivatives.  
QTMS usually highlights the bonds associated with the active centre, which in this case would be 
expected to be close to the amine group.  However, the C1-N2 BCP is separated by least three 
bonds from a BCP that is directly involved with structural or atomic differences.  This raises the 
issue of the sensitivity of BCP properties, that is how many bonds between a BCP are needed 
before the properties of the BCP are unaffected by substitutions.  This is something which is 
unresolved.             
Visual inspection of the structures showed that substitutions a number of bonds away from the 
mechanistically important NH2 group can significantly affect the mutagenic potency of these types 
of compounds.  The importance of the C6-C7 bond to the model demonstrates that properties of 
this BCP capture structural changes.   
Eight out of the nine BCP properties of the C6-C7 are found in the top ten most important 
properties to model M16.  We constructed a model using only the BCP properties of the C6-C7 
bond (M20) and saw slight improvements.  Compound 16 was identified as an outlier being the 
only group 1 compound that had a phenyl substituent.  It was removed from the modelling and 
the    and    improved (See M21).  Surprisingly, the electron density at the C6-C7 BCP produced a 
linear correlation with LogMP (Figure 5.13).    
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Figure 5.13.  A plot of the electron density at the C6-C7 BCP versus the logMP. 
 
Correlations of the BCP descriptors with LogMP were found but these required the splitting of the 
initial data set of 80 compounds.  Furthermore, certain compounds had to be excluded to produce 
reasonable correlations.  In an attempt to gain more insight into the use of BCP descriptors for 
this data set, we employed a number of statistical techniques.  Our aim was to improve the 
models while reducing the numbers of descriptors used.  We also wanted to investigate which 
descriptors and bonds contributed most to explaining the experimental mutagenic potency for 
both the aromatic amines and the MIA derivatives.  Two methods have previously been used in 
the context of QTMS for this purpose. 
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Feature selection has been performed by Esteki et al.64, 112 using multi-linear regression.  The same 
technique was performed with our set of aromatic amines and MIA derivatives, separately.  All 
the BCP descriptors from one bond are used to construct a multi-linear regression model.  The 
same was performed for the rest of the bonds in the common skeleton.  For example, this 
involves constructing fourteen models for the aromatic amines (one for each bond in the common 
skeleton).  The models are ranked according to their    value and the bonds that have the highest 
   are considered most important.  The same is performed with the BCP descriptors from the 
bonds selected as the most important.  For example, all the electron density descriptors for the 
selected bonds are used to construct a model.  The descriptors that have the highest    are 
considered most important.  The most important descriptors from the most important bonds are 
then only considered for further modelling.  All the multi-linear regression was performed using 
TSAR234 software package. 
We also performed a hierarchical PLS approach to select the most important descriptors and 
bonds.  PLS models were constructed for each BCP descriptor from all the bonds in the common 
skeleton.  Subsequently, descriptors with small VIP scores were gradually deleted until a model 
with only one descriptor remained.  A model was then constructed from the top two descriptors 
in each of the descriptor models and the stepwise deletion of descriptors repeated.  The    and 
   values were then inspected. 
Both these techniques can be used to reduce the number of descriptors used to construct models 
and also highlight which bonds and descriptors are most important.  We used both these 
techniques extensively but no substantial improvement in the models was observed (results not 
shown).           
5.3.3 Changing the Y-Variable 
 
The mutagenic potency of aromatic and heterocyclic amines can be measured in a number of 
different strains of bacteria.  The results presented thus far used the LogMP calculated from the 
response of the bacterial strain TA98 to the test compounds.  Gramatica et al.235 used the 
Debnath data set to construct separate QSAR equations for mutagenic potency measured in 
bacterial strains TA98 and TA100.  They suggested that steric factors were more important in 
predicting the mutagenic potency of the compounds measured in TA98 strain, while polarisability, 
electronic and hydrogen-bonding features were more important in the TA100 strain.  However, 
they highlighted that descriptors were not so easily and singularly interpretable for an 
understanding of the complex underlying mechanisms.    The conclusion may suggest the reason 
for the mediocre results we obtained for the mutagenic potency of the compounds in the TA98 
strain as it is known that QTMS descriptors capture the importance of electronic properties for 
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the property of interest.  For this reason, we investigated the use of BCP descriptors to predict the 
mutagenic potency of aromatic amines measured in the TA100 and the TA98 bacterial strains. 
After removal of diamines and highly conformationally flexible compounds, 60 aromatic amines 
from the Debnath data set203 remained that had LogMP values measured in TA100 (Appendix D).  
A plot of the LogMP in TA100 versus LogMP in TA98 (47 aromatic amines LogMP values in both 
Bacterial strains) revealed that the relative potencies vary widely (Figure 5.14).   
 
 
Figure 5.14.  A plot of the mutagenic potency of 47 aromatic amines measured in TA100 versus TA98.  The red data 
point represents 3-aminoquinoline and shows the largest difference in mutagenic potency depending on the strain in 
which it was measured. 
3-aminoquinoline is a weak mutagen when measured in TA98 strain (LogMP = -3.14) but its 
mutagenic potency is stronger when measured in the TA100 strain (LogMP = 0.07). 
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Hierarchical PLS was performed on the data set with the LogMP measured in TA100 and TA98.  
The best model for the prediction of LogMP measured in TA98 contained 38 compounds and had 
an    and    of 0.69 and 0.61, respectively.  The model was constructed from 2 latent variables 
which contained the information from 13 BCP properties.  We tested the model with 15 aromatic 
amines that had been tested at GSK because ultimately, these are the compounds that we aimed 
to predict.  No LogMP value was provided but a categorisation of positive (assigned 1), negative 
(assigned -1) or equivocal (assigned 0) was enough to test how the model performed on these 
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compounds.  The predictions for the GSK-measured aromatic amines show a spread in potency 
but the model fails to distinguish the correct activity of the compounds (Figure 5.15). 
 
Figure 5.15.  Predicted versus observed LogMP measured in bacterial strain TA98 (blue diamonds).  Predictions for 15 
aromatic amines measured at GSK are also given (red squares = Ames-positive, orange squares = Ames-equivocal and 
green squares = Ames-negative).    
 
The best model for the prediction of LogMP measured in TA100 contained 50 compounds and had 
an    and    of 0.57 and 0.54, respectively (Figure 5.16).  The model was constructed from only 
four ellipticity (ε) descriptors with the information contained in one latent variable.  A linear 
relationship is clearly present; however, at the higher end of the mutagenicity scale the 
relationship plateaus suggesting possibly a non-linear correlation.  A further explanation for this 
observation could be that the 1.5 – 2 LogMP is the upper experimental limit for detecting the 
mutagenic potency.  The spread in LogMP values of the 15 aromatic amines measured at GSK is 
less than the spread for the TA98 model (Figure 5.15).  The strain TA100 is reportedly more 
influenced by the electronic properties of the compounds tested but also fails to distinguish Ames 
results for the GSK compounds. 
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Figure 5.16.  .  Predicted versus observed LogMP measured in bacterial strain TA100.  Predictions for 15 aromatic 
amines measured by GSK are also given.    
 
5.4 Summary 
 
The statistical analysis of QTMS properties failed to produce a robust, predictive model to predict 
the toxicity of AAs.  We have shown that by using BCP descriptors alone, it is unlikely that a single 
model for the prediction of these compounds can be successful.  Reasonable correlations were 
obtained when the data sets were split into congeneric series.  The use of mutagenic potency of 
the AAs measured in the bacterial strain TA100 did not improve the results.  A reason for 
mediocre results could be that other factors than electronic effects have a more significant 
influence on the mutagenic potency of the compounds studied.  However, in any QSAR study the 
integrity of experimental results is vital236.  Merging Ames assay data from different sources 
suffers from interlaboratory variations in techniques. 
 
The national Toxicology Program (NTP) determined the average interlaboratory reproducibility of 
the Ames test data to be 85%200, 223.  This means that 15% of compounds tested will be either false 
positive or false negatives.  Therefore, any models constructed for the discrimination between 
positive and negative compounds can only ever have an 85% chance of the prediction being 
correct if data used is generated in different laboratories.  This highlights the difficulty in bringing 
together data points for a labour-intensive, biological assay in large enough numbers to be able to 
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construct meaningful statistical models.  The literature data phylogeny in Figure 5.17 shows that 
the majority of data used to model the mutagenic potency of AAs are taken from numerous 
laboratories.      
 
   
Figure 5.17.  Literature data phylogeny for Ames data used to model the mutagenic potency of aromatic and 
heterocyclic amines.  
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The two largest literature data sets, Debnath et al.203 and Hatch et al212, were compared.  Ten 
compounds were common to both data sets where the mutagenic potency value was taken from 
different sources. The average difference between the mutagenic potency was 0.70 log units.   All 
LogMP values in the Debnath data set were produced using TA98 +S9 whereas the Hatch data set 
was produced using TA98 or TA1538 which could be the reason for the discrepancies.  Where 
multiple conflicting data was found when compiling the Hatch data set the authors used the 
median value, which could be another reason for these differences.  The use of LogMP as a 
dependent variable has recently been questioned because of the influence of experimental noise, 
variation in environment and differences between laboratories237.  This confirms the questioning 
of the reproducibility of the Ames test by Kazius et al.223, who highlighted that the reproducibility 
is limited by the purity of the tested chemical, inconsistencies in the interpretation of dose-
response curves, interferences by toxic side effects (such as cytotoxicity), variations in the 
methodology employed, and variations in the materials used (bacterial strains and metabolic 
activation mixtures). 
 
Although CYP1A2 is implicated as the major P450 enzyme involved in the metabolism of AAs, it is 
not inconceivable to expect AAs to interact and be metabolised by other P450s.  To investigate 
these possible interactions, we selected 73 AAs (34 Ames-positive and 39 Ames-negative 
according to internal GSK and literature data) based on structural diversity, availability and 
mutagenic potency and submitted them to the standard P450 enzyme inhibition assays at GSK 
consisting of the five pharmaceutically important P450 (3A4 (two different assay standards), 1A2, 
2C19, 2C9 and 2D6 (Figure 5.2)) at a top concentration that allowed inhibition to be measured 
above a pIC50 of 4.3.   These assays are fluorescence intensity-based and in high-throughput 
format.  The results are shown in Table 5.4.  The agreement between the two different 3A4 assays 
was extremely good, so we only report the combined results.  Only ca. 20% of the 73 AAs 
inhibited each of the P450 enzymes but there was little difference between the number of Ames-
positive and -negative AAs, even for CYP1A2.  We submitted the 73 AAs for testing at higher 
concentrations in the 1A2 inhibition assay allowing pIC50 values to be measured down to 3.4.  
More of the AAs were found to inhibit 1A2, but once again the differentiation between Ames-
positive (13 compounds) and –negative (17 compounds) was poor.  These results must be taken 
into context.  The Ames-negative compounds inhibiting CYP1A2 could be enzyme inhibitors but 
not substrates, hence no genotoxic outcome.  The Ames-positive compounds not inhibiting 
CYP1A2 could acquire their genotoxic potential from conversion by other CYP enzymes, hence 
exerting their DNA-modifying effect via a mechanism different from the nitrenium ion pathway.   
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Table 5.4.  The results of 73 AAs submitted for P450 profiling in the major P450 enzymes responsible for the 
metabolism of the majority of drugs.     
P450 Enzyme Minimum pIC50 
Measurable 
Ames-Positive Ames-Negative Total 
3A4 >4.3 6 10 16 
2C19 >4.3 7 8 15 
2C9 >4.3 9 9 18 
2D6 >4.3 9 9 18 
1A2 >4.3 6 10 16 
1A2(Higher Concentration) >3.4 13 17 30 
 
Another complication to consider is the evidence of cooperative binding in the active site of 
CYP1A2238.  Heterotropic cooperativity, in which one ligand modifies catalysis of another ligand, 
has been demonstrated using kinetic studies and computational modelling techniques with 1-
isopropoxy-4-nitrobenzene and 1,4-phenylene diisocyanide239.  In this case the co-occupancy by 
the two molecules led to enhanced binding but reduced catalytic activity.  Homotropic 
cooperativity with CYP1A2 has also been observed with pyrene and benzo[a]pyrene240.  The 
author proposed that co-occupancy of the CYP1A2 active site is a common feature for numerous 
small substrates (and other ligands) but the nature of cooperative behaviour is highly ligand-
dependent.  The active site of CYP1A2 (approximately 370 Å3) is large enough to fit only one α-
naphthoflavone241 molecule but many of the AAs we considered are much smaller.  Cooperativity 
will skew the correlation between a molecular descriptor and the biological test result.  
Furthermore, cooperativity can lead to enhanced and reduced catalytic activity and therefore, 
may increase or decrease the mutagenic potency of AAs.  While docking studies may be used to 
predict co-occupancy, the information provided is unlikely to be sufficient to make predictions 
about the sites of oxidation and so this potential influence on mutagenic potency is difficult to 
include in any QSAR modelling. 
 
Around 2007, GSK had decided to measure the genotoxicity for a set of 500 synthetic building 
blocks to generate a list of Ames-negative AA molecules.  The work started on two compounds 
but stalled due to purification issues which resulted in contradictory Ames results for the same 
compounds.  In the next chapter, we report the outcomes of an investigation into the fidelity of 
the Ames test for a set of AAs.    
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Chapter 6                                                                                                    
Investigating the Reproducibility of the Ames Test with Carbocyclic 
and Heterocyclic Primary Aromatic Amines for Modelling Ames Test 
Classification 
 
6.1 Introduction 
 
m-Toluidine is a recognised Ames-negative aniline242.  It was tested by GSK as the free base in 
DMSO as a brown solution and was Ames-positive, with and without metabolic activation (+/-S9).  
The compound was re-purified, stored frozen and protected from light.  The free base in dimethyl 
sulfoxide (DMSO) was a clear liquid and tested Ames-negative.  The hydrochloride salt, made from 
the re-purified m-toluidine was also Ames negative when tested separately in DMSO and water.  
In other laboratories, 4-aminobenzylamine has also been tested as a brown liquid and produced 
an Ames positive +S9 at only the two highest concentrations and just over the 2-fold positive 
criterion243.  Subsequently, the compound was purified, kept refrigerated and protected from light 
and turned out to be negative243.  These examples suggest that degradation could explain the 
positive Ames outcomes.  In contrast, three samples of 4-aminobenzamide from three different 
suppliers showed 3 very different Ames responses in TA98 +S9 when tested by GSK, whereas 
without metabolic activation (-S9) in TA 98 and in 4 other bacterial strains (+/-S9) the response 
remained below the 2-fold increase threshold for Ames-positive classification (Figure 6.1).  Both 
positive batches were confirmed to be 99.8% pure by HPLC-LCMS.  This chemical has been 
reported as Ames negative, which was confirmed in N-methylpyrrolidine (NMP) as a solvent and 
surprisingly, after standing in DMSO for 1.5 hours244.   
 
 
 
Vehicle 
 DMSO 
 DMSO + 1.5 hour 
 NMP 
Figure 6.1.  The fold increases above the negative controls for the three different batches of 4-aminobenzamide 
(samples 1 and 3 with retests) screened in TA98 +S9 in DMSO or NMP. 
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International guidelines have been developed for laboratories to ensure uniformity of testing 
procedures.  These list DMSO as the solvent of choice if the test compound does not dissolve in 
water.  There are three reasons for selecting DMSO: it dissolves a wide range of chemicals, is 
relatively non-toxic to the bacteria and microsomal S9 enzymes, and it is completely miscible with 
the molten agar used in the Ames test. 
However, DMSO itself is not chemically inert and has been known to affect Ames results231, 245-247.  
Moran et al.248 screened 14 solvents with known mutagens benzo[a]pyrene and 2-aminofluorene 
for their compatibility with the Ames test.  They found 12 solvents to be satisfactory under the 
conditions specified, including DMSO.  They recommended that other solvents be used instead of 
DMSO when the test compound reacts with DMSO or when DMSO could interfere with the 
process of metabolic activation.  Nestmann and co-workers suggested that repeat tests in a 
second solvent should be performed to confirm initial findings246.  Conflicting Ames results for p-
phenylenediamine were followed up by Burnett et al.244 with more detailed studies.  They found 
that fresh solutions of either DMSO or water were non-mutagenic whereas DMSO solutions 
became Ames-positive upon standing, which was not observed for the p-phenylenediamine 
dissolved in water. 
To the best of our knowledge, there are no systematic investigations into the effects of the purity 
of the samples or the presence of DMSO on the Ames test for AAs.  Hence, we performed 
investigations to establish the robustness of the Ames test for AAs pre- and post-purification and 
with the hydrochloride salt forms. 
 
6.2 Methodology 
 
6.2.1 Data Sets 
 
We started out with a set of 22 low molecular weight, commercially available AAs that were 
structurally diverse, known to be Ames-positive and spanning a range of activity.  Initially, it was 
attempted to purify the AAs by distillation or by HPLC.  However, boiling points above 220oC for 
many of the AAs engender the possibility that some of them may decompose during distillation.  
The time and effort required to produce enough of the purified material also precluded HPLC.  It 
was therefore decided to use recrystallisation techniques.  A number of purification and 
availability issues brought the number of molecules down to the 14 listed in Table 6.1.  
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6.2.2 Purification and Conversion to the Hydrochloride Salt 
 
The solvents used to purify the AAs are listed in Table 6.1.  Filtration through a PL-Thiol MP SPE+ 
cartridge (Polymer Laboratories) removed any potential metal impurities and the AAs were 
recrystallised from a variety of solvents.  The crystals were stored at 4oC and protected from light.  
Missing values in Table 6.1 indicate that no suitable solvent was found from which the AA could 
be recrystallised.   
 
If the crystallisation failed, the unpurified material was used after being passed through a 
cartridge.  The AAs were dissolved in ethyl acetate, and then hydrogen chloride in diethyl ether 
was added to give suspensions.  The mixtures were stirred for approximately 30 minutes, the 
solids isolated by filtration and washed with ethyl acetate.  The solids were foil-wrapped to 
exclude light, dried under high vacuum at ambient temperature and then stored at 4oC.  In total 
nine hydrochloride salts were prepared. 
 
The purities of the unpurified, purified and hydrochloride salt materials were determined using 
HPLC with LC/UV/DS/ELSD detection (Table 6.1)1.  The percentage purity could not be determined 
for two compounds (4-aminoacetanilide and 2-amino-5-hydroxybenzoic acid) using this method. 
 
 
 
 
 
 
 
 
 
 
 
                                                             
1 0.01 ml of a 1 mg/ml solution of each compound was injected in CH3CN/H2O/TFA at a concentration ratio of 10:10:1, respectively.  
Samples were analysed using a Luna C18(2) 4.6mm i.d. x 150mm column with a gradient of 3% B to 50% B in 30 minutes, holding at 
50% B for 20 minutes.  A is H2O:TFA, 1000:1 and B is CH3CN:TFA, 1000:2.  The flow rate was 1ml/min.  A UV detector set at 300nm, 
180nm bandwidth with a 550nm, 100nm bandwidth as a reference was used in conjunction with mass spectrometer and an 
evaporative light scattering detector. 
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Table 6.1.  The names, CAS and structures of the 14 AAs, their purification conditions and levels of purity. 
Name 
(CAS #) 
Structure Recrystallisation Solventa % Purity 
   Unpurified    Purified  HCl Salt 
2-aminofluorene 
(153-78-6) 
 
ethanol 99.4 99.7 99.3 
6-aminochrysene 
(2642-98-0) 
 
- 99.4 - - 
2-aminoanthracene 
(613-13-8) 
 
petroleum ether and 
ethanol 
96.0 96.8 100 
1-methyl-2-
aminobenzimidazole 
(1622-57-7) 
 
ethanol followed by water 98.6 99.9 - 
4-phenoxyaniline 
(139-59-3) 
 
- 99.2 - 98.6 
2-amino-5-
phenylpyridine 
(33421-40-8) 
 
- 97.6 - - 
2,4,5-trimethylaniline 
(137-17-7) 
 
petroleum ether and 
ethanol 
99.8 100 98.5 
3-aminobenzonitrile 
(2237-30-1) 
 
petroleum ether and 
cyclohexane 
98.2 95.5 - 
2-Aminonaphtho(2,3-
d)imidazole 
(102408-31-1) 
 
ethanol 99.8 99.4 100 
4-chloro-2-methylaniline 
(95-69-2) 
 
- 94.6 - 99.5 
3-aminoquinoline 
(580-17-6) 
 
- 99.8 - 100 
2-methyl-4-
bromoaniline 
(583-75-5) 
 
cyclohexane 99.9 100 - 
4-aminoacetanilide 
(122-80-5) 
 
ethanol - 
Not 
determine
d 
- 
2-amino-5-
hydroxybenzoic acid 
(394-31-0) 
 
ethanol - 
Not 
determine
d 
- 
a 
The solvent purities were as follows: methanol, 99.9%; cyclohexane, 99.5%; toluene, 99.8%; diethyl ether, 99.0%; dichloromethane, 
99.8%; chloroform 99.8%; methyl pentane, 95.0%. 
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6.2.3 The Ames Test 
 
To evaluate the mutagenic activity of the AAs in relation to the purity, solvent and protomer (i.e. 
freebase or hydrochloride salt), the bacterial tester strains Salmonella typhimurium TA98 and 
TA100, with and without metabolic activation (rat liver homogenate S9), were used in the Ames 
standard plate incorporation assay.  The assay was performed in accordance with the procedure 
described by Maron and Ames189 and regulatory guidelines249.  These two strains were chosen, 
instead of the standard five, as they are often used in cut-down versions of the Ames test250 
because TA98 is capable of detecting frameshift mutations, while TA100 detects base pair 
substitutions180.  A heat map of the Ames test results for 100 substituted anilines tested in 6 
different bacterial strains (+/-S9) collated from GSK and external sources (e.g. National Toxicology 
Database in the US) exemplifies the significance of TA98 and TA100 for this chemotype (Figure 
6.2).  All the compounds in Table 6.1 are known to be Ames positive in either one or both of the 
strains used.  GSK assign a compound equivocal if a clear positive or negative response is not 
observed or if there is contradictory results for the same compound.  
 
Figure 6.2.  Ames test results (red – positive; orange – equivocal; green – negative; white - no data available) for 100 
substituted anilines in 6 bacterial strains +/- S9 based on internal and external data sources. 
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The dilution solvent for compounds was either DMSO (Sigma-Aldrich) or distilled water (GIBCO), 
and all dosing solutions were prepared immediately prior to testing.  All experiments were 
performed with solvent controls and each run in duplicate with the average value reported.  In a 
few cases where large deviations between runs had been observed, they were repeated.  Vehicle 
controls (DMSO or water) were run in quadruplicates with and without metabolic activation (+/-
S9).  The positive controls were run in quadruplicate with and without metabolic activation.  The 
positive control for TA98 +S9 was benzo[a]pyrene (B[a]P) (10 µg/plate), 2-nitrofluorene (2NF) (1 
µg/plate) for TA98 -S9, 2-aminoanthracene (2-ANN) (5 µg/plate) for TA100 +S9 and sodium azide 
(2 µg/plate) for TA100 -S9.  Positive controls were also run in duplicate.  All compounds were 
generally tested at 6 concentrations (5000, 2500, 1500, 500, 150 and 50 µg/plate) in TA100 and 
TA98 +/-S9.  Some tests were repeated at lower concentrations due to toxicity and/or 
precipitation observed at low concentrations in the original tests.  Where repeats were performed 
they are highlighted in Table 6.2.   
 
Here the procedure to perform the plate incorporation assay is explained.  A cartoon 
representation of the preparation of one plate in the Ames test is shown in Figure 6.3.  A 
predetermined number of sterile, capped tubes are filled with 2.0 ml of top agar.  For the plate 
incorporation method without activation (-S9), 0.1 ml of the test solution dissolved in the vehicle 
(water or DMSO) at the required concentration, 0.1 ml of the bacterial strain (TA98 or TA100) and 
0.5 ml of sterile buffer are added to the 2.0 ml of top agar in the sterile tube.  For the assay with 
metabolic activation, 0.5 ml of metabolic activation mixture (containing 10% v/v of S9 fraction) 
replace the 0.5 ml of sterile buffer.  The contents of the tube are mixed by rotating between the 
fingers and poured onto a minimal agar plate.  The plate is moved in a circular fashion to spread 
the agar uniformly.  The overlay agar is allowed to solidify before the plate was incubated at 37oC 
in the dark for 72 hours.  After the incubation period, the numbers of revertant colonies on the 
plate are counted.  The Ames test we perform requires the preparation of 60 (6 (concentrations 
of test compound) x 2 (bacterial strains) x 2 (+/-S9) x 2 (duplicates) + 12 (positive and negative 
controls) = 60) plates prior to counting.     
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Figure 6.3.  Cartoon representation of the plating of a compound at one concentration used to perform an Ames test.  
The figure represents the use of metabolic activation (+S9), without metabolic activation the S9 extract is replaced 
with sterile buffer. 
 
Ames Study Manager, Report Generator and Sorcerer Systems (Perceptive Instruments Ltd.) were 
used to count the number of revertant colonies on plates and curate the raw data.  The addition 
of a small amount of histidine to the top agar allows the plated bacteria to undergo between six 
and eight cell divisions before the histidine is depleted.  If the test compound is mutagenic, the 
revertant bacteria continue to grow in the absence of the histidine and are visible on the plates.  
The revertant colonies are easily scored against the hazy looking background lawn which is made 
up of the histidine-dependent bacteria.  Examination of the background lawn reveals if the test 
compound is toxic to the bacteria.  A “thinning” or complete absence of the background lawn 
compared to the negative controls implies that the compound is toxic.  Cell toxicity and test 
compound precipitation are recorded after being observed with the naked eye and use of a 
microscope.  If precipitation is observed, that plate is counted but no other higher concentrations 
are considered as the availability of the test compound to the bacteria is unknown.  The 
mutagenic activity is described by an induction factor (IF), which is the quotient of the revertants 
per plate at each concentration divided by the average number of revertants per plate of the 
negative controls.  In strains TA98 and TA100, substances with an IF of two or greater, in 
conjunction with a dose-response curve, are considered to be Ames-positive in the test strains 
used.  Dose-response curves can be found in Appendix E for all the Ames tests we performed.  
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Figure 6.4.  A photograph of two plates, after incubation, that have been prepared in the Ames test. The plate on the 
left is a negative control.  The plate on the right is dosed with a chemical that has caused a > two-fold increase 
compared to the control.  The revertant colonies are clearly visible.    
 
6.3 Results and Discussion 
 
The unpurified substances were 94.6 to 99.9% pure according to HPLC-LCMS increasing to 96.8 to 
100% after recrystallisation except in four cases.  For unknown reasons, the purity deteriorated 
for the free base of 3-aminobenzonitrile and the hydrochloride salt of 2,4,5-trimethylaniline.   
 
Ames results were generated for all 14 raw compounds, for a subset of 9 purified samples and a 
slightly different subset of 9 molecules as the hydrochloride salt (Table 6.2).  The anticipated 
transformation from an Ames-positive to an Ames-negative results occurred for only one AA.  4-
aminoacetanilide in TA98 +S9 moved from just above the IF two-fold threshold (IF = 2.2) in the 
unpurified form to just below the threshold (IF = 1.6) as the purified free base.   The Ames tests 
for unpurified and purified free base were repeated using water instead of DMSO (Table 6.3).  The 
Ames results in DMSO were confirmed in water but the IF for the purified compound increased to 
1.8.   Nevertheless, the hydrochloride salt gave a clear positive response in DMSO (IF = 3.0) and in 
water (IF = 2.6) therefore, this AA must still be considered Ames-positive. 
 
Small changes in the induction factor in either direction are observed in several cases. The IF 
(TA100 +S9) for 2,4,5-trimethylaniline diminished from 11.3 to 8.3 from raw (99.8%) to purified 
(100%) material.  Most drastically, aminobenzonitrile’s IF (TA98 +S9) raised from 5.0 to 10.9 due 
to a deterioration in purity from raw (98.2%) to “purified” (95.5%) compound. This amine also 
undergoes a qualitative shift, i.e. from Ames-negative to Ames-positive (TA98 -S9; IF = 2.3) albeit 
only by a marginal amount. The IF’s for the most genotoxic substance in our dataset, 2-
aminofluorene, doubled with and without metabolic activation from raw to purified form despite 
almost identical purities of 99.4 and 99.7%, respectively. For several unpurified AAs the Ames 
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tests on both strains were repeated in duplicate (the IF values are shown in parentheses in Table 
6.2) and the results were remarkably similar. 
 
The 14 AAs can be pooled into 3 groups (Table 6.2): I) those Ames-positive with and without 
metabolic activation, II) those strongly Ames-positive +S9 and III) those marginally Ames-positive 
+S9. Remarkably, the IF for the latter group of five amines changed by less than one unit across 
the Ames tests for all four forms, i.e. unpurified and purified compound, as hydrochloride salt in 
DMSO and in water. This observation is in sharp contrast to the variations in outcome for some of 
the AAs mentioned in the Introduction and can probably be attributed to differences in their 
tendencies for structural deterioration.  
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Table 6.2.  The IF’s in the Ames test for 14 AAs (the highest IF observed and independent of the concentration is given); N denotes a negative test. 
 
a 
The Ames test was limited by toxicity or precipitation and so not all dose levels were counted. 
b 
Toxicity was observed at all doses +S9 in the initial Ames test, hence the test was repeated at 1.5, 5, 15, 50, 150, 500 μg/plate.   
c
 
Values in brackets correspond to repeat experiments in order to investigate the reproducibility. d Compound precipitated out of solution in the initial Ames test so it was repeated at 15, 25, 50, 150, 500, 1500 μg/plate.   
 
Compound name 
Unpurified Purified HCl Salt DMSO HCl Salt Water 
TA98 TA100 TA98 TA100 TA98 TA100 TA98 TA100 
 -S9  +S9  -S9  +S9  -S9  +S9  -S9  +S9  -S9  +S9  -S9  +S9  -S9  +S9  -S9  +S9 
I 2-aminofluorene 10.8a 42.8a N a 13.0a 23.7a 82.0a 3.6a 19.0a - - - - - - - - 
I 6-aminochrysene 
35.5
a
  
(62.0)
b,c 
8.2
a
  
(11.6)
 b,c
 
9.6
a
  
(13.9)
 b,c
 
N
a
 
(10.6)
 b,c 
 
- - - - - - - - - - - - 
II 2-aminoanthracene Na 27.7a N a 4.1a Na 29.6a Na 5.0a - - - - - - - - 
II 1-methyl-2-aminobenzimidazole N 
24.6 
(34.5)
c
 
N 
14.6 
(13.0)
 c N 34.6 N 15.6 N 30.1 N 13.6 N 27.6 N 15.0 
II 4-phenoxyaniline Na 21.2a 2.7a 16.7a - - - - - - - - - - - - 
II 2-amino-5-phenylpyridine N 14.2 N 2.8 - - - - Na 17.2a Na 2.4 Na 14.5a Na Na 
II 2,4,5-trimethylaniline N 
4.1  
(5.0)
c
 
N 
11.3 
(10.0)
c
 
- 4.6 - 8.3 - - - - - - - - 
III 3-aminobenzonitrile N 
5.0  
(5.6)
c
 
N N 2.3 10.9 N N N 4.7 N N N 6.8 N N 
III 2-aminonaphtho(2,3-d)imidazole Na 6.7a Na Na Na 7.2a Na Na - - - - - - - - 
III 4-chloro-o-toluidine Na 2.6a N 1.9a - - - - Na 2.4a Na 2.8 - - - - 
III 3-aminoquinoline N 1.9 N 3.0 - - - - N 2.0 N 2.7 N 2.1 N 3.3 
III 2-methyl-4-bromoaniline Na Na Na 2.4a Na Na Na 2.0a N N N 2.6 Nd 2.1d Nd 3.0d 
III 4-aminoacetanilide N 2.2 N N N N N N N 3.0 N N N 2.6 N N 
III 2-amino-5-hydroxybenzoic acid N 2.1 N N N 3.2 N N N 2.0 N N N
d
 2.1
d
 N
d
 N
d
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Table 6.3.  The IF in the Ames test for 4-aminoacetanilide tested in water as the unpurified and purified. 
Compound name 
Unpurified in Water Purified in Water 
TA98 TA100 TA98 TA100 
- + - + - + - + 
III 4-Aminoacetanilide N 2.4 N N N N N N 
 
These findings can be considered as an endorsement for the reliability of the Ames test for this 
compound class. However, there are several caveats to this statement: 
 
 The variation in purity remained within a narrow band of 95 – 100%  as 
determined by LCMS 
 We did not systematically investigate the relationship between compound purity 
and the reproducibility of the Ames test, which could be very chemotype-
dependent 
 We only tested a small set of AAs, whose structures are probably not wholly 
representative of this compound class 
 We employed only two strains out of the five required for regulatory acceptance 
of the Ames results  
 
Nevertheless, the consistency of the IF values across different assay conditions for the same 
bacterial strain is remarkable and even more so, considering the variety of carbo- and 
heterocycles, of mono- and multicycles and of substitution patterns with electron-donating and –
withdrawing groups used. Furthermore, the formation of the hydrochloride salt did not appear to 
influence the magnitude of the Ames response in the T98 and T100 strains which provides a 
strategy to purifying these types of compounds when other techniques fail. 
 
We subsequently had the stability of 73 low molecular weight AAs determined in DMSO at room 
temperature for one week. We found that nine molecules degraded to a significant degree (12 – 
42%). This emphasises the requirement for this compound class to be kept under appropriate 
storing conditions and for the Ames test only to be conducted when the purity levels are known in 
order to prevent spurious outcomes as reported in the Introduction.  
 
Following on from our findings above, a project started at GSK to systematically perform the five-
strain Ames test on low molecular weight AAs to assemble a reference set for Safety Assessment 
and Genetic Toxicology. This collection has currently grown to around 400 molecules and is 
known from here on as the GSK data set.  The 200-strong Ames-negative compound set is of 
particular interest to chemists as building blocks for chemical synthesis.  Preliminary work has 
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been undertaken to investigate QSAR equations to discriminate between positive and negative 
anilines using the 400 molecule data set.  This work is reported in the following section. 
 
6.4 Predictive Toxicology for Aromatic Amines 
 
As part of the data preparation for this investigation, the Ames classifications of the 400 GSK AAs 
were compared to those published in the literature.  The AA subset of the Organon data set223 
consists of 258 molecules183, after filtering, whereas 674 AAs are listed in the comprehensive 
Bayer compilation of approximately 6500 chemicals tested in the Ames test198.  In the overlap of 
136 compounds with the GSK data set, only seven were classified differently which could be 
explained by the inclusion of an equivocal category in the GSK classifications.  This was 
encouraging considering the interlaboratory difference previously discussed.  It should be noted 
that data from multiple Ames tests for the same compound can exist in the literature and can be 
contradictory.  If a judgement is being made on multiple contradictory literature results, then the 
classification decided can be based upon the individuals’ interpretation of the result which can be 
limited by their experience.  Experts within GSK analyse all the available data and make a 
judgement based on the protocols used for the Ames tests under question (i.e. if regulatory 
guidelines were adhered to).  For a compound to be classified as negative, it must have been 
tested in at least the five bacterial strains required by the regulators, the test must have been 
conducted according to regulatory guidelines and the molecule must have displayed an 
unequivocal negative response in all test strains.  For a compound to be classified as positive, it 
must have shown a clear positive response in at least one of the bacterial strains.  If a compound 
has only been tested in two of the required bacterial strains and was negative, then this does not 
mean the compound is considered Ames-negative as the data would be considered inadequate 
because it does not comprise of a full Ames test.  If the external data is inadequate, or does not 
exist, then the compound is tested in-house and categorised according to GSK’s protocol.  
Therefore, the GSK AA data set contained a combination of classifications based on reliable 
literature/external and in-house data, with a slightly larger proportion based on internal data.  In 
this work we filtered and separated the compounds according to Figure 6.5. 
After visual inspection of the 273 substituted anilines we removed 4 large drug-like compounds 
and one iodine containing compound.  We focussed on the subset of 234 substituted anilines 
(known from here as the aniline data set) with only one primary amine (NH2) group attached to 
the aromatic ring to simplify the modelling.  The 234 anilines were grouped into seven different 
categories depending on their Ames classification (Figure 6.5) 
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Figure 6.5.  The structural criteria we applied to separate the GSK data set.* 4 large drug-like compounds and one 
iodine containing compound removed. 
 
Table 6.4.   The classification of the 234 anilines in the GSK data set. 
Ames Classification 
All Ortho Meta Para +S9 -S9 
Negative Negative 105 66 21 18 
Positive Negative 89 39 32 18 
Equivocal Negative 2 2 0 0 
Equivocal Equivocal 3 2 1 0 
Positive Positive 28 16 7 5 
Negative Positive 3 3 0 0 
Positive No Data 4 2 1 1 
 
It can be seen from Table 6.4 that the data set contained an approximate 50:50 split between 
Ames-positive with metabolic activation (+S9)  and Ames-negative with and without metabolic 
activation (+/-S9).  These two categories agree with the recognised mechanism of metabolic 
activation of AAs that causes them to become mutagenic or not.  The category that contained the 
next greatest number of compounds was Ames-positive with and without metabolic activation 
(+/-S9).  We previously highlighted two compounds (2-aminofluorene and 6-aminochrysene) that 
also displayed these results for the Ames tests in bacterial strains TA98 and TA100 that we 
performed.  It is known that in addition to DNA adduct formation through the activation of AAs by 
P450 1A2, intercalation into the DNA without the formation of a covalent bond is another 
mechanism that can lead to genotoxicity and therefore to an Ames-positive result +/-S9183.  With 
the aim to avoid additional mechanisms of genotoxicity, we focussed on the compounds that are 
395 Primary Aromatic 
Amines 
122 Heterocyclic Anilines 273 Substituted Anilines 
234 Mono-NH2 Aniline* 34 Multiple-NH2 Aniline 
130 
Ortho 
42 
Para 
62 
Meta 
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thought to act through CYP1A2 activation.  The final data set contained 105 ortho-, 53 meta-, and 
36-para substituted anilines.   
Our motivation for this work stemmed from the encouraging results obtained for the 
discrimination of Ames classifications for AAs using descriptors generated from quantum 
mechanics183, 221.  For the 194 anilines, we calculated the reaction energies for the equations that 
display the largest discrimination for AAs according to Leach et al.221 discussed in Chapter 5 and 
represented in Equation 6.1 and Equation 6.2.  We also calculated the relative stability of the 
nitrenium ion, using aniline as the reference, according to the equation utilised by Bentzien et 
al.183 (Equation 6.3).  To make a fair comparison, the geometries were optimised at the 
(U)B3LYP/6-31G* level of theory.  Bentzien et al.  suggested that the AM1 semiempirical level was 
a good compromise between accuracy and speed, however, as Leach et al. obtained their results 
at the (U)B3LYP/6-31G* level we opted for the higher level of theory.  A single conformation was 
generated for all structures using the LigPrep251 application in Schrödinger’s Maestro252 modelling 
platform.  The structures were visually inspected and changed if they were obviously not the 
lowest energy conformers.  Geometry optimisation was then performed using GAUSSIAN0348.  All 
the equations require the syn and anti conformations of the nitrenium ion to be considered.  We 
optimised both conformers and the lowest energy conformations were used in the calculations, 
which is suggested by the authors from both publications. 
          
             Equation 6.1 
 
                     Equation 6.2 
 
          
              Equation 6.3 
 
Equation 6.1 is considered as a surrogate reaction to represent the energy changed for the 
combined process of protonation and deprotonation of the hydroxylamine to react with DNA 
(Figure 5.3).  Equation 6.2 was used by Leach et al. to model the formation of the nitrenium ion 
from the N-acetoxy or N-sulphate esters, formed in second phase metabolism of the 
hydroxylamine by N-acetyltransferase and sulphotransferase enzymes (Figure 5.3)253.  The origins 
of Equation 6.3 were discussed in Chapter 5.  The relationship between the reaction energies 
calculated from the three equations was investigated.  The results are shown in the correlation 
matrix in Table 6.5.  
Table 6.5.  Correlation matrix of the energies calculated from Equation 6.1, Equation 6.2 and Equation 6.3. 
 Equation 6.1 Equation 6.2 Equation 6.3 
Equation 6.1 1.000 0.995 0.995 
Equation 6.2 - 1.000 0.989 
Equation 6.3 - - 1.000 
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The correlation matrix showed the energies were highly correlated and so would discriminate 
between the anilines virtually identically.  Because of this reason we only considered the results 
obtained from Equation 6.3 from here. 
We discussed in Chapter 5 that the classification of Ames-positive and negative correlates with 
the energy calculated from Equation 6.3 which uses aniline as a reference.  Bentzien et al.183 
classified an AA as Ames-negative if the ΔΔE, calculated from Equation 6.4, was positive i.e. the 
nitrenium ion was less stable than that of aniline and vice versa.  This method makes the 
assumption that aniline, as the parent compound, is the most stable of the Ames-negative AAs.  
Bentzien et al. observed a significant improvement in correct predictions when an uncertainty 
interval of ΔΔE = ±21 kJmol-1 around the reference energy (0 kJmol-1) was introduced, where any 
AA with a calculated energy between this interval was not considered. 
                                       Equation 6.4 
    
We employed a slightly different approach to discriminate between the anilines.  We only 
considered the meta- and para-substituted anilines (89 anilines in total) that were classified Ames 
negative +/- S9 (39 anilines) and Ames positive +S9 only (50 aniline).  The 89 meta-/para-
substituted anilines had a variety of electron-withdrawing and electron donating substitutions 
and included fused rings. The Ames-positive anilines were assigned a value of 1 and the Ames-
negative a value of -1.  Using SIMCA-P54 we constructed a discrimination model using ΔΔE.  The 
model assigned a value between -1 and 1 to the anilines.  Subsequently, any aniline with a 
negative value is considered to be predicted as Ames-negative and any aniline with a positive 
value Ames-positive.  We did not apply an uncertainty interval.  We report the results in the 2 x 2 
confusion matrix, also known as a truth table (Table 6.6).  The term sensitivity is defined as the 
ratio of true positives divided by all experimental positives.  Similarly, specificity is the ratio of 
true negatives divided by all experimental negatives and accuracy is defined as true positives 
summed with true negatives divided by the sample size.  
Table 6.6.  Truth table for Ames Prediction of the 89 meta- and para-substituted anilines in the GSK data set using the 
nitrenium ion stability hypothesis. 
 Predicted Ames Positive Predicted Ames Negative 
Ames Positive Experimental 40 (50) 10 
Ames Negative Experimental 14 25 (39) 
Accuracy 0.73, Sensitivity 0.80, Specificity 0.64 
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The accuracy of 0.73 is slightly lower compared to that (0.85) reported by Bentzien et al.183 .  
However, the sensitivity and specificity were similar.  We subsequently used these results as a 
benchmark to compare our model discussed below. 
In Chapters 3 and 4, we reported the use of BCP properties in predicting pKa values for phenols, 
carboxylic acids and anilines.  Compound pKa values are dependent on the stability of the related 
ion in solution.  The stability of the nitrenium ion of parent anilines has been determined as 
important in discriminating between Ames-positive and Ames-negative compounds.  In Chapter 4, 
we found that the C-N bond length can be used to predict the pKa of anilines.  In Chapter 5 we 
found that the electron density at the C-N BCP can be linked to the difference in mutagenic 
potency of AAs.  Accordingly, we investigated if the electron density at the C-N BCP in the data set 
of 89 meta- and para-substituted anilines could discriminate between the Ames-positive and 
Ames-negative compounds.  Our work and findings are reported below. 
 
The electron densities at the C-N BCPs of the anilines were calculated from the previously 
(U)B3LYP/6-31G* optimised structures using MORPHY9849.  In SIMCA-P, ΔΔE from the model 
discussed above, was replaced with the corresponding electron density.  The results from the 
reconstructed model are shown in Table 6.7 and graphically in Figure 6.6 .      
Table 6.7.  Truth table for Ames Prediction of the 89 meta- and para-substituted anilines in the GSK data set using the 
electron density at the C-N BCP. 
 Predicted Ames Positive Predicted Ames Negative 
Ames Positive Experimental 41 (50) 9 
Ames Negative Experimental 17 22 (39) 
Accuracy 0.70, Sensitivity 0.82, Specificity 0.56 
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Figure 6.6.  A graphical representation of the discrimination of the 89 meta- and para-substituted Ames-positive and 
Ames-negative anilines using the electron density at the C-N BCP. 
 
According to the model, a relatively lower electron density at the C-N BCP corresponds to Ames –
positive anilines and conversely a relative higher electron density at the C-N BCP corresponds to 
Ames-negative anilines.  The accuracy of 0.70 and sensitivity of 0.82 is comparable to that 
obtained using ΔΔE, where an accuracy and sensitivity of 0.73 and 0.80 were obtained, 
respectively.  However, the specificity of 0.56 is lower than that obtained using ΔΔE (0.64).  The 
specificity can be increased by changing the 0 threshold (X-axis in Figure 6.6) used to discriminate 
between Ames-positive and Ames-negative, although it would be at the expense of the sensitivity.  
In relation to the predictions of Ames classification for AAs, it is a difficult choice whether 
improved sensitivity or specificity is desirable.  Increasing sensitivity means that more Ames-
positive compounds are predicted correctly, therefore there are fewer predicted false-negatives.  
However, this is at the expense of the specificity and so there will be an increase in number of 
false-positive predictions.  A false-negative prediction (wrongly identified as an Ames-negative 
compound) could lead to a compound being used in drug design that when tested later in the 
Ames test is found to be positive.  A false-positive prediction (wrongly identified as Ames-positive 
compound) could lead to a useful compound being disregarded.  The desired levels of sensitivity 
and specificity can depend on what stage in drug design the prediction is being made and how it is 
applied250.  The advantage of using one descriptor (i.e. the electron density at the C-N BCP) to 
discriminate between the anilines is that it allows chemists to target this property when 
considering using meta- or para-substituted  aniline building blocks.  A relatively low electron 
density at the C-N BCP should be avoided.  Furthermore, using just the electron density at the C-N 
bond requires one geometry optimisation compared to the two required to calculate ΔΔE. 
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The mediocre accuracy of the model created using the electron density at the C-N bond was 
disappointing considering meta- and para-substituted anilines had only been used.   To 
understand false predictions, clearly visible in Figure 6.6, we investigated the individual data 
points. We start with the nine false-negative predictions in turn (Figure 6.7).     
 
  
4-amino-2-chlorobenzonitrile 7-amino-4-hydroxy-2-
napthalenesulphonic acid 
  
methyl 4-amino-2-hydroxybenzoate 4-aminobenzamide 
 
 
4-aminobenzonitrile 3,4,5-trifluoroaniline 
 
 
methyl 4-aminobenzoate 7-quinolineamine 
 
 
4-(6-methyl-1,3-benzothiazol-2-
phenyl)amine 
 
Figure 6.7.  The structures and chemical names of the anilines classified as false-negatives using the electron density 
at the C-N BCP (Figure 6.6).  
 
According to Figure 6.2 the vast majority of positive Ames results are detected in the bacterial 
strains TA98 and TA100, which is the reason we restricted our Ames testing to these two strains.  
There is a slim chance that any of nine compounds are Ames-positive in one of the other bacterial 
strains.  The classification for 4-amino-2-chlorobenzonitrile was based on GSK data and was found 
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was based on a GSK five-strain Ames test where a clear positive response (IF = 6.8 at 5000 
µg/plate) was observed in TA98 +S9.  4-aminobenzonitrile was positive in TA98 +S9 (IF = 3.1 at 
1600 µg/plate) based on GSK data.  A different source242 classified this compound as negative.  
However, the Ames test was not performed to the maximum concentration of 5000 µg of test 
compound/plate, therefore the former classification must stand.  The classification for methyl 4-
aminobenzoate was based on a positive response (IF = 3.8 at 5000 µg/plate) observed in TA98 
+S9.  4-(6-methyl-1,3-benzothiazol-2-phenyl)amine was tested under the National Toxicology 
Programme in the US and positive responses were observed in both TA98 and TA100 +S9.  Mixed 
external data254 exists for 7-amino-4-hydroxy-2-napthalenesulphonic acid ranging from negative 
+S9 to positive +S9 in both TA98 and TA100.  The mixed Ames results for 4-aminobenzamide have 
been discussed in the introduction and are shown in Figure 6.1.  No explanation can yet be 
offered to explain these results so this compound must still be considered Ames positive.  A clear 
positive response (IF = 6 at 1600 µg/plate) for 3,4,5-trifluoroaniline was observed in TA98 +S9.  
The origins of this compound displaying a positive response are unclear as similar structures, for 
example 2,3-difluoroaniline and 2,5-difluoro-4-bromoaniline are Ames-negative.  7-
Quinolineamine was classified as positive +S9 however, there is literature evidence255 that 
suggests this compound is Ames-positive in TA98 and TA100 +/- S9.  Considering this result, 7-
quinolineamine would have been filtered from our data set of 89 meta-/para-substituted anilines.  
Furthermore, quinoline itself is Ames-positive and so the origins of the positive result for 7-
quinolineamine cannot be specifically attributed to the amine function256.  Based on evidence 
presented above, we believe we have justification to remove at least half the predicted false-
negative anilines from the data set.    
Next we discuss the 17 false-positive predictions (Figure 6.8).  In contrast to Ames-positive 
anilines, for a compound to be classified as negative it must have been tested in at least the five 
bacterial strains required by the regulatory and up to a maximum concentration of 5000 µg/plate, 
providing the test is not limited by toxicity or solubility.  Explaining false-positive predictions is 
more difficult because in many of the Ames tests, no response is observed at all.  4-[(1-
methylethyl)oxy]aniline has been tested by GSK in the standard Ames test and an adapted version 
(i.e. the preincubation Ames assay180) , which can be used when a dose-response is observed in 
the standard test but does not reach the two-fold threshold required for an Ames-positive 
classification.  In the standard Ames test with 4-[(1-isopropyl)oxy]aniline an IF of 1.7 was observed 
at 5000 µg/plate.  In the adapted test the number of revertants still did not reach the two-fold 
threshold but the test was limited by toxicity to 3000 µg/plate.  4-[(1-isopropyl)oxy]aniline has a 
structure similar  to other compounds in the aniline data set that are correctly predicted as Ames-
positive, for example 4-methoxyaniline and 4-ethoxyaniline.  However, according to the criteria 
for determining Ames classification, this compound must be considered negative.  The false-
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positive prediction for 4-amino-2-fluorophenol may be explained by the maximum concentration 
counted in the Ames test being limited by toxicity.  For the remaining compounds the Ames test 
results (mainly based on GSK and NTP data) all displayed clear negative responses.      
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4-ethylaniline Proprietary Structure  
 
 
 3-chloroaniline 
Figure 6.8.   The structures and chemical names of the anilines classified as false-positives using the electron density 
at the C-N BCP.  
 
The origin of the experimental data for ten of the most extreme outliers in either classification 
was analysed and three predicted false-negative compounds (i.e. 4-aminobenzonitrile, methyl 4-
aminobenzoate, and 3,4,5-trifluoroaniline) were selected for Ames retesting in the most 
indicative bacterial strain (TA98) for AAs (Figure 6.2).  These three compounds had previously 
tested negative in TA100 +/-S9 and positive in TA98 +S9 but the purity was unknown.  Their 
purities were confirmed to be 100% by LCMS.  4-aminobenzonitrile displayed a clear positive 
response but methyl 4-aminobenzoate and 3,4,5-trifluoroaniline were negative in TA98 +S9 
(Figure 6.9).  The experimental results used to construct our model were corrected for these two 
compounds and 4-aminobenzamide and 7-quinolineamine were removed based on the 
discussions above.  The improved statistics for the new model are shown in Table 6.8.       
Table 6.8.  Updated truth table for Ames Prediction of the 87 meta- and para-substituted anilines in the GSK data set 
using the electron density at the C-N BCP.  
 Predicted Ames Positive Predicted Ames Negative 
Ames Positive Experimental 40 (46) 6 
Ames Negative Experimental 13 28 (41) 
Accuracy 0.78, Sensitivity 0.87, Specificity 0.68 
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Figure 6.9.  Does-response curves for the original Ames data and the retest data for 4-aminobenzonitrile, methyl 4-
aminobenzoate and 3,4,5-trifluoroaniline in bacterial strain TA98 +S9.    
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It is worth mentioning here a note of caution when collecting Ames results for AAs from the 
literature, although this did not apply to the meta- and para-substituted anilines we investigated.  
Many AAs were tested under the National Toxicology programme (NTP) in the US.  Their criteria 
for determining Ames classification is based on statistically significant increases in the number of 
revertants compared to the negative controls and not an increase over a specified threshold.  This 
means that for some compounds the classifications can differ, obviously affecting modelling 
attempts and results.  Furthermore, many of the NTP Ames tests employed both rat and hamster 
S9 to mimic metabolic activation.  It is known that the use of hamster S9 produces higher 
responses and therefore can be considered more sensitive257.  Some AAs have been classified as 
Ames-positive based on a positive response being observed with hamster S9 only.  However, 
current guidelines only require the use of rat S9.  To produce models for the prediction of Ames 
results for AAs, it is therefore important to be careful when mixing results obtained with S9 
extracted from different animal species where the classification differs.                 
6.5 Summary 
 
We investigated the reproducibility of the Ames test for a data set of 14 AAs.  We found that the 
small changes in purity, the protomer (i.e. free base and hydrochloride salt) tested and the 
solvent (i.e. DMSO or water) had only marginal influences on the IF’s and did not result in a 
change of any Ames classification.  These results formed the basis for the systematic Ames testing 
of synthetic building block AAs leading to a data set of 400 molecules.  We subsequently extracted 
a set of 89 meta- and para-substituted anilines and constructed predictive models, using the 
electron density at the BCP or ΔΔE as the only descriptors, to discriminate between Ames-positive 
and Ames-negative compounds in this class.  The statistics for the model compare favourably to 
similar methods published in the literature183.  We were able to explain some of the false-negative 
and false-positive-predictions.  These are currently being considered for repeat Ames tests.  Three 
compounds have been retested and the model correctly predicted two of the compounds as 
Ames-negative.  The considerations and difficulties in modelling AAs have been highlighted. We 
believe this method can be applied to different AAs subsets for the prediction of Ames test 
classifications.   
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Chapter 7                                                                                                                
Conclusions and Future Work 
 
The use of QCT descriptors has been extended to predict two different properties of interest to 
the industrial sponsor and the wider scientific community.  We have constructed models for one 
of the largest data sets so far used for QTMS applications to predict pKa values for carboxylic 
acids.  It was not surprising that the SVM statistical learning method performed the best but it 
was unexpected that the linear PLS method would provide very similar CV statistics.  It was 
advantageous that the less CPU intensive HF/6-31G(d) level of theory provided comparable 
results to the more demanding B3LYP/6-311G(2d,p) level of theory.  The predicted pKa values 
from the models constructed from the 228 carboxylic acids compared favourably to commonly 
used pKa prediction tools.  The ortho-substituted benzoic acids were the least well predicted 
because QCT descriptors mainly account for the electronic contributions to the predicted 
property and do not fully capture steric effects.   
 
To improve pKa predictions for ortho-substituted compounds, we used data sets containing 
benzoic acids, phenols and anilines.  We considered the use of ab initio bond lengths exclusively 
as descriptors to predict pKa.  The aim was to investigate their effectiveness in pKa prediction but 
we also focused on comparing single-bond-length models and all-bond-length models.  Ab intio 
bond lengths can be extracted directly from the optimised geometries and do not require a 
further programme, such as MORPHY, to calculate the BCP properties.  The results indicate that 
single-bond-length, compound-class specific models can be used to predict the pKa of meta-/para-
substituted compounds but this is not the case for ortho-substituted compounds.  However, we 
identified high-correlation subsets that were able to accommodate the steric effects specific only 
to ortho-substituted compounds.  These high-quality models provided us with the confidence to 
successfully challenge the assigned experimental pKa values of compounds that were outliers.  It is 
remarkable that models constructed from a single bond length are able to accurately predict the 
pKa for a set of drug compounds used as a test set.   
 
Extending the use of QCT descriptors for biological property prediction, we investigated their 
application to predict the mutagenicity of carbocyclic and heterocyclic aromatic amines.  This 
class of compounds is synthetically very useful to medicinal chemists involved in drug design but 
they are often used with trepidation because of the large percentage of genotoxic compounds 
found in this group of chemicals.  Surprisingly, the comprehensive literature on the prediction of 
the mutagenic potency, measured in the Ames test, for these compounds is divided over which 
properties are important.   
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Comprehensive investigations into the prediction of mutagenic potencies taken from the 
literature produce a number of models but these failed to classify a test set of GSK Ames data.  It 
became apparent that contradictory Ames test results existed for several compounds; something 
that is problematic to modelling methods.  The systematic experimental investigation of AAs in 
the Ames test confirmed the reproducibility of this test but did not account for interlaboratory 
variations.  We questioned whether the prediction of mutagenic potency using literature data of 
variable quality is possible or even worthwhile in relation to the use of such a model at GSK.  A 
recent, carefully constructed list at GSK provides Ames test results from external and internal data 
for approximately 400 aromatic and heterocyclic aromatic amines.  The majority of the Ames-
positive compounds are only positive with metabolic activation.  This agrees with the widely 
accepted mechanism involving metabolic activation of these compounds by CYP1A2 to reactive 
metabolites that invoke a genotoxic response.  Still, for a considerable number of compounds, the 
Ames results are inconsistent with this mechanism.  Furthermore, our P450 enzyme inhibition 
assay results suggest that other cytochrome P450s could further complicate the mechanism 
leading to genotoxicity. 
 
In consideration of the above, a model was constructed using the electron density at the common 
Carbon-Nitrogen BCP of meta-/para-substituted anilines, which had Ames test results consistent 
with the accepted mechanism (i.e. negative without and positive with metabolic activation).  The 
model correctly classified 70% of the anilines.  Three outliers in the model were retested after 
establishing their purity levels.  It was encouraging that two of the compounds turned out to be 
negative as opposed to the original positive outcome for molecules of unknown purity.  When the 
classification for these compounds was updated and two compounds with a high potential for 
genotoxic mechanisms were removed, the model correctly classified 78% of the anilines.       
 
The two properties predicted in this work required very different considerations.  However, there 
were examples in both cases where models constructed using QCT descriptors were able to 
correctly challenge experimentally determined pKa values and Ames classifications.  QCT 
descriptors, calculated from solutions to the Schrödinger equation, have a strong physical basis 
but their calculations take longer than other popular descriptors.  This work has demonstrated 
their successful extension to larger data sets and in conjunction with the ever increasing speed of 
modern computation their routine use in drug discovery is an exciting opportunity.  
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The suggestion and opportunities for future work are listed below. 
 In Chapter 3 we discussed the prediction of pKa for carboxylic acids using QCT descriptors.  
Beyond extending this work to other classes of compounds, QTMS needs to match 
experiment by taking into account the nature of different tautomers present. 
 The QTMS method can be extended to predict pKa values for multiprotic compounds.  
Multiple ionisation centres have complex effects on the ionisation of a particular group.  
Hence for many of the published methods, results are limited to a series of monoprotic 
structures.  However, as QCT descriptors are based on ab initio calculations, these effects 
will automatically be encapsulated in the wave function and thus the descriptors and 
therefore the final prediction.  A similar method to that of Jelfs et al.79, who developed an 
algorithm that applies multiple predictive models in a stepwise manner and reproduces 
the correct ionisation order for different groups within a compound, should be used. 
 In Chapter 4 we demonstrated that a single ab initio bond length can be used to predict 
pKa.  In the case of ortho-substituted compounds, the consideration of conformation was 
important to model construction.  The dependence of conformation on QCT descriptors 
should be fully investigated.  This should involve returning to previous data sets used in 
QTMS analysis and investigating if unexplained outliers were caused by conformational 
differences to the rest of the data set.  This analysis may also be able to explain the so 
called “active centre contamination” in VIP plots. 
 Presently high-correlation subsets are visually identified.  Different clustering methods 
should be explored to investigate if they choose the same compounds for the same high-
correlation subsets or if less chemically intuitive, higher-correlation subsets are found. 
 A direct comparison using single-bond-length models to other QCT descriptor models 
should be performed to understand the added value of using QCT descriptors. 
 In Chapter 5 and Chapter 6 we discussed the collaborative work involving screeners, 
medicinal chemists, toxicologists, analytical and computational chemists, performed to 
purify a set of aromatic amines, screen them in the Ames test and use the data to 
generate predictive models.  With the knowledge gained from this work, carefully 
designed studies should be carried out to answer the questions that remain open. These 
are discussed below.  
 The models constructed to discriminate Ames outcomes for meta-/para-substituted 
anilines should be extended to account for all AAs.  As more compounds are added to the 
GSK data set, these models can be continually tested and updated.  Investigations into 
how the compounds in the data set need to be split into subsets and whether better 
models are constructed using high-correlation subsets should be performed. 
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 Direct comparisons between external and internal Ames test results should be made to 
fully appreciate the limits of using data from mixed sources for this class of compound.  
Models constructed using only data generated at GSK will avoid the problems associated 
with interlaboratory variations. 
 P450 enzyme inhibition data should be collected for all compounds considered in 
modelling to exclude mechanisms other than DNA modifications via the nitrenium ion 
formation.  Ames-positive +S9 compounds that do not interact with 1A2 are either 
inherently genotoxic or are metabolised by another P450 enzyme.  Outliers identified in 
computational models should be excluded if strong interactions with P450 enzymes other 
than CYP1A2 are observed.   
 To fully understand the influence of DMSO in the Ames test, the Ames-positive 
compounds that were found to degrade in DMSO should be systematically Ames-tested in 
another solvent.  The degradation products should be identified to understand the 
mechanism involved and explain the Ames test outcomes. 
 Recently, workers have proposed chemical models for the activation of aromatic 
amines258, 259  to avoid the use of the S9 metabolic activating mix, which itself is toxic to 
the bacterial strains.  The Ames results generated from such a model should be compared 
to the standard Ames test results.  While such a system is not accepted by the regulators, 
it simplifies the mechanisms involved and may be useful in explaining the current 
difficulties in modelling Ames data for this class of compound. 
 Ultimately, the generated models should be made available to the medicinal chemists so 
they can predict the likelihood of genotoxicity for an untested AA that they want to 
employ in synthesis or that appears as an impurity or metabolic product. 
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223 
 
 
 The carboxylic acids and associated experimental pKa values. 
ID CAS no. Chemical Name Exp. pKa 
meta- and para-substituted benzoic acids    
1 000051-44-5 3,4-dichlorobenzoic acid 3.64 
2 000051-36-5 3,5-dichlorobenzoic acid 3.54 
3 000057-66-9 4-[(dipropylamino)sulfonyl]benzoic acid/probenecid 3.40 
4 000062-23-7 4-nitrobenzoic acid 3.44 
5 000065-85-0 benzoic acid 4.19 
6 000074-11-3 4-chlorobenzoic acid 3.98 
7 000093-09-4 2-naphthalenecarboxylic acid 4.17 
8 000093-07-2 3,4-dimethoxybenzoic acid 4.36 
9 000098-73-7 4-(1,1-dimethylethyl)benzoic acid 4.40 
10 000099-96-7 4-hydroxybenzoic acid 4.54 
11 000099-94-5 4-methylbenzoic acid 4.37 
12 000099-50-3 3,4-dihydroxybenzoic acid 4.48 
13 000099-34-3 3,5-dinitrobenzoic acid 2.82 
14 000099-10-5 3,5-dihydroxybenzoic acid 4.04 
15 000099-05-8 3-aminobenzoic acid 4.74 
16 000099-04-7 3-methylbenzoic acid 4.27 
17 000100-09-4 4-(methyloxy)benzoic acid 4.47 
18 000121-92-6 3-nitrobenzoic acid 3.46 
19 000121-34-6 4-hydroxy-3-(methyloxy)benzoic acid 4.51 
20 000149-91-7 3,4,5-trihydroxybenzoic acid 4.21 
21 000150-13-0 4-aminobenzoic acid 4.85 
22 000455-38-9 3-fluorobenzoic acid 3.86 
23 000456-22-4 4-fluorobenzoic acid 4.14 
24 000528-45-0 3,4-dinitrobenzoic acid 2.82 
25 000530-57-4 4-hydroxy-3,5-bis(methyloxy)benzoic acid 4.34 
26 000535-80-8 3-chlorobenzoic acid 2.81 
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27 000536-66-3 4-(1-methylethyl)benzoic acid 4.35 
28 000585-76-2 3-bromobenzoic acid 3.81 
29 000586-89-0 4-acetylbenzoic acid 3.70 
30 000586-76-5 4-bromobenzoic acid 4.00 
31 000586-38-9 3-(methyloxy)benzoic acid 4.09 
32 000619-86-3 4-(ethyloxy)benzoic acid 4.45 
33 000619-66-9 4-formylbenzoic acid 3.77 
34 000619-65-8 4-cyanobenzoic acid 3.55 
35 000619-64-7 4-ethylbenzoic acid 4.35 
36 000619-21-6 3-formylbenzoic acid 3.84 
37 000619-05-6 3,4-diaminobenzoic acid 3.49 
38 001132-21-4 3,5-dimethoxybenzoic acid 3.97 
39 001877-72-1 3-cyanobenzoic acid 3.60 
40 002215-77-2 4-(phenyloxy)benzoic acid 4.52 
41 003739-38-6 3-(phenyloxy)benzoic acid 3.92 
42 004052-30-6 4-(methylsulfonyl)benzoic acid 3.64 
43 005438-19-7 4-(propyloxy)benzoic acid 4.46 
44 007496-53-9 4-(glycylamino)benzoic acid 4.20 
ortho-substituted benzoic acids   
45 000050-85-1 2-hydroxy-4-methylbenzoic acid 3.40 
46 000050-84-0 2,4-dichlorobenzoic acid 2.68 
47 000050-79-3 2,5-dichlorobenzoic acid 2.47 
48 000050-78-2 2-(acetyloxy)benzoic acid 3.49 
49 000050-31-7 2,3,6-trichlorobenzoic acid 1.50 
50 000050-30-6 2,6-dichlorobenzoic acid 1.59 
51 000059-07-4 4-amino-2-(ethyloxy)benzoic acid 5.09 
52 000061-68-7 2-[(2,3-dimethylphenyl)amino]benzoic acid 4.20 
53 000065-49-6 4-amino-2-hydroxybenzoic acid 3.66 
54 000069-72-7 2-hydroxybenzoic acid 2.97 
55 000083-40-9 2-hydroxy-3-methylbenzoic acid 2.95 
56 000088-65-3 2-bromobenzoic acid 2.88 
57 000089-86-1 2,4-dihydroxybenzoic acid 3.11 
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58 000089-56-5 2-hydroxy-5-methylbenzoic acid 3.15 
59 000089-55-4 5-bromo-2-hydroxybenzoic acid 2.66 
60 000089-52-1 2-(acetylamino)benzoic acid 3.40 
61 000091-52-1 2,4-dimethyloxybenzoic acid 4.36 
62 000091-40-7 2-(phenylamino)benzoic acid 3.99 
63 000092-70-6 3-hydroxy-2-naphthalenecarboxylic acid 2.79 
64 000096-97-9 2-hydroxy-5-nitrobenzoic acid 2.12 
65 000099-60-5 2-chloro-4-nitrobenzoic acid 2.14 
66 000118-92-3 2-aminobenzoic acid 4.95 
67 000118-91-2 2-chlorobenzoic acid 2.89 
68 000119-90-1 2-methylbenzoic acid 3.98 
69 000129-66-8 2,4,6-trinitrobenzoic acid 0.65 
70 000133-90-4 3-amino-2,5-dichlorobenzoic acid 3.40 
71 000303-38-8 2,3-dihydroxybenzoic acid 2.91 
72 000303-07-1 2,6-dihydroxybenzoic acid 1.05 
73 000321-14-2 5-chloro-2-hydroxybenzoic acid 2.65 
74 000445-29-4 2-fluorobenzoic acid 3.27 
75 000490-79-9 2,5-dihydroxybenzoic acid 2.95 
76 000552-16-9 2-nitrobenzoic acid 2.17 
77 000577-56-0 2-acetylbenzoic acid 4.13 
78 000579-75-9 2-(methyloxy)benzoic acid 3.90 
79 000609-99-4 2-hydroxy-3,5-dinitrobenzoic acid 0.70 
80 000610-30-0 2,4-dinitrobenzoic acid 1.42 
81 000632-46-2 2,6-dimethylbenzoic acid 3.35 
82 000652-32-4 2,3,5,6-tetrafluoro-4-methylbenzoic acid 2.00 
83 000947-84-2 2-biphenylcarboxylic acid 3.46 
84 001466-76-8 2,6-bis(methyloxy)benzoic acid 3.44 
85 001521-38-6 2,3-dimethyloxybenzoic acid 3.98 
86 001918-00-9 3,6-dichloro-2-(methyloxy)benzoic acid 1.97 
87 002243-42-7 2-(phenyloxy)benzoic acid 3.53 
88 002438-04-2 2-(1-methylethyl)benzoic acid 3.63 
89 002516-96-3 2-chloro-5-nitrobenzoic acid 2.17 
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90 003970-35-2 2-chloro-3-nitrobenzoic acid 2.02 
91 004727-29-1 2-[(phenylamino)carbonyl]benzoic acid 2.50 
92 005344-49-0 2-chloro-6-nitrobenzoic acid 1.34 
93 021327-86-6 2-chloro-6-methylbenzoic acid 2.75 
94 025784-02-5 2-[(2-amino-2-oxoethyl)amino]benzoic acid 4.20 
aliphatic carboxylic acids  
95 000050-21-5 2-hydroxypropanoic acid 3.86 
96 000053-86-1 [1-[(4-chlorophenyl)carbonyl]-2-methyl-5-(methyloxy)-1H-indol-3-yl]acetic acid/indomethacin 4.50 
97 000061-78-9 N-[(4-aminophenyl)carbonyl]glycine 3.80 
98 000061-33-6 3,3-dimethyl-7-oxo-6-[(phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid/benzylpenicillin 2.74 
99 000061-32-5 6-({[2,6-bis(methyloxy)phenyl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acidmethicillin 2.77 
100 000064-19-7 acetic acid 4.76 
101 000068-11-1 mercaptoacetic acid 3.55 
102 000075-99-0 2,2-dichloropropanoic acid 1.79 
103 000075-98-9 2,2-dimethylpropanoic acid 5.03 
104 000076-93-7 hydroxy(diphenyl)acetic acid 3.05 
105 000076-05-1 trifluoroacetic acid 0.52 
106 000076-03-9 trichloroacetic acid 0.51 
107 000077-06-5 gibberellic acid 4.00 
108 000079-43-6 dichloroacetic acid 1.26 
109 000079-31-2 2-methylpropanoic acid 4.84 
110 000079-14-1 hydroxyacetic acid 3.83 
111 000079-11-8 chloroacetic acid 2.87 
112 000079-09-4 propanoic acid 4.88 
113 000079-08-3 bromoacetic acid 2.89 
114 000081-25-4 3,7,12-trihydroxycholan-24-oic acid 4.98 
115 000085-34-7 (2,3,6-trichlorophenyl)acetic acid 3.70 
116 000086-87-3 1-naphthalenylacetic acid 4.23 
117 000087-51-4 1H-indol-3-ylacetic acid 4.75 
118 000087-08-1 3,3-dimethyl-7-oxo-6-{[(phenyloxy)acetyl]amino}-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid/phenoxymethylpenicillin 2.79 
119 000088-09-5 2-ethylbutanoic acid 4.71 
120 000090-64-2 hydroxy(phenyl)acetic acid 3.41 
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121 000093-76-5 [(2,4,5-trichlorophenyl)oxy]acetic acid 2.83 
122 000093-72-1 2-[(2,4,5-trichlorophenyl)oxy]propanoic acid 2.84 
123 000094-82-6 4-[(2,4-dichlorophenyl)oxy]butanoic acid 4.95 
124 000094-81-5 4-[(4-chloro-2-methylphenyl)oxy]butanoic acid 6.20 
125 000094-75-7 [(2,4-dichlorophenyl)oxy]acetic acid 2.73 
126 000094-74-6 [(4-chloro-2-methylphenyl)oxy]acetic acid 3.13 
127 000097-61-0 2-methylpentanoic acid 4.79 
128 000098-89-5 cyclohexanecarboxylic acid 4.90 
129 000099-66-1 2-propylpentanoic acid 4.60 
130 000102-32-9 (3,4-dihydroxyphenyl)acetic acid 4.25 
131 000103-82-2 phenylacetic acid 4.31 
132 000104-03-0 (4-nitrophenyl)acetic acid 3.85 
133 000104-01-8 [4-(methyloxy)phenyl]acetic acid 4.36 
134 000107-94-8 3-chloropropanoic acid 3.99 
135 000107-92-6 butanoic acid 4.82 
136 000116-53-0 2-methylbutanoic acid 4.81 
137 000117-34-0 diphenylacetic acid 3.94 
138 000120-36-5 2-[(2,4-dichlorophenyl)oxy]propanoic acid 3.10 
139 000122-88-3 [(4-chlorophenyl)oxy]acetic acid 3.10 
140 000122-59-8 (phenyloxy)acetic acid 3.17 
141 000123-76-2 4-oxopentanoic acid 4.64 
142 000141-82-2 propanedioic acid 2.85 
143 000144-49-0 fluoroacetic acid 2.59 
144 000300-85-6 3-hydroxybutanoic acid 4.41 
145 000305-03-3 4-{4-[bis(2-chloroethyl)amino]phenyl}butanoic acid/chlorambucil 5.75 
146 000306-08-1 [4-hydroxy-3-(methyloxy)phenyl]acetic acid 4.41 
147 000327-97-9 3-{[(2E)-3-(3,4-dihydroxyphenyl)-2-propenoyl]oxy}-1,4,5-trihydroxycyclohexanecarboxylic acid/chlorogenic acid 2.66 
148 000331-25-9 (3-fluorophenyl)acetic acid 4.13 
149 000348-10-7 [(2-fluorophenyl)oxy]acetic acid 3.08 
150 000372-09-8 cyanoacetic acid 2.45 
151 000404-98-8 [(3-fluorophenyl)oxy]acetic acid 3.13 
152 000405-79-8 [(4-fluorophenyl)oxy]acetic acid 3.13 
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153 000405-50-5 (4-fluorophenyl)acetic acid 4.24 
154 000462-60-2 N-(aminocarbonyl)glycine 3.89 
155 000467-69-6 9-hydroxy-9H-fluorene-9-carboxylic acid/flurenol 1.09 
156 000473-81-4 2,3-dihydroxypropanoic acid 3.55 
157 000501-52-0 3-phenylpropanoic acid 4.66 
158 000503-74-2 3-methylbutanoic acid 4.77 
159 000503-66-2 3-hydroxypropanoic acid 4.51 
160 000515-30-0 2-hydroxy-2-phenylpropanoic acid 3.53 
161 000516-05-2 methylpropanedioic acid 3.12 
162 000539-35-5 6-(4-oxo-1,3-thiazolidin-2-yl)hexanoic acid/mycobacidin 5.10 
163 000581-96-4 2-naphthalenylacetic acid 4.25 
164 000588-32-9 [(3-chlorophenyl)oxy]acetic acid 3.07 
165 000588-22-7 [(3,4-dichlorophenyl)oxy]acetic acid 2.92 
166 000594-61-6 2-hydroxy-2-methylpropanoic acid 3.61 
167 000595-46-0 dimethylpropanedioic acid 3.15 
168 000595-37-9 2,2-dimethylbutanoic acid 5.03 
169 000598-78-7 2-chloropropanoic acid 2.80 
170 000598-72-1 2-bromopropanoic acid 2.97 
171 000601-75-2 ethylpropanedioic acid 2.96 
172 000614-61-9 [(2-chlorophenyl)oxy]acetic acid 3.05 
173 000616-62-6 propylpropanedioic acid 2.99 
174 000617-31-2 2-hydroxypentanoic acid 2.89 
175 000622-47-9 (4-methylphenyl)acetic acid 4.37 
176 000646-07-1 4-methylpentanoic acid 4.84 
177 000689-13-4 N-formyl-N-hydroxyglycine 3.50 
178 000940-64-7 [(4-methylphenyl)oxy]acetic acid 3.21 
179 001643-15-8 [(3-methylphenyl)oxy]acetic acid 3.20 
180 001759-53-1 cyclopropanecarboxylic acid 4.83 
181 001798-99-8 [(3-bromophenyl)oxy]acetic acid 3.09 
182 001798-11-4 [(4-nitrophenyl)oxy]acetic acid 2.89 
183 001821-12-1 4-phenylbutanoic acid 4.76 
184 001877-75-4 {[4-(methyloxy)phenyl]oxy}acetic acid 2.31 
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185 001877-73-2 (3-nitrophenyl)acetic acid 3.97 
186 001878-91-7 [(4-bromophenyl)oxy]acetic acid 3.13 
187 001878-88-2 [(3-nitrophenyl)oxy]acetic acid 2.95 
188 001878-87-1 [(2-nitrophenyl)oxy]acetic acid 2.90 
189 001878-85-9 {[2-(methyloxy)phenyl]oxy}acetic acid 3.23 
190 001878-82-6 [(4-cyanophenyl)oxy]acetic acid 2.93 
191 001878-68-8 (4-bromophenyl)acetic acid 4.19 
192 001878-66-6 (4-chlorophenyl)acetic acid 4.19 
193 001878-65-5 (3-chlorophenyl)acetic acid 4.14 
194 001878-49-5 [(2-methylphenyl)oxy]acetic acid 3.23 
195 001879-58-9 [(3-cyanophenyl)oxy]acetic acid 3.03 
196 001879-56-7 [(2-bromophenyl)oxy]acetic acid 3.13 
197 002088-24-6 {[3-(methyloxy)phenyl]oxy}acetic acid 3.14 
198 002270-20-4 5-phenylpentanoic acid 4.88 
199 002976-75-2 (1-naphthalenyloxy)acetic acid 3.20 
200 003813-05-6 (4-chloro-2-oxo-1,3-benzothiazol-3(2H)-yl)acetic acid 3.04 
201 005292-21-7 cyclohexylacetic acid 4.80 
202 006324-11-4 [(2-hydroxyphenyl)oxy]acetic acid 3.02 
203 010502-44-0 hydroxy[4-(methyloxy)phenyl]acetic acid 3.42 
204 014387-10-1 (4-ethylphenyl)acetic acid 4.37 
205 015307-86-5 {2-[(2,6-dichlorophenyl)amino]phenyl}acetic acid/ diclofenac 4.15 
206 015687-27-1 2-[4-(2-methylpropyl)phenyl]propanoic acid/ibuprofen 4.45 
207 016484-77-8 2-[(4-chloro-2-methylphenyl)oxy]propanoic acid 3.68 
208 016563-41-0 3-(1-naphthalenyloxy)propanoic acid 4.00 
209 018046-21-4 [4-(4-chlorophenyl)-2-phenyl-1,3-thiazol-5-yl]acetic acid/fentiazac 3.60 
210 020225-24-5 2-ethylpentanoic acid 4.71 
211 022071-15-4 2-[3-(phenylcarbonyl)phenyl]propanoic acid/ketoprofen 4.45 
212 022131-79-9 [3-chloro-4-(2-propen-1-yloxy)phenyl]acetic acid/alcofenac 4.29 
213 022204-53-1 2-[6-(methyloxy)-2-naphthalenyl]propanoic acid/naprosyn 4.15 
214 029679-58-1 2-[3-(phenyloxy)phenyl]propanoic acid/fenoprofen 4.50 
215 032857-63-9 [4-(1,1-dimethylethyl)phenyl]acetic acid 4.42 
216 036330-85-5 4-(4-biphenylyl)-4-oxobutanoic acid/fenbufen 4.51 
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217 038194-50-2 ((1E)-5-fluoro-2-methyl-1-{[4-(methylsulfinyl)phenyl]methylidene}-1H-inden-3-yl)acetic acid/sulindac 4.70 
218 040828-46-4 2-[4-(2-thienylcarbonyl)phenyl]propanoic acid/suprofen 3.91 
219 040843-25-2 2-({4-[(2,4-dichlorophenyl)oxy]phenyl}oxy)propanoic acid 3.43 
220 053808-88-1 [3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl]acetic acid/ionazolac 4.30 
221 055335-06-3 [(3,5,6-trichloro-2-pyridinyl)oxy]acetic acid 2.68 
222 055863-26-8 (11-oxo-6,11-dihydrodibenzo[b,e]thiepin-2-yl)acetic acid/tiopinac 3.71 
223 058667-63-3 N-(3-chloro-4-fluorophenyl)-N-(phenylcarbonyl)alanine 3.72 
224 069335-91-7 2-[(4-{[5-(trifluoromethyl)-2-pyridinyl]oxy}phenyl)oxy]propanoic acid 3.12 
225 069806-34-4 2-[(4-{[3-chloro-5-(trifluoromethyl)-2-pyridinyl]oxy}phenyl)oxy]propanoic acid 2.90 
226 074103-06-3 5-(phenylcarbonyl)-2,3-dihydro-1H-pyrrolo[1,2-a]pyrrole-1-carboxylic acid/ketorolac 3.49 
227 089894-13-3 [(4-chloro-3-nitrophenyl)oxy]acetic acid 2.96 
228 104273-73-6 4-(cyclopropylcarbonyl)-3,5-dioxocyclohexanecarboxylic acid 5.32 
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Tehan 
ID ID SMILES Chemical Name Exp pKa Ref. 
Meta/Para-Substituted Phenols 
   
1 1 NCCc1ccc(O)cc1 4-(2-aminoethyl)phenol 9.77 1 
2 2 Cc1c(Cl)ccc(O)c1 3-methyl-4-chlorophenol 9.20 1 
3 3 CC(Cc1ccc(O)cc1)(C)C 4-tert-amylphenol 10.43 1 
4 4 c1(cc(O)ccc1[N+](=O)[O-])C(F)(F)F 3-trifluoromethyl-4-nitrophenol 6.07 1 
5 5 c1(Cl)c(C)cc(cc1C)O 4-chloro-3,5-dimethylphenol 9.70 1 
6 6 c1(ccc(cc1)O)c2ccccc2 4-phenylphenol 9.55 1 
7 7 C(OCCCC)(=O)c1ccc(cc1)O 4-hydroxy nutyl benzoate 8.47 1 
8 8 c1(Cl)c(Cl)ccc(O)c1 3,4-dichlorophenol 8.63 1 
9 9 c1(C)cc(O)ccc1C 3,4-dimethylphenol 10.36 1 
10 10 C(C)(C)(C)c1ccc(cc1)O 4-t-butylyphenol 10.39 1 
11 11 C(F)(F)(F)c1cccc(O)c1 3-trifluoromethylphenol 8.95 1 
12 12 C(C)(=O)c1ccc(cc1)O 4-hydroxyacetophenone 8.05 1 
13 13 c1(C(C)C)ccc(cc1)O 4-isopropylphenol 10.24 1 
14 14 O=Cc1cccc(O)c1 3-hydroxybenzaldehyde 8.98 1 
15 15 [N+](=O)([O-])c1ccc(cc1)O 4-nitrophenol 7.15 1 
16 16 C(C)(=O)Nc1ccc(cc1)O n-(4-hydroxyphenyl)acetamide 9.38 1 
17 17 c1(ccc(cc1)O)Cl 4-chlorophenol 9.41 1 
18 18 c1(O)ccc(cc1)C 4-cresol 10.26 1 
19 19 c1(ccc(cc1)O)Br 4-bromophenol 9.17 1 
20 20 c1(ccccc1)O phenol 9.99 1 
21 21 c1(O)cc(C)cc(C)c1 3,5-dimethylphenol 10.19 1 
22 22 c1c(cccc1Cl)O 3-chlorophenol 9.12 1 
23 23 c1c(C)cccc1O 3-cresol 10.09 1 
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24 24 C(OCC)(=O)c1ccc(cc1)O 4-hydroxybenzoic acid, ethyl ester 8.34 1 
25 25 c1(cccc(O)c1)C(C)=O 3-hydroxyacetophenone 9.25 1 
26 26 c1(ccc(cc1)O)N 4-aminophenol 10.45 1 
27 27 O=Cc1ccc(cc1)O 4-hydroxybenzaldehyde 7.61 1 
28 28 c1(O)ccc(cc1)CC 4-ethylphenol 10.00 1 
29 29 c1(O)ccc(cc1)OC 4-methoxyphenol 10.10 1 
30 30 c1c(cccc1O)OC 3-methoxyphenol 9.65 1 
31 31 c1(ccc(cc1)O)F 4-fluorophenol 9.91 1 
32 32 c1c(cccc1F)O 3-fluorophenol 9.21 1 
33 33 C(F)(F)(F)c1ccc(cc1)O 4-trifluoromethylphenol 8.68 1 
34 34 c1(O)cc(OC)cc(OC)c1 3,5-dimethoxyphenol 9.34 1 
35 35 c1(ccc(cc1)O)I 4-iodophenol 9.21 1 
36 36 [N+](=O)([O-])c1cccc(O)c1 3-nitrophenol 8.36 1 
37 37 c1(cc(O)ccc1[N+](=O)[O-])[N+](=O)[O-] 3,4-dinitrophenol 5.42 1 
38 38 c1(cccc(O)c1)c2ccccc2 3-phenylphenol 9.64 1 
39 39 c1(cccc(O)c1)C(C)(C)C 3-(1,1-dimethylethyl)-phenol 10.12 1 
40 40 [N+](=O)([O-])c1cc(O)cc(c1)[N+](=O)[O-] 3,5-dinitrophenol 6.69 1 
41 41 c1(Cl)cc(O)cc(Cl)c1 3,5-dichlorophenol 8.18 1 
42 42 c1c(cccc1N)O 3-aminophenol 9.86 1 
43 43 c1c(cccc1Br)O 3-bromophenol 9.03 1 
44 44 c1(Cl)c(Cl)cc(cc1Cl)O 3,4,5-trichlorophenol 7.84 1 
45 45 c1(cccc(O)c1)C(C)C 3-isopropylphenol 10.16 1 
46 46 c1c(CC)cccc1O 3-ethylphenol 9.90 1 
47 47 c1c(cccc1O)OCC 3-ethoxyphenol 9.65 1 
48 48 c1(O)ccc(cc1)OCC 4-ethoxyphenol 10.13 1 
49 49 c1(Br)cc(O)cc(Br)c1 3,5-dibromophenol 8.06 1 
50 50 c1c(cccc1I)O 3-iodophenol 9.03 1 
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51 51 c1(O)ccc(cc1)CCC 4-propylphenol 10.34 1 
52 52 c1(O)cc(CC)cc(C)c1 3-ethyl-5-methylphenol 10.10 1 
53 53 N#Cc1ccc(cc1)O 4-cyanophenol 7.97 1 
54 54 N#Cc1cccc(O)c1 3-cyanophenol 8.61 1 
55 55 c1(O)ccc(cc1)CS 4-methiophenol 9.53 1 
56 56 c12CCCc1ccc(O)c2 5-indanol 10.32 1 
57 57 [N+](=O)([O-])c1c(C)ccc(O)c1 3-nitro-4-cresol 8.62 1 
58 58 C(C)(=O)c1ccc(cc1)O hydroxyacetophenone 8.05 1 
Ortho-Substituted Phenols (Capable of forming internal hydrogen bonds) 
   
1 59 c1(ccccc1O)C(N)=O 2-hydroxybenzamide 8.89 1 
2 60 C(=O)(Nc1ccccc1)c2ccccc2O salicylanilide 7.40 1 
3 61 c1(ccccc1O)C(OC)=O methyl salicylate 9.87 1 
4 62 c1(O)c(cccc1C=O)OC 2-vanillin 7.91 1 
5 63 c1(cc(cc(Cl)c1O)Cl)C(=O)Nc2ccc(cc2)Cl 3,5,4'-trichloro salicylanilide 4.70 1 
6 64 C(=O)(Nc1ccccc1Cl)c2ccccc2O 2'-chloro salicylanilide 7.31 1 
7 65 c1(c(O)ccc(c1)N(=O)=O)C(=O)Nc2ccccc2 5-nitro salicylanilide 3.03 1 
8 66 C(=O)(Nc1ccc(cc1)Br)c2ccccc2O 4'-bromo salicylanilide 7.31 1 
9 67 c1(cc(ccc1O)Br)C(=O)Nc2ccc(cc2)Cl 4'-chloro-5-bromo salicylanilide 6.00 1 
10 68 C(=O)(Nc1ccc(cc1)Cl)c2ccccc2O 4'-chloro salicylanilide 7.30 1 
11 69 c1(cc(cc(Cl)c1O)Cl)C(=O)Nc2ccccc2 3,5-dichloro salicylanilide 4.70 1 
12 70 c1(cc(ccc1O)Cl)C(=O)Nc2ccccc2 5-chlorosalicylanilide 6.17 1 
13 71 c1(cc(ccc1O)Cl)C(=O)Nc2ccccc2C 5-chloro-2'-methyl salicylanilide 6.60 1 
14 72 C(=O)(Nc1ccc(Cl)cc1Cl)c2ccccc2O 2',4'-dichloro salicylanilide 7.14 1 
15 73 N(=O)(=O)c1ccccc1NC(=O)c2ccccc2O 2'-nitro salicylanilide 6.91 1 
16 74 c1(cc(ccc1NC(=O)c2ccccc2O)Cl)N(=O)=O 2'-nitro-4'-chloro salicylanilide 6.74 1 
17 75 c1(ccc(Br)c(C)c1O)C(NC)=O 5-bromo-2-hydroxy-n,3-dimethyl-benzamide 7.52 1 
18 76 c1(cc(cc(Cl)c1O)Cl)C(=O)Nc2ccc(cc2)F 3,5-dichloro-4'-fluoro salicylanilide 4.80 1 
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19 77 c1(cc(cc(Br)c1O)Br)C(=O)Nc2ccc(Cl)cc2N(=O)=O 3,5-dibromo-2'-nitro-4'-chloro salicylanilide 4.11 1 
20 78 C(=O)(Nc1ccc(Cl)cc1C)c2ccccc2O 2'-methyl-4'-chloro salicylanilide 7.43 1 
21 79 c1(cc(ccc1O)F)C(=O)Nc2ccc(Br)cc2C 5-fluoro-2'-methyl-4'-bromo salicylanilide 7.10 1 
22 80 c1(cc(ccc1O)F)C(=O)Nc2ccc(Cl)cc2C 5-fluoro-2'-methyl-4'-chloro salicylanilide 7.30 1 
23 81 c1(cc(cc(Br)c1O)Br)C(=O)Nc2ccc(F)cc2F 3,5-dibromo-2',4'-difluoro salicylanilide 4.77 1 
24 82 c1(cc(cc(Cl)c1O)Cl)C(=O)Nc2ccc(F)cc2F 3,5-dichloro-2',4'-difluoro salicylanilide 4.77 1 
25 83 c1(cc(cc(Cl)c1O)Cl)C(=O)Nc2ccc(Cl)cc2N(=O)=O 3,5,-4'-trichloro-2'-nitro salicylanilide 4.11 1 
26 84 c1(cc(cc(Cl)c1O)Cl)C(=O)Nc2ccc(cc2C)N(=O)=O 3,5-dichloro-2'-methyl-4'-nitro salicylanilide 4.41 1 
Ortho-Substituted Phenols 
   
1 85 c1(c(O)ccc(c1)[N+](=O)[O-])[N+](=O)[O-] 2,4-dinitrophenol 4.09 1 
2 86 c1(Cl)c(O)c(Cl)cc(Cl)c1Cl 2,3,4,6-tetrachlorophenol 5.22 1 
3 87 c1(c(cccc1N(=O)=O)O)N(=O)=O 2,3-dinitrophenol 4.96 1 
4 88 c1(Cl)c(Cl)c(O)c(c(Cl)c1Cl)Cl pentachlorophenol 4.70 1 
5 89 c1(O)c(cccc1Cl)Cl 2,6-dichlorophenol 6.79 1 
6 90 c1(O)c(C)cccc1Cl 2-methyl-6-chlorophenol 8.69 1 
7 91 c1(cc(cc([N+](=O)[O-])c1O)[N+](=O)[O-])[N+](=O)[O-] 2,4,6-trinitrophenol 0.38 1 
8 92 c1(cc(Cl)cc([N+](=O)[O-])c1O)[N+](=O)[O-] 4-chloro-2,6-dinitrophenol 2.96 1 
9 93 c1(cc(cc(C(C)CC)c1O)[N+](=O)[O-])[N+](=O)[O-] 2-sec-butyl-4,6-dinitrophenol 4.62 1 
10 94 [N+](=O)([O-])c1ccccc1O 2-nitrophenol 7.23 1 
11 95 c1(ccccc1O)C(C)C 2-isopropylphenol 10.47 1 
12 96 c1(ccccc1O)C(C)(C)C 2-t-butylphenol 10.28 1 
13 97 c1(O)c(Cl)cc(cc1Cl)Cl 2,4,6-trichlorophenol 6.23 1 
14 98 c1(O)cc(C)ccc1C(C)C thymol 10.62 1 
15 99 c1(C(C)C)c(O)cc(c(Cl)c1)C chlorothymol 9.98 1 
16 100 [N+](=O)([O-])c1c(O)ccc(Cl)c1 4-chloro-2-nitrophenol 6.46 1 
17 101 c1(ccccc1O)c2ccccc2 2-phenylphenol 9.92 1 
18 102 c1(ccccc1OC)O 2-methoxyphenol 9.98 1 
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19 103 c1(ccccc1CC)O 2-ethylphenol 10.20 1 
20 104 c1(OC)cc(C)ccc1O 4-methyl-2-methoxyphenol 10.28 1 
21 105 c1(ccccc1OCC)O 2-ethoxyphenol 10.11 1 
22 106 c1c(Cl)c(O)cc(Cl)c1Cl 2,4,5-trichlorophenol 7.40 1 
23 107 c1(O)cc(C)ccc1C 2,5-dimethylphenol 10.41 1 
24 108 c1(ccccc1O)Cl 2-chlorophenol 8.56 1 
25 109 c1(ccccc1O)Br 2-bromophenol 8.45 1 
26 110 c1(ccccc1O)N 2-aminophenol 9.75 1 
27 111 c1(ccccc1C)O 2-cresol 10.28 1 
28 112 c1(c(O)ccc(C(C)(C)C)c1)C(C)(C)C 2,4-di-t-butylphenol 11.72 1 
29 113 c1(OC)cc(ccc1O)C=CC 2-methoxy-4-(1-propenyl)phenol 9.88 1 
30 114 c1(OC)cc(CC=C)ccc1O eugenol 10.19 1 
31 115 c1(ccc(c(Cl)c1)O)C(C)(C)C 4-(tert-butyl)-2-chlorophenol 8.58 1 
32 116 c1(ccc(c(C)c1)O)C(C)(C)C 4-(t-butyl)-2-cresol 10.59 1 
33 117 [N+](=O)([O-])c1ccc(c(N)c1)O 2-amino-4-nitrophenol 7.60 1 
34 118 [N+](=O)([O-])c1cc(Br)c(c(Br)c1)O 2,6-dibromo-4-nitrophenol 3.39 1 
35 119 c1(C)cc(C)ccc1O 2,4-dimethylphenol 10.60 1 
36 120 c1(O)c(Br)cc(cc1Br)Br 2,4,6-tribromophenol 6.10 1 
37 121 N(=O)(=O)c1c(O)ccc(N)c1 phenol, 4-amino-2-nitro- 7.81 1 
38 122 [N+](=O)([O-])c1cc(C)ccc1O 4-methyl-2-nitrophenol 7.40 1 
39 123 c1(Cl)c(O)ccc(Cl)c1 2,4-dichlorophenol 7.89 1 
40 124 c1(OC)cc(ccc1O)C=O vanillin 7.40 1 
41 125 c1(O)c(cccc1C(C)(C)C)C(C)(C)C 2,6-di-t-butylphenol 11.70 1 
42 126 c1(O)c(cc(cc1C(C)(C)C)C)C(C)(C)C 2,6-di-t-butyl-4-methylphenol (bht) 12.23 1 
43 127 c2(cc(cc(C1CCCCC1)c2O)[N+](=O)[O-])[N+](=O)[O-] 2-cyclohexyl-4,6-dinitrophenol 4.52 1 
44 128 [N+](=O)([O-])c1ccc(cc1O)[N+](=O)[O-] 2,5-dinitrophenol 5.21 1 
45 129 c1(ccccc1O)F 2-fluorophenol 8.70 1 
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46 130 [N+](=O)([O-])c1ccc(cc1O)F 5-fluoro-2-nitrophenol 6.07 1 
47 131 c1(O)c(C)cc(c(C)c1)C 2,4,5-trimethylphenol 10.57 1 
48 132 c1(C)c(C)cccc1O 2,3-dimethylphenol 10.54 1 
49 133 c1(O)c(C)cc(cc1C)C 2,4,6-trimethylphenol 10.86 1 
50 134 c1(ccccc1O)I 2-iodophenol 8.51 1 
51 135 c1(c(O)c(C)cc(c1)[N+](=O)[O-])[N+](=O)[O-] 4,6-dinitro-o-cresol 4.31 1 
52 136 c1(O)c(O)ccc(CCN)c1C 2-methyldopamine= 9.54 1 
53 137 [N+](=O)([O-])c1cccc(c1O)[N+](=O)[O-] 2,6-dinitrophenol 3.97 1 
54 138 c1(O)c(C)cccc1C 2,6-dimethylphenol 10.62 1 
55 139 c1(Cl)c(cccc1Cl)O 2,3-dichlorophenol 7.70 1 
56 140 c1(O)c(Cl)ccc(Cl)c1 2,5-dichlorophenol 7.51 1 
57 141 [N+](=O)([O-])c1cccc(Cl)c1O 6-chloro-2-nitrophenol 5.48 1 
58 142 c1(Br)c(Br)c(O)c(c(Br)c1Br)Br pentabromophenol 4.62 1 
59 143 c1(O)c(cccc1Br)Br 2,6-dibromophenol 6.67 1 
60 144 c1(cc(C)cc([N+](=O)[O-])c1O)[N+](=O)[O-] 2,6-dinitro-p-cresol 4.23 1 
61 145 N#Cc1ccccc1O 2-cyanophenol 6.86 1 
62 146 [N+](=O)([O-])c1ccc(cc1O)Cl 5-chloro-2-nitrophenol 6.05 1 
63 147 c1(Br)c(O)ccc(Br)c1 2,4-dibromophenol 7.79 1 
64 148 [N+](=O)([O-])c1cc(Cl)c(c(Cl)c1)O 2,6-dichloro-4-nitrophenol 3.55 1 
65 149 [N+](=O)([O-])c1ccc(c(Cl)c1)O 2-chloro-4-nitrophenol 5.45 1 
66 150 c1(O)cc(ccc1OC)C=O isovanillin 8.89 1 
67 151 c1(ccccc1CCC)O 2-propylphenol 10.47 1 
68 152 c1(O)cc(C)cc(C)c1C 2,3,5-trimethylphenol 10.67 1 
69 153 c1(C)cc(c([N+]([O-])=O)cc1)O 5-methyl-2-nitrophenol 7.41 1 
70 154 c2(cc(cc(c1ccccc1)c2O)[N+](=O)[O-])[N+](=O)[O-] 2,4-dinitro-6-phenylphenol 3.85 1 
71 155 c1(C(C)(C)C)cc(C(C)(C)C)cc(C(C)(C)C)c1O 2,4,6-tri(tert-butyl)phenol 12.19 1 
72 156 c1(F)c(F)c(O)c(c(F)c1F)F pentafluorophenol 5.53 1 
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73 157 [N+](=O)([O-])c2c(O)ccc(c1ccccc1)c2 4-phenyl-2-nitrophenol 6.73 1 
74 158 c1(Cl)c(Cl)ccc(Cl)c1O 2,3,6-trichlorophenol 5.80 1 
75 159 c1(O)c(Cl)c(Cl)cc(Cl)c1Cl 2,3,5,6-tetrachlorophenol 5.14 1 
76 160 c1(cc(cc(Cl)c1O)[N+](=O)[O-])[N+](=O)[O-] 6-chloro-2,4-dinitrophenol 2.10 1 
77 161 [N+](=O)([O-])c1c(O)ccc(OC)c1 4-methoxy-2-nitrophenol 7.31 1 
78 162 c1(C)cc(Cl)ccc1O 2-methyl-4-chlorophenol 9.71 1 
79 163 c1(O)c(Br)cc(cc1Br)C#N bromoxynil 3.86 1 
80 164 c1(cc(C)cc(C)c1O)C(C)(C)C 2-(1,1-dimethylethyl)-4,6-dimethylphenol 12.04 1 
81 165 c1(O)c(cccc1C(C)C)C(C)C phenol, 2,6-bis(1-methylethyl)- 11.10 1 
82 166 c1(cc(C)ccc1O)C(C)(C)C 2-(tert-butyl)-4-methylphenol 11.72 1 
83 167 [N+](=O)([O-])c1cc(C)c(c(C)c1)O 2,6-dimethyl-4-nitrophenol 7.07 1 
84 168 c1(O)c(Cl)cc(cc1Cl)C 4-methyl-2,6-dichlorophenol 7.19 1 
85 169 c1(O)c(Cl)cc(cc1Cl)Br 4-bromo-2,6-dichlorophenol 6.21 1 
86 170 [N+](=O)([O-])c1c(O)ccc(C(C)CC)c1 4-(sec-butyl)-2-nitrophenol 7.59 1 
87 171 C(O)(=O)c1ccc(O)c(Cl)c1 3-chloro-4-hydroxybenzoic acid 7.52 1 
88 172 c1(Cl)c(Cl)c(O)cc(Cl)c1Cl 2,3,4,5-tetrachlorophenol 6.35 1 
89 173 N(=O)(=O)c1ccc(c(O)c1)C phenol, 2-methyl-5-nitro- 8.59 1 
90 174 Cl-c(cc(c1)C)c(c1)O 2-chloro-4-methylphenol 8.74 1 
91 175 c2(c(ON=Cc1cc(Br)c(c(Br)c1)O)ccc(c2)N(=O)=O)N(=O)=O bromofenoxim 5.46 1 
Meta/Para-Substituted Benzoic Acids 
   
1 176 C(O)(=O)c1ccc(c(Cl)c1)Cl 3,4-dichlorobenzoic acid 3.64 1 
2 177 c1(cc(Cl)cc(Cl)c1)C(O)=O 3,5-dichlorobenzoic acid 3.54 1 
3 178 S(=O)(=O)(N(CCC)CCC)c1ccc(cc1)C(O)=O probenecid 3.40 1 
4 179 [N+](=O)([O-])c1ccc(cc1)C(O)=O p-nitrobenzoicacid 3.44 1 
5 180 C(O)(c1ccccc1)=O benzoic acid 4.19 1 
6 181 C(O)(=O)c1ccc(cc1)Cl 4-chlorobenzoic acid 3.98 1 
7 182 C(O)(=O)c2ccc1c(cccc1)c2 2-naphthoic acid 4.17 1 
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8 183 C(O)(=O)c1ccc(c(OC)c1)OC 3,4-dimethoxybenzoic acid 4.36 1 
9 184 C(O)(=O)c1ccc(cc1)C(C)(C)C 4-(tert-butyl)-benzoic acid 4.40 1 
10 185 C(O)(=O)c1ccc(cc1)O p-hydroxybenzoic acid 4.54 1 
11 186 C(O)(=O)c1ccc(cc1)C p-toluic acid 4.37 1 
12 187 C(O)(=O)c1ccc(c(O)c1)O 3,4-dihydroxybenzoic acid 4.48 1 
13 188 [N+](=O)([O-])c1cc(cc(c1)[N+](=O)[O-])C(O)=O 3,5-dinitrobenzoic acid 2.82 1 
14 189 c1(cc(O)cc(O)c1)C(O)=O 3,5-dihydroxybenzoic acid 4.04 1 
15 190 C(O)(=O)c1cccc(N)c1 3-aminobenzoic acid 4.74 1 
16 191 C(O)(=O)c1cccc(C)c1 m-toluic acid 4.27 1 
17 192 C(O)(=O)c1ccc(cc1)OC p-methoxybenzoic acid 4.47 1 
18 193 [N+](=O)([O-])c1cccc(c1)C(O)=O m-nitrobenzoic acid 3.46 1 
19 194 C(O)(=O)c1ccc(c(OC)c1)O 4-hydroxy-3-methoxybenzoic acid 4.51 1 
20 195 c1(O)c(O)cc(cc1O)C(O)=O 3,4,5-trihydroxybenzoic acid 4.21 1 
21 196 C(O)(=O)c1ccc(cc1)N 4-aminobenzoic acid 4.85 1 
22 197 C(O)(=O)c1cccc(F)c1 m-fluorobenzoic acid 3.86 1 
23 198 C(O)(=O)c1ccc(cc1)F p-fluorobenzoic acid 4.14 1 
24 199 c1(cc(ccc1[N+](=O)[O-])C(O)=O)[N+](=O)[O-] 3,4-dinitrobenzoic acid 2.82 1 
25 200 c1(O)c(OC)cc(cc1OC)C(O)=O 4-hydroxy-3,5-dimethoxybenzioc acid 4.34 1 
26 201 C(O)(=O)c1cccc(Cl)c1 m-chlorobenzoic acid 3.81 1 
27 202 C(O)(=O)c1ccc(cc1)C(C)C cumic acid 4.35 1 
28 203 C(O)(=O)c1cccc(Br)c1 m-bromobenzoic acid 3.81 1 
29 204 C(O)(=O)c1ccc(cc1)C(C)=O p-acetylbenzoic acid 3.70 1 
30 205 C(O)(=O)c1ccc(cc1)Br p-bromobenzoic acid 4.00 1 
31 206 C(O)(=O)c1cccc(OC)c1 m-methoxybenzoic acid 4.09 1 
32 207 C(O)(=O)c1cccc(I)c1 3-iodobenzoic acid 3.85 1 
33 208 C(O)(=O)c1ccc(cc1)OCC p-ethoxybenzoic acid 4.45 1 
34 209 c(cc(c1)C(=O)O)c(c1)C=O 4-formylbenzoic acid 3.77 1 
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35 210 N#Cc1ccc(cc1)C(O)=O p-cyanobenzoic acid 3.55 1 
36 211 C(O)(=O)c1ccc(cc1)CC 4-ethylbenzoic acid 4.35 1 
37 212 C(O)(=O)c1ccc(cc1)I 4-iodobenzoic acid 4.00 1 
38 213 C(O)(=O)c1cccc(c1)C=O 3-formylbenzoic acid 3.84 1 
39 214 Nc1ccc(cc1N)C(O)=O 3,4-diamino-benzoic acid 3.49 1 
40 215 c1(cc(OC)cc(OC)c1)C(O)=O 3,5-dimethoxybenzoic acid 3.97 1 
41 216 C(O)(=O)c1cccc(c1)C#N m-cyanobenzoic acid 3.60 1 
42 217 C(O)(=O)c1ccc(cc1)Oc2ccccc2 p-phenoxybenzoic acid 4.52 1 
43 218 C(O)(=O)c2cccc(Oc1ccccc1)c2 m-phenoxybenzoic acid 3.92 1 
44 219 S(C)(=O)(=O)c1ccc(cc1)C(O)=O p-methylsulfonylbenzoic acid 3.64 1 
45 220 C(O)(=O)c1ccc(cc1)OCCC 4-propoxybenzoic acid 4.46 1 
46 221 O=C(O)c(cccc1O)c1 4-[(acetylamino)amino]-benzoic acid 4.20 1 
Ortho-Substituted Benzoic Acids 
   
1 222 c1(ccc(cc1O)C)C(O)=O 4-methylsalicylic acid 3.40 1 
2 223 c1(ccc(cc1Cl)Cl)C(O)=O 2,4-dichlorobenzoic acid 2.68 1 
3 224 c1(cc(Cl)ccc1Cl)C(O)=O 2,5-dichlorobenzoic acid 2.47 1 
4 225 c1(ccccc1OC(C)=O)C(O)=O acetylsalicylic acid 3.49 1 
5 226 c1(c(Cl)ccc(Cl)c1Cl)C(O)=O 2,3,6-trichlorobenzoic acid 1.50 1 
6 227 c1(c(cccc1Cl)Cl)C(O)=O 2,6-dichlorobenzoic acid 1.59 1 
7 228 c1(ccc(cc1OCC)N)C(O)=O 2-ethoxy-4-aminobenzoic acid 5.09 1 
8 229 c1(ccccc1Nc2cccc(C)c2C)C(O)=O mefenamic acid 4.20 1 
9 230 c1(ccc(cc1O)N)C(O)=O p-aminosalicylic acid 3.66 1 
10 231 c1(ccccc1O)C(O)=O salicylic acid 2.97 1 
11 232 c1(cccc(C)c1O)C(O)=O 3-methylsalicylic acid 2.95 1 
12 233 c1(ccccc1I)C(O)=O 2-iodobenzoic acid 2.93 1 
13 234 c1(ccccc1Br)C(O)=O o-bromobenzoic acid 2.88 1 
14 235 c1(ccc(cc1O)O)C(O)=O 2,4-dihydroxybenzoic acid 3.11 1 
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15 236 c1(cc(C)ccc1O)C(O)=O 5-methylsalicylic acid 3.15 1 
16 237 O=C(O)c(c(O)ccc1Br)c1 5-bromosalicylic acid 2.66 1 
17 238 c1(ccccc1NC(C)=O)C(O)=O n-acetyl-o-aminobenzoic acid 3.40 1 
18 239 c1(ccc(cc1OC)OC)C(O)=O 2,4-dimethoxybenzoic acid 4.36 1 
19 240 c1(ccccc1Nc2ccccc2)C(O)=O n-phenyl-o-aminobenzoic acid 3.99 1 
20 241 c2(C(O)=O)c(O)cc1ccccc1c2 2-naphthalenecarboxylic acid, 3-hydroxy- 2.79 1 
21 242 [N+](=O)([O-])c1ccc(c(C(O)=O)c1)O 5-nitrosalicylic acid 2.12 1 
22 243 [N+](=O)([O-])c1ccc(c(Cl)c1)C(O)=O 2-chloro-4-nitro-benzoic acid 2.14 1 
23 244 c1(ccccc1N)C(O)=O 2-aminobenzoic acid 4.95 1 
24 245 c1(ccccc1Cl)C(O)=O 2-chlorobenzoic acid 2.89 1 
25 246 C(O)(=O)c1ccccc1C o-toluic acid 3.98 1 
26 247 c1(cc(I)ccc1O)C(O)=O 2-hydroxy-5-iodo-benzoic acid 2.62 1 
27 248 c1(C(O)=O)c(cc(cc1[N+](=O)[O-])[N+](=O)[O-])[N+](=O)[O-] 2,4,6-trinitrobenzoic acid 0.65 1 
28 249 c1(cc(I)cc(I)c1O)C(O)=O 3,5-diiodosalicylic acid 2.30 1 
29 250 c1(cc(Cl)cc(N)c1Cl)C(O)=O 3-amino-2,5-dichlorobenzoic acid 3.40 1 
30 251 c1(cccc(O)c1O)C(O)=O 2,3-dihydroxybenzoic acid 2.91 1 
31 252 c1(c(cccc1O)O)C(O)=O 2,6-dihydroxybenzoic acid 1.05 1 
32 253 c1(cc(Cl)ccc1O)C(O)=O 5-chlorosalicylic acid 2.65 1 
33 254 c1(ccccc1F)C(O)=O 2-fluorobenzoic acid 3.27 1 
34 255 c1(cc(O)ccc1O)C(O)=O 2,5-dihydroxybenzoic acid 2.95 1 
35 256 [N+](=O)([O-])c1ccccc1C(O)=O 2-nitrobenzoic acid 2.17 1 
36 257 c1(ccccc1C(C)=O)C(O)=O o-acetylbenzoic acid 4.13 1 
37 258 c1(ccccc1OC)C(O)=O o-methoxybenzoic acid 3.90 1 
38 259 c1(cc(cc(C(O)=O)c1O)N(=O)=O)N(=O)=O 2-hydroxy-3,5-dinitro-benzoic acid 0.70 1 
39 260 c1(cc(ccc1C(O)=O)[N+](=O)[O-])[N+](=O)[O-] 2,4-dinitrobenzoic acid 1.42 1 
40 261 C(O)(=O)c1c(C)cccc1C 2,6-dimethylbenzoic acid 3.35 1 
41 262 c1(C(O)=O)c(F)c(F)c(c(F)c1F)C 2,3,5,6-tetrafluoro-4-methyl-benzoic acid 2.00 1 
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42 263 c1(ccccc1c2ccccc2)C(O)=O [1,1-biphenyl]-2-carboxylic acid 3.46 1 
43 264 c1(c(cccc1OC)OC)C(O)=O 2,6-dimethoxybenzoic acid 3.44 1 
44 265 c1(cccc(OC)c1OC)C(O)=O 2,3-dimethoxybenzoic acid 3.98 1 
45 266 c1(c(Cl)ccc(Cl)c1OC)C(O)=O 3,6-dichloro-2-methoxybenzoic acid 1.97 1 
46 267 c1(ccccc1Oc2ccccc2)C(O)=O o-phenoxybenzoic acid 3.53 1 
47 268 c1(ccccc1C(C)C)C(O)=O o-isopropylbenzoic acid 3.63 1 
48 269 [N+](=O)([O-])c1ccc(c(C(O)=O)c1)Cl 2-chloro-5-nitrobenzoic acid 2.17 1 
49 270 [N+](=O)([O-])c1cccc(C(O)=O)c1Cl 2-chloro-3-nitrobenzoic acid 2.02 1 
50 271 c2c(NC(c1c(C(O)=O)cccc1)=O)cccc2 n-phenylphthalamic acid 2.50 1 
51 272 N(=O)(=O)c1cccc(Cl)c1C(O)=O 2-chloro-6-nitro-benzoic acid 1.34 1 
52 273 c1(c(C)cccc1Cl)C(O)=O 2-chloro-6-methyl-benzoic acid 2.75 1 
53 274 c1(ccccc1NCC(N)=O)C(O)=O 2-[(acetylamino)amino]-benzoic acid 4.20 1 
Anilines 
   
1 275 Nc1cc(C(O)=O)ccc1 3-aminobenzoic acid 4.53 3 
2 276 Nc1ccc(C(O)=O)cc1 4-aminobenzoic acid 2.38 2 
3 277 Nc1cc(O)c(C(O)=O)cc1 p-aminosalicylic acid 2.05 2 
4 278 Nc1ccc(O)cc1 4-amino-phenol 5.48 2 
5 279 Nc1cc(O)ccc1 3-amino-phenol 4.37 2 
6 280 Nc1cc(N(=O)=O)cc(N(=O)=O)c1 3,5-dinitroaniline 0.30 2 
7 281 Nc1cc(Cl)cc(Cl)c1 3,5-dichloroaniline 2.51 2 
8 282 Nc2ccc(c1ccccc1)cc2 4-aminobiphenyl 4.35 2 
9 283 Cc1c(N(=O)=O)ccc(N)c1 3-methyl-4-nitroaniline 1.64 2 
10 284 C(c1ccccc1)(=O)c2ccc(cc2)N 4-benzoylaniline 2.24 2 
11 285 [N+](=O)([O-])c1c(C)cc(cc1C)N 3,5-dimethyl-4-nitrobenzenamine 2.54 2 
12 286 [N+](=O)([O-])c1c(C)ccc(N)c1 2-nitro-p-toluidine 0.40 2 
13 287 S(C)(=O)(=O)c1ccc(cc1)N 4-methylsulfonylaniline 1.35 2 
14 288 N(=O)(=O)c1c(Cl)ccc(N)c1 4-chloro-3-nitro-benzenamine 1.90 2 
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15 289 C(F)(F)(F)c1ccc(cc1)N p-trifluoromethylaniline 2.45 2 
16 290 C(OC)(=O)c1ccc(cc1)N methyl-p-aminobenzoate 2.47 2 
17 291 C(OCCCC)(=O)c1ccc(cc1)N butyl-p-aminobenzoate 2.47 2 
18 292 C(OCCC)(=O)c1ccc(cc1)N propyl-p-aminobenzoate 2.49 2 
19 293 C(OCC)(=O)c1ccc(cc1)N p-aminobenzoic acid, ethyl ester 2.51 2 
20 294 c1(Cl)c(Cl)ccc(N)c1 3,4-dichloroaniline 2.97 2 
21 295 C(F)(F)(F)c1cccc(N)c1 3-trifluoromethylaniline 3.49 2 
22 296 c1c(cccc1N)Br m-bromoaniline 3.58 2 
23 297 c1c(cccc1N)I 3-iodo-benzenamine 3.61 2 
24 298 c1(ccc(cc1)I)N 4-iodo-benzenamine 3.78 2 
25 299 c1(ccc(cc1)Br)N p-bromoaniline 3.86 2 
26 300 c1(C)cc(ccc1Br)N 3-methyl-4-bromoaniline 4.05 2 
27 301 c1(ccccc1N)C(O)=O 2-aminobenzoic acid 2.14 2 
28 302 c1(ccccc1O)N o-aminophenol 4.84 2 
29 303 [N+](=O)([O-])c1ccc(c(N)c1)O 2-amino-4-nitrophenol 3.10 2 
30 304 c1(Br)c(N)ccc(Br)c1 2,4-dibromoaniline 2.30 2 
31 305 [N+](=O)([O-])c1cc(C)ccc1N 3-nitro-4-toluidine 3.03 2 
32 306 c1(ccccc1N)c2ccccc2 2-aminobiphenyl 3.83 2 
33 307 [N+](=O)([O-])c1cc(Cl)c(c(Cl)c1)N 2,6-dichloro-4-nitroaniline -2.55 2 
34 308 [N+](=O)([O-])c1cc(C)c(c(C)c1)N 2,6-dimethyl-4-nitrobenzenamine 0.98 2 
35 309 c1(N)c(Cl)ccc(Cl)c1 2,5-dichloroaniline 2.05 2 
36 310 c1(c(N)ccc(c1)[N+](=O)[O-])[N+](=O)[O-] 2,4-dinitroaniline -4.25 2 
37 311 [N+](=O)([O-])c1c(N)ccc(Cl)c1 4-chloro-2-nitroaniline -1.02 2 
38 312 [N+](=O)([O-])c1ccc(c(Cl)c1)N 2-chloro-4-nitroaniline -0.94 2 
39 313 c1(N)c(F)c(F)c(c(F)c1F)F 2,3,4,5,6-pentafluoroaniline -0.28 2 
40 314 c1(N)c(cccc1Cl)Cl 2,6-dichloroaniline 0.42 2 
41 315 N(=O)(=O)c1c(N)ccc(OC)c1 4-methoxy-2-nitro-benzenamine 0.77 2 
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42 316 [N+](=O)([O-])c1ccc(c(C)c1)N 4-nitro-2-toluidine 1.04 2 
43 317 c1(Cl)c(cccc1N)Cl 2,3-dichloroaniline 1.76 2 
44 318 c1(Cl)c(N)ccc(Cl)c1 2,4-dichloroaniline 2.00 2 
45 319 c1(ccccc1N)C(OCC)=O o-aminobenzoic acid, ethyl ester 2.18 2 
46 320 c1(ccccc1N)C(OC)=O methyl anthranilate 2.23 2 
47 321 [N+](=O)([O-])c1ccc(c(N)c1)C 5-nitro-2-toluidine 2.35 2 
48 322 c1(c(C)c(C)c(c(C)c1C)N)[N+](=O)[O-] 2,3,5,6-tetramethyl-4-nitrobenzenamine 2.36 2 
49 323 [N+](=O)([O-])c1ccc(c(N)c1)OC 2-methoxy-5-nitroaniline 2.49 2 
50 324 c1(ccccc1Br)N o-bromoaniline 2.53 2 
51 325 c1(ccccc1I)N 2-iodoaniline 2.60 2 
52 326 N(=O)(=O)c1cccc(c1N)N(=O)=O 2,6-dinitroaniline -5.00 2 
53 327 c1(N)c(Cl)cc(cc1Cl)Cl 2,4,6-trichloroaniline -0.03 2 
54 328 c1c(Cl)c(Cl)cc(Cl)c1N 2,4,5-trichloroaniline 1.09 2 
55 329 c1(N)c(OC)ccc(OC)c1 2,5-dimethoxyaniline 3.93 2 
Han 2006 - Fluorophenols 
   
# 330 Oc1ccc(F)cc1F 2,4-difluorophenol 8.58 4 
# 331 Oc1c(F)cccc1F 2,6-difluorophenol 7.51 4 
# 332 Oc1c(F)c(F)cc(F)c1F 2,3,5,6-tetrafluorophenol 6 4 
Regnar 2000 
   
      R_3 333 COc1cc(CO)ccc1O 4-(hydroxymethyl)-2-(methoxy)phenols 9.78 5 
      R_4 334 COCc1ccc(O)c(OC)c1 2-(methyloxy)-4-[(methyloxy)methyl]phenol 9.79 5 
      R_7 335 COC(=O)c1ccc(O)c(OC)c1 methyl 4-hydroxy-3-(methyloxy)benzoate 8.3 5 
      R_8 336 COc1cc(CCO)ccc1O 4-(2-hydroxyethyl)-2-(methoxy)phenol 10.09 5 
      
R_10 337 COc1cc(ccc1O)C(C)O 4-(1-hydroxyethyl)-2-(methoxloxy)phenol 9.83 5 
      
R_11 338 COC(C)c1ccc(O)c(OC)c1 2-(methyloxy)-4-[1-(methyloxy)ethyl]phenol 9.75 5 
      
R_12 339 COc1cc(ccc1O)C(O)CO 1-[4-hydroxy-3-(methyloxy)phenyl]-1,2-ethanediol 9.5 5 
      340 COc1cc(ccc1O)C(C)=O 1-{4-hydroxy-3-(methyloxy)phenyl]ethanone 7.81 5 
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R_14 
      
R_16 341 CCCc1ccc(O)c(OC)c1 2-(methyloxy)-4-propylphenol 9.85 5 
      
R_20 342 COc1cc(\C=C\CO)ccc1O 4-[(1E)-3-hydroxy-1-propen-1-yl]-2-(methyloxy)phenol 9.54 5 
      
R_21 343 COc1cc(\C=C\C=O)ccc1O (2E)-3-[4-hydroxy-3-(methyloxy)phenyl]-2-propenal 7.94 5 
      
R_23 344 CCC(O)c1ccc(O)c(OC)c1 4-(1-hydroxypropyl)-2-(methyloxy)phenol 9.83 5 
      
R_25 345 CCC(=O)c1ccc(O)c(OC)c1 1-[4-hydroxy-3-(methyloxy)phenyl]-1-propanone 7.98 5 
      
R_26 346 COc1cc(ccc1O)C(=O)C(C)O 2-hydroxy-1-[4-hydroxy-3-(methyloxy)phenyl]-1-propanone 7.32 5 
      
R_27 347 COc1cc(ccc1O)C(O)C(CO)Oc1ccccc1OC 
1-[4-hydroxy-3-(methyloxy)phenyl]-2-{[2-(methyloxy)phenl]oxy}-1,3-
propanediol 9.88 5 
      
R_33 348 COCc1cc(\C=C/Oc2ccccc2OC)ccc1O 2-[methyloxy)methyl]-4-((Z)-2-{[2-methyloxy)phenyl]oxy}ethenyl)phenol 9.49 5 
      
meta/para nitrophenols added 
   
# 349 Oc1ccc(c(F)c1)[N+]([O-])=O 3-fluoro-4-nitrophenol 5.3 6 
# 350 Oc1cc(F)c(c(F)c1)[N+]([O-])=O 3,5-difluoro-4-nitrophenol 4.4 6 
# 351 Cc1cc(O)ccc1[N+]([O-])=O 3-methyl-4-nitrophenol 7.29 7 
# 352 Cc1cc(O)cc(C)c1[N+]([O-])=O 3,5-dimetyl-4-nitrophenol 8.25 8 
# 353 Oc1ccc(c(Cl)c1)[N+]([O-])=O 3-chloro-4-nitrophenol 6.49 8 
      
Meta-Anilines 
   
 
354 Nc1cccc(N)c1 3-aminoaniline 4.88 9 
 
355 Nc1cccc(Cl)c1 3-chloroaniline 3.34 9 
 
356 Nc1cccc(c1)C#N 3-cyanoaniline 2.76 9 
 
357 Nc1cccc(F)c1 3-fluoroaniline 3.59 9 
 
358 COc1cccc(N)c1 3-methoxyaniline 4.2 9 
 
359 Cc1cccc(N)c1 3-methylaniline 4.69 9 
 
360 Nc1cccc(c1)[N+]([O-])=O 3-nitroaniline 2.5 9 
246 
 
 
361 Cc1cc(C)cc(N)c1 3,4-dimethylaniline 5.17 9 
 
362 Nc1ccc(O)c(N)c1 3-amino-4-hydroxyaniline 5.7 9 
 
363 COc1ccc(N)cc1Br 3-bromo-4-methoxyaniline 4.08 9 
 
364 Cc1ccc(N)cc1Br 3-bromo-4-methylaniline 3.98 9 
 
365 Cc1ccc(N)cc1Cl 3-chloro-4-methylaniline 4.05 9 
 
366 Nc1cc(Br)cc(Br)c1 3,5-dibromoaniline 2.34 9 
 
367 COc1cc(N)cc(OC)c1 3,5-dimethoxyaniline 3.82 9 
 
368 Cc1cc(C)cc(N)c1 3,5-dimethylaniline 4.91 9 
 
369 COc1cc(N)cc(Cl)c1 3-chloro-5-methoxyaniline 3.1 9 
 
370 COc1cc(N)cc(c1)[N+]([O-])=O 3-methoxy-5-nitroaniline 2.11 9 
 
371 Nc1cc(Br)c(O)c(Br)c1 3,5-dibromo-4-hydroxyaniline 3.2 9 
 
372 COc1c(Br)cc(N)cc1Br 3,5-dibromo-4-methoxyaniline 2.98 9 
 
373 Cc1c(Br)cc(N)cc1Br 3,5-dibromo-4-methylaniline 2.87 9 
      
Zhang 
   
 
373 OC(=O)c1ccccc1O 2-hydroxybenzoic acid 2.98 10 
 
374 OC(=O)c1cccc(O)c1 3-hydroxybenzoic acid 4.08 10 
 
375 OC(=O)c1ccc(O)cc1 4-hydroxybenzoic acid 4.58 10 
 
376 OC(=O)c1cccc(O)c1O 2,3-hydroxybenzoic acid 2.98 10 
 
377 OC(=O)c1ccc(O)cc1O 2,4-hydroxybenzoic acid 3.29 10 
 
378 OC(=O)c1cc(O)ccc1O 2,5-hydroxybenzoic acid 2.97 10 
 
379 OC(=O)c1c(O)cccc1O 2,6-hydroxybenzoic acid 1.3 10 
 
380 OC(=O)c1ccc(O)c(O)c1 3,4-hydroxybenzoic acid 4.48 10 
 
381 OC(=O)c1cc(O)cc(O)c1 3,5-hydroxybenzoic acid 4.04 10 
 
382 OC(=O)c1c(O)cc(O)cc1O 2,4,6-hydroxybenzoic acid 1.68 10 
 
383 OC(=O)c1cc(O)c(O)c(O)c1 3,4,5-hydroxybenzoic acid 4.19 10 
 
384 OC(=O)c1ccccc1 hydroxybenzoic acid 4.2 10 
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Drug Molecules Liao 
   
 
385 CC(=O)Nc1ccc(O)cc1 Acteaminophen 9.63 11 
 
386 CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)ccc(Cl)c4[C@@]3(C)O)=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O Chlortetracycline 9.3 11 
 
387 CN(C)[C@H]1[C@@H]2C(O)[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O Oxytetracycline 9.11 11 
 
388 CN(C)[C@H]1[C@@H]2C[C@H]3C(C(=O)c4c(O)cccc4[C@@]3(C)O)=C(O)[C@]2(O)C(=O)C(C(N)=O)=C1O Tetracycline 9.69 11 
 
389 Oc1c(I)cc(Cl)c2cccnc12 Clioquinol 8.16 11 
 
390 C[C@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CC[C@H]2O 17a-Dihydroequiline 10.29 11 
 
391 C[C@]12CC[C@H]3C(=CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O 17b-Dihydroequilin 9.77 11 
 
392 C[C@]12CCc3c(ccc4cc(O)ccc34)C1CC[C@@H]2O Equilenin 9.77 *** 
 
393 CSCC[C@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)CNC(=O)CNC(=O)[C@H](N)Cc1ccc(O)cc1)C(O)=O Enkephalin 9.89 11 
 
394 C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@H]2O 17B-Estradiol 10.71 11 
 
395 C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CCC2=O Estrone 10.34 11 
 
396 C[C@]12CC[C@H]3[C@@H](CCc4cc(O)ccc34)[C@@H]1CC[C@@]2(O)C#C Ethinyl estradiol 10.4 11 
 
397 CC(C)NCC(O)c1ccc(O)c(O)c1 Isoproterenol 10.07 11 
 
398 C[C@H](CCc1ccccc1)NC[C@@H](O)c1ccc(O)c(c1)C(N)=O Labetalol 7.41 11 
 
399 CN1CC[C@@]23[C@H]4Oc5c2c(CC1C3C=C[C@@H]4O)ccc5O Morphine 9.4 11 
 
400 CN1CC[C@@]23[C@H]4Oc5c2c(CC1C3C=C[C@@H]4O)ccc5O Normoorphine 9.8 11 
 
401 CCCN(C)[C@H]1C=C(OC2OC(C(O)[C@H](O)[C@H]2O)C(O)=O)[C@@H]2Oc3c4C2C1CCc4ccc3O Morphine-6-glucuronide 9.36 11 
 
402 N[C@@H](Cc1ccc(O)cc1)C(O)=O Tyrosine 10.27 11 
 
403 COc1cc(C=O)ccc1O Vanillin 7.4 11 
 
404 COc1ccc(C=O)cc1O iso-Vanillin 8.89 11 
 
405 COc1cccc(C=O)c1O ortho-Vanillin 7.91 11 
 
406 Nc1ccc(cc1)C(O)=O 4-Aminobenzoic acid 2.5 11 
 
407 CCOC(=O)c1ccc(N)cc1 Benzocaine 2.52 11 
 
408 CCN(CC)CCOC(=O)c1ccc(N)cc1 Procaine  2.29 11 
 
409 CC(=O)NS(=O)(=O)c1ccc(N)cc1 Sulfacetamide 1.76 11 
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Appendix D 
 
Hatch Data set 
CAS ID Structure LogMP 
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Gramatica  data set 
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Ames Results
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Ames Results
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Ames Results
2-aminoanthracene
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Ames Results
1-methyl-2-aminobenzimidazole
T
A
9
8
T
A
1
0
0
-S9 +S9
N
N
NH
2
Toxicity
Precipitation
0
0.2
0.4
0.6
0.8
1
1.2
1.4
50 150 500 1500 2500 5000
Dose level per plate (µg)
R
a
ti
o
 t
re
a
te
d
 /
 s
o
lv
e
n
t
0
2
4
6
8
10
12
14
16
18
50 150 500 1500 2500 5000
Dose level per plate (µg)
R
a
ti
o
 t
re
a
te
d
 /
 s
o
lv
e
n
t
0
5
10
15
20
25
30
35
40
50 150 500 1500 2500 5000
Dose level per plate (µg)
R
a
ti
o
 t
re
a
te
d
 /
 s
o
lv
e
n
t
0
0.2
0.4
0.6
0.8
1
1.2
1.4
50 150 500 1500 2500 5000
Dose level per plate (µg)
R
a
ti
o
 t
re
a
te
d
 /
 s
o
lv
e
n
t
 
269 
 
Ames Results
4-phenoxyaniline
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Ames Results
2-amino-5-phenylpyridine
T
A
9
8
T
A
1
0
0
-S9 +S9
Toxicity
Precipitation
N
NH
2
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
50 150 500 1500 2500 5000
Dose level per plate (µg)
R
a
ti
o
 t
re
a
te
d
 /
 s
o
lv
e
n
t
0
0.5
1
1.5
2
2.5
3
50 150 500 1500 2500 5000
Dose level per plate (µg)
R
a
ti
o
 t
re
a
te
d
 /
 s
o
lv
e
n
t
0
5
10
15
20
50 150 500 1500 2500 5000
Dose level per plate (µg)
R
a
ti
o
 t
re
a
te
d
 /
 s
o
lv
e
n
t
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
50 150 500 1500 2500 5000
Dose level per plate (µg)
R
a
ti
o
 t
re
a
te
d
 /
 s
o
lv
e
n
t
 
271 
 
Ames Results
2,4,5-trimethylaniline
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Ames Results
3-Aminobenzonitrile
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Ames Results
2-aminonaphtho(2,3-d)imidazole
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Ames
4-Chloro-2-methylaniline
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Ames Results
3-aminoquinoline
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Ames Results
4-bromo-2-methylaniline
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Ames Results
4-Aminoacetanilide
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Ames Results
2-amino-5-hydroxybenzoic acid
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Ames Results
2-ethylaniline
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